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Abstract 
A major issue of conventional chemotherapy is the lack of selective delivery which results in 
high systemic exposure and severe side effects. The limitations of small molecular weight 
drugs for cancer therapy prompted the development of diverse nanocarrier systems for 
targeted drug delivery. The impressive progress in nanomaterial science and increased 
understanding of the nano-bio interface allowed the progression of these systems. However, 
the targeted delivery remains challenging due to obstacles that are encountered during the 
drug delivery process, particularly, in the tumor microenvironment (TME). (Multi)stimuli-
responsive nanocarriers have the potential to overcome the faced barriers by taking 
advantage of altered pathological characteristics in the TME and/or intracellular signals.  
The motivation of the presented work was to incorporate rational design features into novel 
responsive nanomedicines to address the limitations of conventional chemotherapeutic drugs 
and tackle issues of current drug delivery systems (DDS). For this purpose, prodrugs of the 
chemotherapeutic agent doxorubicin (Dox) were combined with three nanocarrier designs 
including polymer-drug conjugates, a nanoemulsion (NE), and nanogels (NGs). The Dox 
prodrugs comprised cleavable motifs which introduce a responsiveness towards endogenous 
stimuli into the nanocarriers. The nanocarrier architectures with different sizes and 
compositions were evaluated in terms of controlled drug release, drug-carrier compatibility, 
carrier degradability, and transport restrictions in the TME, all of which are important aspects 
for an efficient delivery process.  
The choice of the cleavable linkage strongly affects the specificity of the desired responsive 
behavior. To address this aspect, Dox prodrugs with pH- or protease-cleavable bonds were 
evaluated regarding their impact on the intracellular drug release. Activatable fluorescence 
probes were utilized to follow the drug release from polymer-drug conjugates in real-time. 
This assessment of the linker formed the basis for the rational design of two prodrug-based 
nanomedicines with adjusted cleavage properties. First, a pH-sensitive Dox prodrug was 
entrapped in a NE to form a DDS with explicit intracellular drug release. The second design 
was based on dual-responsive nanogels as multistage delivery systems with specific 
extracellular response to protease and acid-mediated intracellular payload release.  
Initially, we evaluated the impact of the cleavable linkage on the drug release using 
theranostic polymer conjugates (TPC) with activatable fluorescence probes. The TPC represent 
model DDS that consist of dendritic polyglycerol (dPG) as polymeric carrier labeled with an 
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indodicarbocyanine (IDCC) dye that quenches the fluorescence of Dox, conjugated through a 
cleavable linker. Cleavage of the conjugates was mediated either by acidic pH or protease 
activity. By tracking the fluorescence recovery in a cell-based microplate assay, we were able 
to obtain characteristic release profiles of Dox for different cell lines. Here, the pH-cleavable 
linker was found to be cleaved mainly intracellularly, whereas the protease-sensitive system 
suffered from extracellular drug release. The intracellular release was crucial to treat 
multidrug-resistant cells and overcome their resistance mechanisms. It can be highlighted that 
the modular synthetic approach, combined with the cell-based assay, has potential to extend 
the common in vitro methods to evaluate DDS performance. 
The results of this study motivated us to develop a pH-sensitive Dox prodrug (C16-Dox) to 
efficiently dissolve the drug in the nanodroplets of an oil/water NE. By attaching a 
hydrophobic alkyl chain (C16), Dox was provided with an amphiphilic character for increased 
drug-carrier compatibility. pH-sensitive properties of the prodrug allowed the intracellular 
release of the drug from the NE by recovering the hydrophilic parent drug. The new 
formulation of Dox (NE-C16-Dox) was compared with free Dox in a murine breast cancer 
model. Enhanced delivery to tumor tissue and reduction of systemic toxicity allowed the 
administration of a higher Dox dose in the NE formulation as compared to the free drug. The 
high dosage significantly inhibited the primary tumor growth and prevented the formation of 
distant lung metastasis without signs of side effects. The improved chemotherapeutic index 
compared to free Dox indicates that NE-C16-Dox is a promising formulation for breast cancer 
treatment 
At last, we combined protease- and pH-sensitive moieties into a multistage nanocarrier to 
enhance drug transport in tumor tissue. Matrix metalloproteinase (MMP)-sensitive NGs 
(pNGs) were developed which consists of a dPG scaffold crosslinked with a fluorogenic 
peptide. The crosslinker integrates biodegradability to the nanocarrier mediated by proteases 
in the TME. The intrinsic reporter moiety of the crosslinker allowed us to study the influence 
of different pNG compositions on the degradation profile in detail. One pNG candidate was 
chosen to conjugate the therapeutic drug Dox through a pH-sensitive linkage to dPG. The 
degradable multistage pNGs demonstrated deeper penetration into multicellular tumor 
spheroids (MCTS) as compared to their non-degradable counterparts. Hence, the triggered 
size reduction of the pNGs by enzymatic degradation facilitated the infiltration of the 
nanocarrier into dense tissue and thereby promoted the delivery of the therapeutic cargo. 
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Kurzzusammenfassung 
Ein Hauptproblem der konventionellen Chemotherapie ist die hohe systemische Exposition, 
die zu schweren Nebenwirkungen führen kann. Die Schwierigkeiten in Verbindung mit 
niedermolekularen Wirkstoffen für die Krebstherapie führten zur Entwicklung verschiedener 
Nanotransportsysteme für den gezielten Wirkstofftransport (targeted drug delivery). 
Aufgrund des Fortschritts in der Nanomaterialforschung und des besseren Verständnisses der 
Nano-Bio-Grenzfläche können diese Systeme weiter verbessert werden. Der gezielte 
Wirkstofftransport bleibt jedoch aufgrund der physiologischen Hindernisse, die während des 
Transportprozesses, insbesondere im Tumormikromileu (TMM), auftreten eine 
Herausforderung. (Multi)-Stimuli-responsive Nanotransportern (Nanocarrier) haben das 
Potenzial, die Barrieren zu überwinden, indem sie die veränderten pathologischen 
Eigenschaften des TMM nutzen.  
Die Motivation dieser Arbeit war es rationales Design in neuartige, Prodrug-basierte 
Nanotransporter zu integrieren, um die Komplikationen herkömmlicher Chemotherapeutika 
zu reduzieren und die Probleme derzeitiger Wirkstofftransportsystemen (Drug delivery 
systems) zu überwinden. Zu diesem Zweck wurden Prodrugs des Chemotherapeutikums 
Doxorubicin (Dox) mit drei Nanotransportsystemen kombiniert, darunter Polymer-Wirkstoff-
Konjugate, eine Nanoemulsion (NE) und Nanogele (NGs). Die Dox-Prodrugs enthalten 
spaltbare Gruppen, die eine Reaktivität auf endogene Stimuli in die Nanotransporter 
einführen. Die Nanocarrier-Architekturen mit unterschiedlichen Größen und 
Zusammensetzungen wurden im Hinblick auf die kontrollierte Freisetzung von 
Medikamenten, die Kompatibilität mit dem Transporter und die Abbaubarkeit des 
Nanocarriers sowie Transportbeschränkungen im TMM untersucht. 
Die Wahl der spaltbaren Verknüpfung beeinflusst stark die Spezifität der gewünschten 
Reaktivität. Um den Einfluss des gewählten Linkers auf die intrazelluläre Wirkstofffreisetzung 
zu bewerten, wurden Dox-Prodrugs mit pH- oder Protease-spaltbaren Bindungen in 
Kombination mit aktivierbaren Fluoreszenzsreportern verwendet. Die Reporter erlaubten es 
die Wirkstofffreisetzung von Polymer-Wirkstoff-Konjugaten in Echtzeit zu verfolgen. Die 
Evaluierung der spaltbaren Linker bildete die Grundlage für das rationale Design von zwei 
Prodrug-basierten Nanotransportern mit angepassten Spaltungseigenschaften. Zunächst 
wurde eine pH-empfindliche Dox-Prodrug in ein NE eingeschlossen, um ein DDS mit expliziter 
intrazellulärer Wirkstofffreisetzung zu erhalten. Das zweite Design basierte auf Nanogelen mit 
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zwei sensitiven Gruppen für ein mehrstufiges Transportersystem mit spezifischer Reaktion auf 
extrazelluläre Proteasen und säurekatalysierter intrazellulären Freisetzung des Wirkstoffs. 
Zunächst wurde die Auswirkung von verschiedenen spaltbaren Bindungen auf die 
Wirkstofffreisetzung untersucht. Dazu wurden theranostischen Polymerkonjugaten (TPC) mit 
aktivierbarer Fluoreszenzreportern verwendet. Die TPC stellen Modell-Wirkstofftransporter 
dar, die aus dendritischen Polygycerol (dPG) als polymerem Träger bestehen, das mit einem 
Indodicarbocyanin (IDCC)-Farbstoff markiert ist Die Nähe des Farbstoffes zu Dox, das über eine 
spaltbare Bindung an das dPG konjugiert wurde, wurde die Fluoreszenz von Dox unterdrückt.  
Die Spaltung der Konjugate konnte entweder durch saure Hydrolyse oder durch die Aktivität 
von Protease geschehen. In einem zellbasierten, vergleichenden Assay konnte durch das 
Verfolgen des Fluoreszenzsignals charakteristische Freisetzungsprofile für verschiedene 
Zelllinien erhalten werden. Dabei wurde festgestellt, dass der pH-spaltbare Linker 
hauptsächlich intrazellulär gespalten wurde, während das proteaseempfindliche System 
extrazellulären Wirkstofffreisetzung zeigte. Die intrazelluläre Wirkstofffreisetzung war 
entscheidend, um multiresistente Zellen zu behandeln und ihre Resistenzmechanismen zu 
überwinden. Der modulare Syntheseansatz in Kombination mit dem zellbasierten Assay kann 
die üblichen In-vitro-Methoden zur Bewertung der Wirkstofftransporterperformance 
erweitern, da das Design leicht für verschiedene Träger/Linker-Systeme sowie verschiedene 
Zelllinien eingesetzt werden kann. 
Die Ergebnisse dieser Studie haben uns motiviert, eine pH-empfindliche Dox-Prodrug (C16-
Dox) zu entwickeln, um den Wirkstoff effizient in die Nanotröpfchen einer Öl/Wasser-NE 
einzubringen. Durch Bindung einer hydrophoben Alkylkette (C16) erhielt Dox einen 
amphiphilen Charakter, was die Wirkstoff-Carrier-Kompatibilität erhöhte. Die pH-
empfindlichen Eigenschaften der Prodrug ermöglichten die intrazelluläre Freisetzung von Dox 
durch Rückbildung des freien Wirkstoffs. Die neue Dox-Formulierung (NE-C16-Dox) wurde in 
einem In-vivo-Brustkrebsmodell mit freiem Dox verglichen. Eine verbesserte Akkumulation im 
Tumorgewebe und eine Verringerung der systemischen Toxizität ermöglichten die 
Verabreichung einer höheren Dosis von Dox in der NE-Formulierung im Vergleich zum freien 
Wirkstoff. Die höhere Dosierung inhibierte das primäre Tumorwachstum signifikant und 
verhinderte die Bildung von Lungenmetastasen ohne Anzeichen von Nebenwirkungen. Der 
verbesserte chemotherapeutische Index im Vergleich zu freiem Dox weist darauf hin, dass NE-
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C16-Dox eine vielversprechende Formulierung für die Behandlung von Brustkrebs sein und 
wird daher für klinische Studien in Betracht gezogen.  
Schließlich kombinierten wir Protease- und pH-empfindliche Komponenten in einem multi-
responsiven Nanocarrier, um den gehinderten Wirkstofftransport im Tumorgewebe zu 
verbessern. Dazu wurden Matrix-Metalloprotease (MMP)-sensitive NGs (pNGs) entwickelt, 
die aus einem dPG-Gerüst bestehen, das mit einem fluorogenen Peptid vernetzt ist. Der 
Vernetzer integriert biologische Abbaubarkeit in den Nanocarrier, die durch Proteasen im TME 
verursacht werden kann. Der intrinsische Reporter des Vernetzers erlaubte es uns, den 
Einfluss verschiedener pNG-Zusammensetzungen auf das Zerfallsprofil im Detail zu 
untersuchen. Ein pNG-Kandidat wurde ausgewählt, um den therapeutischen Wirkstoff Dox 
über eine pH-sensitive Bindung an dPG zu konjugieren. Die abbaubaren mehrstufigen pNGs 
zeigten eine tiefere Eindringtiefe in multizellulären Tumor-Sphäroiden (MCTS) im Vergleich zu 
ihren nicht abbaubaren Gegenstücken. Es konnte somit gezeigt werden, dass die endogen 
gesteuerte Verkleinerung der pNGs durch enzymatischen Abbau die Infiltration des 
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Even though nanoparticles have existed since long, the technological advances to investigate 
and control matter at the nanoscale prompted the development of new materials and 
applications. Nanotechnology is an advancing field with interdisciplinary research focusing on 
the control of material at the nanoscale by engineering structures on the molecular level. 
Within this field, nanomedicine encompasses the application of nanotechnology in the 
healthcare sector.1 The aim of nanomedicine is the design of nano-sized multifunctional 
therapeutics and drug delivery systems (DDS) to yield more effective therapies.2-5 In addition, 
analytical tools and devices for a better understanding of the molecular basis of disease, 
patient predisposition, and response to therapy are developed.6 This opened up new 
perspectives, for instance, in regenerative medicine, for drug delivery strategies, medical 
diagnostics, and therapeutics and lead to rapidly emerging biomedical tools ranging from 
nanoparticle coated medicinal implants7 to contrast agents for diagnostic imaging8 and to 
potential drug and gene delivery vehicles.9 In addition, versatile nanomaterials with novel 
optical properties10 as well as nanomaterials with intrinsic therapeutic nature11 were 
generated. The advances in nanotechnology knowledge now allow to include diverse 
properties into nanomaterials that can be modulated according to the desired applications. 
1.1.1 Rationale for nanomedicine in cancer therapy 
The efficient treatment of diseases is often limited by the intrinsic shortcomings of small 
molecular weight drugs. The lack of selective delivery of anticancer compounds to malignant 
tissue results in high systemic exposure leading to severe side effects. This causes dose-limits 
for the drug in question and therefore a poor therapeutic index. Besides low target specificity, 
a rapid drug clearance leads to poor bioavailability of the so-called ‘small molecule’ drugs. 
Another class of biotherapeutics including proteins, peptides, oligonucleotides, and 
antibodies is rapidly evolving and has demonstrated striking therapeutic activities as 
alternatives to conventional small molecule drugs. The clinical translation of therapeutic 
proteins is, however, severely hindered due to their possible fast degradation in vivo, poor cell 
penetration, and inefficient intracellular trafficking.12 Furthermore, new drug candidates 
often fail the transition to clinical trials due to deficient physicochemical properties such as 
low water solubility. These limitations prompted the development of new formulation and 
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modification approaches to improve the therapeutic efficiency and patient survival compared 
to conventional therapies.13-14 Nanocarriers have emerged that offer the multifunctionality to 
incorporate required features to revolutionize the delivery across all barriers.15-16 For a 
targeted and on-demand delivery of therapeutics, carrier platforms must be carefully 
designed in coherence with the faced biological barriers. This can provide DDS with the 
capacity to reach the therapeutic target and carry out their functions with maximum 
efficacy.17-18  
 
Figure 1. The rationale of nanomedicine for cancer therapy. 
In Figure 1, the four main contributions of nanocarriers to improve cancer therapy are 
presented. (1) Protection of the cargo: The connection of the therapeutic agent with a carrier 
can enhance crucial parameters such as their solubility and in vivo stability resulting in 
improved bioavailability. Thereby, nanocarriers modulate both the pharmacokinetic and 
pharmacodynamic profiles of the loaded or conjugated drugs. (2) Passive and active targeting: 
The nanoscale size and surface properties of nanocarriers can be optimized to extend blood 
circulation time and to target diseased tissue which will be discussed in detail in the next 
chapter. (3) Stimuli-responsiveness: To enhance the targeted delivery, nanocarriers are 
provided with controlled drug release properties which can be triggered by external or 
internal stimuli (Chapter 1.2). (4) Imaging modalities: Beyond therapeutic moieties, imaging 
modalities can be added for diagnostic purposes and for monitoring of nanocarrier delivery 
paving the way for personalized therapy (chapter 1.2.4).  
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1.1.2 Role of the nanoscale size  
Several reasons underline the potential of nanosized materials in nanomedicine. Particles in 
the nanoscale are characterized by an enormous surface area which allows the interaction 
with the surrounding environment with increased reactivity compared to macroscopic 
structures. Since processes in biological systems take place in the nanoscale, artificial 
nanosized particles enable to optimize the precise interaction with biological targets to 
develop new strategies for therapy and diagnostic. Moreover, quantum effects dominate the 
properties of materials at this scale. For instance, nanosized metal particles display altered 
optical properties. Upon interaction with visible or near infrared light, plasmon oscillation 
generates intense electromagnetic fields at the metal surface. These surface plasmons can 
decay by the emission of photons or non-radiative relaxation via heat irradiation. Both are 
used in nanomedicine to develop diagnostic and therapeutic approaches.19  
With regards to tumor treatment, particles in the nanoscale can alter the biodistribution of 
loaded payloads. The particles with sizes between 10 and 200 nm avoid clearing mechanisms 
present in kidney and liver and therefore prolong half-life in the body. In addition, tumor 
physiology with rapidly dividing cancer cells results in the formation of the new vasculature 
that is architecturally abnormal and exhibits an increased permeability. The prolonged 
circulation in combination with leaky vasculature can yield enhanced accumulation of 
nanoscale particles in the tumor tissue. In addition, poor lymphatic drainage of the tumor 
increases retention of the nanoparticles. The phenomenon is referred to as the enhanced 
permeation an retention (EPR) effect (Figure 2a).20  
 
Figure 2. Schematic representation of (a) passive targeting by the EPR effect and (b) cell 
internalization mechanisms including active targeting. Adapted from Khandare et al.5 with 
permission of reference 5. Copyright 2012 Royal Society of Chemistry.  
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In contrast, nanoparticles are less prone to pass through the epithelial wall of healthy tissue. 
The EPR effect has become the foundation of passive targeting of nanocarriers to solid tumors 
and is closely influenced by the size of the particles. Sizes in the range of 20–200 nm were 
found to be optimal to take advantage of the effect.21It is noteworthy that tumor 
heterogeneity and complexity observed for different kind of cancers strongly influences tumor 
extravasation and accumulation. Thus, the EPR effect was found to be highly variable with 
large differences between tumor types, metastasis, between animals and human, and even 
between single patients and appear to be only effective in certain subgroups of patients. A 
pioneering study has been done by Harrington et al., who quantified EPR-mediated passive 
tumor accumulation using 111In-labeled PEGylated liposomes a radiolabeled nanocarrier (111In-
labeled PEGylated liposomes) in patients suffering from different types of tumors.22 In total, 
the levels of accumulation varied from 2.7 to 53.0% of injected dose (ID)/kg of tumor. The 
highest accumulation was observed in head and neck cancer (33 ± 16% ID/kg), intermediate 
accumulation was noted in lung carcinoma (18 ± 6% ID/kg), and relatively low levels were 
detected in breast cancer (5 ± 3% ID/kg). The results indicated that a high degree of 
heterogeneity in tumor uptake of for this nanomedicine, both between patients with different 
types of tumors and between patients with the same tumor type is present.23 Due to the 
variability of the EPR effect, nanoparticles are designed with active targeting ligands that can 
bind to specific receptor on the cell surface (Figure 2b). Here, the strategy is based on the 
overexpression of receptors on tumor cell compared to healthy cells. Therefore, the 
probability to bind to the intended target is increased. However, the non-specific interaction 
with plasma proteins impair active-targeting strategies since the adhered proteins may shield 
targeting ligands and these nanocarriers might lose their targeting capability.24  
1.1.3 Impact of nanocarrier design on drug delivery  
Despite efforts to develop non-invasive administration (for example, oral, pulmonary, nasal 
and transdermal) in cancer therapy, most nanocarriers are administered intravenously for 
systemic transport to the malignant tissue. Multiple biological steps in the systemic delivery 
can influence the fate of the nanotherapeutic including nanocarrier-protein interaction, blood 
circulation, extravasation into and interaction with the perivascular tumor microenvironment 
(TME), tumor tissue penetration and cell internalization. Conversely, the properties of 
nanocarriers such as size, surface features, geometry, elasticity, rigidity, composition and 
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targeting ligand can influence these biological processes; thus, influencing the delivery of the 
therapeutic agent (Figure 3a).25 
 
Figure 3. The impact of nanocarrier design on systemic delivery. (a) Nanocarriers from 
different materials have diverse physicochemical properties and can be modified with 
multiple functionalities. The properties affect the fate of the nanocarrier including (b) 
interactions with serum proteins, (c) blood circulation, (d) biodistribution, (e) extravasation to 
tumor microenvironment and penetration within the tumor tissue, and (f) tumor cell targeting 
and intracellular trafficking. (g) Nanocarriers can also display stimuli-sensitive behavior for 
controlled drug release (ID = injected dose).15 Adapted from reference 15 with permission of 
Springer Nature. Copyright 2017. 
Interaction with serum proteins 
After injection, the nanocarrier’s surface is immediately covered with serum proteins which 
yield the formation of a so-called protein corona (Figure 3b).26-27 The adsorption of proteins 
alters the properties of injected nanoparticles in terms of particle size, stability and surface 
properties. Since the corona provides the exterior entity, it determines the physiological 
response which influences the biodistribution as well as cellular uptake and intracellular 
trafficking (Figure 3c–f). For instance, coverage with opsonins is recognized by the 
mononuclear phagocytic system (MPS) and leads to subsequent sequestration.28 Vice versa, 
the nature of protein corona depends on nanoparticle properties including size, the surface 
chemistry, and hydrophobicity.21 This can be used to prompt the binding of proteins which 





There is a close connection between the blood circulation time and the effectiveness of 
passive extravasation and accumulation of the nanocarrier in tumor tissue (Figure 3c). 
Therefore, it is desirable to design nanoparticles that show prolonged circulation. The fast 
renal and biliary clearance usually is avoided by the application of nanocarriers with sizes 
above 10 nm and neutral charge. However, nanoparticles with sizes over 10 nm need to be 
biodegradable to avoid long-term accumulation in the body and to allow clearance from the 
body. The liver and spleen typically filter particles in the range of 200–500 nm, but do not 
necessarily excrete them.30 Therefore, nanoparticles should be smaller for systemic 
applications or if larger than 200 nm, they need to display a soft and deformable nature to 
stay in circulation. Another major factor limiting circulation time is the nonspecific interaction 
between nanocarriers and serum proteins discussed above, which can promote opsonization, 
recognition, and sequestration by the MPS. The grafting of poly(ethylene glycol) (PEG) to the 
surface is a common strategy to reduce interaction with the plasma proteins since PEGylation 
provides a hydrated layer31. This provides the carrier with so-called ‘stealth’ properties as the 
hydrophilic and neutral nature of the polymer induces steric repulsion of plasma constituents. 
Another strategy is the coating of nanoparticles with cell membranes extracted, for instance, 
from red blood cells to provide a biomimetic surface.32 The elasticity of particles has been 
recognized to influence MPS sequestration showing longer circulation times for soft and 
flexible particles.33 
Extravasation to malignant tissue 
At the site of disease, escaping the circulation is required to enter the diseased tissue 
(Figure 3d+e). For malignant tissue, disorganized vasculature due to uncontrolled 
angiogenesis leads to endothelial dysfunction and blood vessel fenestrations. This ‘leakiness’ 
is distinct from healthy tissue and promotes the accumulation of nanoparticle as mentioned 
before. Besides the abnormal tumor vasculature, the physicochemical properties of 
nanocarriers impact the tumor extravasation and accumulation. For instance, 30, 50, 70 and 
100 nm polymeric micelles all demonstrated similar extravasation and therapeutic activity in 
hyperpermeable murine colon adenocarcinoma, whereas only the 30 nm micelles showed 
sufficient accumulation in hypopermeable pancreatic tumors.34. Interestingly, nanoparticle 
shapes with elongated structures tend to accumulate and adhere to endothelial cells better 
than spherical particles and can, therefore, enhance the extravasation into tumor tissue.35 
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Tumor penetration 
While extravasation and accumulation are crucial in drug delivery, deep and uniform tumor 
penetration of nanotherapeutics need to be addressed for optimal therapeutic outcomes 
(Figure 3e). The TME present several physiological barriers to the delivery of nanomedicines 
such as heterogeneous tumor vasculature and constricted vessels due to growth-induced 
stress. Furthermore, a dense extracellular matrix composed of collagen fibers and other 
proteins, and the elevated interstitial fluid pressure (IFP) induced by hyperpermeability of the 
abnormal vasculature and lack of functional lymphatics in the tumor tissue impair the delivery 
(Figure 4).  
 
Figure 4. Intratumoral barriers to nanocarrier-based drug transport.36 Reprinted with 
permission of reference 36. Copyright 2016 American Chemical Society. 
The elevated interstitial fluid pressure reduces convective transport away from the site of 
extravasation, while dense extracellular matrix hinders diffusion of nanoparticles into the 
interstitial space.37 This results in barely diffused tumor core which displays a harsh 
environment with low pH and low oxygen pressure.38 Here, the most aggressive tumor cells 
are harbored that have the potential to regenerate the tumor if not eliminated completely.39-
40 Furthermore, low exposure of drug in some regions of the tumor could promote the 
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development of drug resistance.41-42 Studies have demonstrated that size and binding affinity 
of the nanocarrier affect both diffusion kinetics and depth of tissue penetration. For optimal 
tumor penetration, the physicochemical properties of the nanocarrier need to be carefully 
tuned to penetrate the diffusional barriers.  
Large sizes of nanoparticle impede the efficient penetration of the DDS since they become 
trapped in the dense extracellular matrix shortly after extravasation.43 Cabral et al showed 
that nanocarriers aiming for high EPR-based accumulation (100 nm) do not easily penetrate 
into tumor tissue which leads to heterogeneous distribution of the DDS in the malignant tissue 
after extravasation of the nanoparticles from the vasculature.36, 43-45. Smaller nanocarriers 
(30 nm) could more readily diffuse within the tumor tissue. However, when the particles 
become very small particles (<5 nm) they are quickly cleared from the tissue. An optimal size 
that balances drug accumulation and penetration of tumors is critical for improving the 
therapeutic efficacy of nano-based drugs.  
In addition, the high affinity of target ligands and antibodies has an impairing effect on the 
penetration because these structures are immobilized by the strong binding or the 
internalization into cells close to the extravasated area. Several strategies have been 
employed to improve the intratumoral delivery.43, 46 The use of promoter drugs has been 
suggested. These physiologically active agents improve the exposure of tumor cells to 
anticancer drugs by increasing the blood flow or by reducing endothelial barrier function, 
interstitial pressure, or stromal barriers.47 Another strategy is to employ hyperthermia to 
increase the vascular permeability of macromolecular delivery systems.48 Directly modulating 
the tumor stroma by extracellular matrix (ECM) degrading enzymes like collagenase or 
hyaluronidase have also been employed to enhance nanocarrier distribution in tumors.49 
These strategies can be combined with nanomedicine in order to modulate the tumor tissue 
for a more effective nano-based treatment. With regards to the nanocarrier themselves, 
Surface modification with tumor penetrating peptides, such as the cyclic peptide 
CRGDK/RGPD/EC (also called iRGD), has been shown to increase the depth of delivery into 
tumor tissue.50 Recently, multistage systems have been proposed to address the low 
penetration of nanoparticles.51 When the particles reach the tumor, they release smaller 
entities upon exposure to the TME. These units can then more readily diffuse within the dense 
interstitial space. 
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Cell internalization 
Cell internalization can also have an impact on enhancing retention in the tumor and usually, 
nanocarriers are expected to overcome the cell membrane to deliver its cargo for therapeutic 
effect in the cytoplasm or nucleus (Figure 3f). While small, hydrophobic molecules can simply 
diffuse through the membrane, nanoscale constructs usually require active uptake 
mechanisms. Several endocytic mechanisms can be prompted to facilitate the internalization 
of nanocarriers.52 During endocytosis, plasma membrane invagination results in the 
internalization of externally disposed solutes, particles, or pathogens. The distinct mechanism 
of endocytosis is important as it determines the path of trafficking through various subcellular 
compartments. For example, clathrin-mediated endocytosis leads to localization in lysosomal 
compartments, whereas internalization through a caveolin-mediated process is not.53 The 
upper size limit of a clathrin-coated vesicle is around 200 nm external diameter, which should 
be considered when designing a nanocarrier system. In clathrin-mediated endocytosis, the 
pathway eventually leads to lysosomes with harsh acidic and proteolytic conditions which 
contribute to the degradation of nanoparticles, drug, and genetic material. Here, endosomal 
escape is necessary to avoid degradation and to reach the desired cellular compartment. 
Multiple strategies have been tested to facilitate endosomal escape into the cytosol, such as 
pore-forming peptides and proteins or pH-buffering substances utilizing the “proton sponge 
effect”.54 The mode of cellular internalization can be modulated by the attachment of ligands 
on the surface of nanoparticles (Figure 3f). For instance, folic acid, albumin, and cholesterol 
have been shown to promote uptake through caveolin-mediated endocytosis, whereas 
ligands for glycoreceptors trigger clathrin-mediated endocytosis.55 As an alternative, the 
presentation of cell-penetrating peptides, such as a trans-activating transcriptional activator 
peptide on the surface of nanoparticles can facilitate macropinocytosis.56 The nanoparticle 
surface properties also influence the internalization. In particular, cationic surface charge is 
associated with increased internalization for different cell lines. Since cationic particle can be 
recognized by the MPS, charge-conversion strategies aimed at site-specific switching of 
surface charge in response to environmental stimuli, such as pH.57 
Finally, the therapeutic agent needs to be released at the site of disease which can be enabled 
by different modes including diffusion- and degradation-based mechanism (Figure 3g). To 
precisely control the drug release, stimuli-responsive bonds and moieties can be introduced 
into the nanocarrier which will be discussed in detail in chapter 1.2. In general, stimuli-
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sensitive nanocarrier respond to environmental changes associated with the TME and tumor 
cells (e.g., pH, redox state, and enzymes) or can be activated by external stimuli ( e.g., 
temperature, light, magnetic field, or ultrasound) to trigger the release of the payload.58 
Takin all this into account, certain general requirements for the design of drug delivery 
vehicles for intravenous administration can be stated. These include the possibility to carry 
enough dose of the respective drug with high stability in circulation aiming for minimal 
elimination or degradation of the cargo. Moreover, the carrier should avoid non-specific 
interactions with plasma components and fast organ clearance to enable longer circulation. 
This provides the basis for active or passive targeting to the diseased tissue. The carrier should 
enable efficient distribution through the malignant tissue and the interaction with cells has to 
be tailored to ensure cellular internalization; e.g., by adsorption or endocytosis. Optimal 
would be a controlled drug release mechanism to increase the specificity of the DDS. In 
addition, nanocarriers should be biocompatible and non-immunogenic. As the parameters for 
maximum efficacy in drug delivery are better understood, a diverse range of nanostructures 
has been evolved to incorporate design features to address these requirements (Chapter 1.3). 
1.1.4 Prodrug concept 
An established concept in medicinal chemistry to reduce the side effects of parental drugs and 
improve targeted delivery is to suppress the activity and thereby mask the toxicity by attaching 
other chemical groups. These so-called prodrugs are chemically modified versions of the 
pharmacologically active agent that are converted by chemical or enzymatic reactions in vivo 
to release the active drug. Besides masking the toxicity, prodrugs can also improve 
physicochemical or pharmacokinetic properties of a drug, for instance, by enhancing 
membrane permeability or solubility, and by prolonging activity.59 Esterification of charged 
groups such as carboxylic acids and phosphates is commonly used to enhance the lipophilicity 
of the parent drug improving the passive membrane permeability.60 In a physiological 
environment, esters can be easily hydrolyzed by ubiquitous esterases found in the blood, liver 
and other organs and tissues.  
Regarding cancer therapy, site-specific activity is crucial to reduce side effects. Elevated levels 
of enzymes in tumor tissue have been exploited to activate the prodrugs61 As an example, 
capecitabine is an orally administered carbamate prodrug of 5-fluorouracil that undergoes 
three enzymatically catalyzed reactions to release the active drug (Scheme 1). Besides 
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enzymes, other stimuli can be employed to activate the drug at the site of tumor tissue; e.g., 
acidic pH, hypoxia, or reductive species. 
 
Scheme 1. Enzymatic bioconversion of capecitabine to 5’-fluorouracil. 
In accordance with the prodrug concept, the conjugation of a drug through a cleavable linker 
to a polymeric carrier can result in a macromolecular prodrug (Chapter 1.3.1). This requires 
that the drug has distinctly decreased activity when bound to the carrier and upon cleavage 
of the linker under tumor-associated or intracellular conditions, the parental drug is released. 
Overall, the use of prodrugs in drug delivery provides important benefits such as: (i) a 
controlled drug release mediated by chemical or enzymatic hydrolysis of the prodrug; (ii) an 
increase of the drug stability and solubility and, (iii) a reduced toxicity before activation.59 The 





1.2 Stimuli-responsive nanomaterials 
Besides passive and active targeting, on-demand processes are a smart strategy to achieve 
nanomedicine-mediated tumor targeting. Nanomaterials offer a platform to incorporate 
stimuli-sensitive moieties into a drug delivery system, by exploiting different materials and 
interactions. Stimuli-responsive nanomaterials can be distinguished by the function that is 
performed upon stimulus such as drug release, morphological change 
(shrinkage/swelling/rearrangement), partial or complete disintegration, catalytic action or 
energy conversion (heat production) or by the stimulus that triggers the response. In general, 
these stimuli can be divided into the ones that originate from an external source or the ones 
that exploit internal alterations (Figure 5).  
 
Figure 5. Overview of external and internal stimuli to trigger responsive drug release and 
associated design challenges.13 Adapted with permission of reference 13 under Creative 
Commons license (http://creativecommons.org/licenses/by/4.0/). 
Internal stimuli have the advantage that the nanocarrier can be triggered autonomously but 
it can be challenging to reach the site of action in the first place. In addition, the claimed 
alterations used as an internal trigger can differ between preclinical and clinical models. The 
challenges for external trigger lay in the selective application of the exogenous stimulus which 
may require elaborate techniques and equipment that may not be practical or cost-effective. 
Another problem with exogenous stimuli can arise from the depth of penetration required for 
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applications in the body. Furthermore, the need for site-specific application of the external 
stimulus implies that the diseased tissue can be spatially differentiated from healthy tissue, 
which could be questionable for certain diseases such as infiltrative neoplasms. 
Since the stimulus is restricted to the site of the disease (endogenous) or is applied at the 
disease site (exogenous), a control over the spatiotemporal activation of the nanomedicine is 
obtained. This requires that the cargo is not active when associated with the carrier and that 
both form a stable linkage through either covalent or non-covalent interactions. This approach 
is complex as it requires the application of biocompatible materials that can undergo a specific 
response to an applied stimulus which may include protonation, hydrolytic cleavage, a 
molecular or supramolecular conformational change, or a response to specific physical 
stimulation (Figure 6).58  
 
Figure 6. Chemical functionalities and polymers utilized for responsive behavior.62 Adapted 
with permission from reference 62. Copyright 2018 Royal Society of Chemistry. 
To introduce stimuli-sensitive behavior, dynamic covalent chemistry or non-
covalent/supramolecular interactions are applied. Dynamic covalent chemistry relies on the 
reversible formation and cleavage of strong covalent bonds. Therefore, it combines the 
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rearrangement capability of supramolecular chemistry and the robustness of covalent bonds. 
Compared to supramolecular interactions, dynamic covalent reactions usually have slower kinetics 
and require the assistance of catalysts to achieve rapid equilibrium.63 In the scope of drug delivery, 
these catalysts are the stimuli to trigger a specific response and include protons, enzymes, redox-
active substances, among others.  
1.2.1 Exogenous stimuli 
Drug delivery systems that take advantage of externally applied stimuli such as ultrasound, 
magnetic field, light, and temperature, offer spatiotemporal control over the activation of 
materials. Here, the idea is that the activation or cargo release can be induced directly at the 
desired site by application of an external source.  
Thermo-responsive polymers have been used as building blocks to create smart drug delivery 
system that present precise control of the response towards a thermal trigger.64 Two types of 
thermoresponsive polymers can be distinguished which present either a lower critical solution 
temperature (LCST) or an upper critical solution temperature (UCST). LCST and UCST represent 
respectively the critical lower and upper temperature below and above the polymer and 
solvent are completely miscible.65 Polymers that exhibit an LCST are perfectly soluble in water 
below the transition temperature. When the environment is heated above the LCST, the 
polymer chains dehydrate and become water insoluble caused by a change of the hydration 
state. Poly(N-isopropylacrylamide) (PNIPAm) is the most extensively studied 
thermoresponsive polymer with an LCST around 32 °C.66 It is a versatile building block since 
the transition temperature can be conveniently adjusted by copolymerization with other 
acrylic monomers. If hydrophilic monomers like acrylic acid (AA) are incorporated randomly 
into the polymer, the phase transition temperature is increased.67 Micelles based on block-
co-polymers incorporated thermoresponsive polymers to use the hydrophilic-hydrophobic 
transition to assemble or disassemble and thereby trigger cellular uptake68-69 or release an 
encapsulated guest.70 Thermoresponsive NGs are a versatile tool for drug delivery. 
Thermoresponsive NGs incorporating acrylated dPG as macrocrosslinker into PNIPAm NGs 
have been introduced with tunable transition temperature depending on the dPG content. 
The hydrophilic dPG avoided macroscopic precipitation of the NGs but still showed a 
significant decrease in size above the LCST.71 Other monomers, like N,N-diethylacrylamide, 
methylvinylether, N-vinyl caprolactam, Nethyl oxazoline, Poly(oligoethylene glycol) 
methacrylates, and N-isopropylmethacrylamide, as well as natural occurring peptide motifs 
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that show thermoresponsive behavior such as elastin, collagen, gelatin have been investigated 
as well. The most commonly employed UCST polymer in drug delivery is poly(2-vinylpyridine). 
Ultrasound has been used as diagnostic tool but also as a trigger for drug release; e.g., from 
sensitive polymeric matrices by site-specific sonication. Ultrasonic contrast agents are 
encapsulated in the nanocarriers that release microbubbles which can be imaged for 
diagnostic purposes. This strategy has also been applied for ultrasound-mediated drug release 
from NE. Paclitaxel-loaded NE was locally converted into microbubbles in malignant tissue 
under the action of tumor-directed ultrasound.72 In addition, ultrasound can promote the 
uniform distribution of nanocarriers and drug throughout the tumor tissue.73 
The use of magnetic actuation can be employed to remotely guide the drug delivery system 
to the target site.74 Furthermore, one intrinsic property of magnetic materials is their ability 
to produce heat when exposed to an alternating magnetic field which can be applied for 
hyperthermia treatment. In combination with thermoresponsive polymer, this can be used as 
an actuator for drug release.75 Iron oxide nanoparticles are the most commonly used 
component to this end. To allow biomedical applications, magnetic particles are usually 
merged with polymeric materials. The magnetic particles are generally either embedded into 
the polymer matrix or core-shell type nanocarriers are employed.74  
Light-sensitive nanodevices display a photochemical reaction upon irradiation.76 Different 
mechanism for light-sensitive moieties have been employed that can undergo isomerization, 
oxidation, or bond cleavage which leads to disassembly of the nanocarrier or release of a 
therapeutic agent. In addition, surface plasmon absorption and photothermal effects are 
other forms of photochemical properties that can be used for therapy and diagnostic. Light 
usually suffers from low penetration depths (∼10 mm) as a result of strong scattering and 
absorption in soft tissue. Depending on the depth of penetration required for applications, 
penetration of the radiation may become an issue. Incorporation of bonds that are sensitive 
to longer wavelength allows the application of NIR laser (700−1000 nm) as the trigger which 
enables deeper tissue penetration.77 
1.2.2 Endogenous stimuli 
Endogenous stimuli refer to altered conditions within certain cellular compartments or in the 
diseased tissue. These stimuli include local environmental factors such as pH, redox potential, 
and temperature, as well as enzymes, ionic strength, small molecules, partial oxygen pressure, 
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osmotic pressure, nucleic acids, proteins, and peptides. Enzymatically catalyzed processes 
present ideal triggers for the selective responses due to the high specificity for their substrate 
and their catalytic properties. Highly specific cleavage-activated systems like enzyme 
activation and phosphorylation are widely found in biochemistry, and therefore inspiration 
should be taken from nature as a model I incorporate similar designs in drug delivery systems.  
pH-sensitivity 
Extra- and intracellular pH gradients are utilized as an endogenous trigger for DDS which 
selectively release their therapeutic cargo at the site of action. Nanocarriers with pH-sensitive 
modalities can facilitate the release of the payload at the targeted disease by either swelling, 
shrinkage or degradation of sensitive crosslinks.78 The most obvious gradient with extreme pH 
values can be found in the gastro-intestinal systems from very acidic to basic (~2.0–8.0). This 
presents a challenge as well as an opportunity to design controlled release delivery systems 
for oral administration. In addition, pathological states such as in inflamed, infected, or 
malignant tissue are associated with lower pH values that differ from the physiological pH of 
7.4. In cancer tissues, the cells predominantly produce their energy through a high rate of 
aerobic glycolysis followed by high lactate formation resulting in lower extracellular pH of 6–
7.79-80 During endocytic internalization, the pH decreases from typical extracellular pH values 
of 7.2-7.4 to reduced pH of 6-6.8 in endosomes. Further endosomal processing leads to pH 5-
6 in the late endosome stage.81 Finally, endocytosed materials may be delivered to the 
lysosomes with pH reduced to 4-5. Interestingly, viruses take advantage of those pH gradients 
to access the cytosol by a pH-triggered conformational change of viral proteins that allow 
them to penetrate, fuse with, or even completely disrupt the endosomal membrane. 
Polymeric micelles, polymersomes, and nanogels have been provided with tertiary amino, 
carboxyl or other ionizable groups that can act as pH-sensitive moieties as a change in pH can 
alter the protonation state of these basic/acidic functionalities. The change in protonation 
state can alter hydrophobicity, conformation, or electrostatics leading to morphological 
changes of the scaffold. Upon the variation of pH, these structures swell or collapse due to 
electrostatic repulsion or attraction, respectively. The most common polymers to incorporate 
pH-sensitivity by ionizable groups are poly(acrylamide), poly(acrylic acid), poly(methacrylic 
acid), poly(diethylaminoethyl methacrylate), and poly(dimethylaminoethyl methacrylate) 
(Figure 6).82  
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In polymer-drug conjugates, cleavage of the pH-sensitive linkage that connects the drug to the 
carrier presents a useful strategy to trigger intracellular drug release. For the conjugation of 
drugs to a polymeric backbone, pH-sensitive linkages such as hydrazone, acetal/ketal, 
orthoesters, cis-aconityl, and imines are broadly applied (Figure 7). The hydrolytic stability of 
these bonds depends on the chemical environment which allows the fine-tuning of the 
cleavability towards specific pH values. Therefore, DDS with stable carrier-drug linkage can be 
designed that avoid non-specific and premature release at neutral pH but allow release at 
lower pH for predominately intracellular release.  
 
Figure 7. Overview of pH-sensitive bonds including pH values and cleavage site.83 Adapted 
with permission from reference 83. Copyright 2014 Elsevier.  
The Dox derivative aldoxorubicin contains a hydrazone bond which is one of the most 
successful pH-sensitive functionalities since it is stable at neutral pH but is readily cleaved in 
acidic intracellular compartments. Bearing further a maleimide group aldoxorubicin was 
developed as a thiol-binding prodrug for the auto conjugation to cysteine residues of albumin 
enhancing the circulation time of the drug to increase tumor accumulation. The linker remains 
stable during circulation and can release Dox at acidic conditions present in intracellular 
compartments. Aldoxorubicin is currently in phase III clinical studies for the treatment of soft 
tissue sarcoma and showed progression-free survival in leiomyosarcoma and liposarcoma and 
minimal cardiac toxicity, which represents a significant advantage to Dox.84 Aldoxorubicin was 
also employed to prepare pH-sensitive macromolecular prodrugs based on dendritic 







Many materials in living organisms respond to or are degraded by enzymes. Inspired by this, 
enzymes have been increasingly used as a trigger for responsive materials. In contrast to other 
stimuli-responsive systems, enzymes offer a high selectivity and specificity for their substrates 
and high catalytic activity. In pH- and temperature-responsive systems an equilibrium state is 
reached when the stimulus is applied. This also implies that it can be reverted to their original 
state when the stimulus is not present anymore. On the contrary, enzyme-sensitive systems 
often involve the formation or cleavage of bonds, which are mostly not reversible, except for 
some phosphatase/kinase systems. In general, enzyme-responsive moieties show not only 
structural conversion upon enzymatic reactions but all kinds of changes in functionality 
including variation in chemical as well as physical properties. The incorporation of enzyme-
sensitive functionalities is often based on natural materials like peptide sequences or natural 
polymers. Beside peptide sequences, non-peptide substrates have been used including 
functional side groups (phenols), polysaccharides, and (phosphate-)esters. Besides bond 
formation and bond cleavage, oxidation and reduction, as well as isomerization reactions, can 
be performed by enzymes. In addition, other responses of material are possible upon enzyme 
action: change in hydrophilicity and steric effects, charges or functional groups may be 
introduced or removed, the chain length of block copolymers or crosslinks may be altered. 
Concerning biomedical applications and in particular cancer therapy, the altered expression 
or activity of enzymes in association with the disease can be utilized as a suitable trigger for 
material response. As the enzyme expression is regulated by cells and therefore localized, a 
controlled response at the diseased site is possible. In the past, a range of different enzymes 
has been employed in enzyme-sensitive drug delivery systems. The most common classes are 
proteases, endonucleases, kinases (phosphorylation), and phosphatases (dephosphorylation). 
An overview of enzymes with altered expression in tumor tissue is given in Table 1. The altered 
expression patterns of enzymes represent biochemical signatures that can be used for 
diagnosis or in therapy as a site-specific trigger for drug release. This can be achieved by 
introducing specific substrate sequences either into the nanocarrier scaffold, e.g. as a 
crosslinker or in the linker segment through which the drug is conjugated to the nanoparticle. 
Overexpression of matrix metalloproteinases (MMPs) has been shown to be a relatively 
specific biomarker of malignant tissues. Intracellular proteases, such as cathepsin B, which 
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degrade proteins in lysosomes, have been intensively investigated for the site-specific release 
of drugs by the incorporation of specific peptide sequences.86 
 
Table 1. Overview of enzymes for enzyme-responsive nanocarriers.87-88 
Substrate Enzyme Function Occurrence 
Proteins Cathepsin B 
Cathepsin H 
Cathepsin L 
Lysosomal degradation of 
proteins 
In mammalian cell lysosomes; over-
expressed in various cancer types 
 Cathepsin D Degradation of extracellular 
matrix 
Over-expressed in various cancer 
types 
 Plasmin Fibrinolysis, degradation of 
blood plasma proteins 
In animals; increased concentrations 




Degradation of extracellular 
matrix 
In urine and the blood stream; 




Degradation of extracellular 
matrix and collagens 
In most multicellular organisms 
including animals and plants, 
implicated in several diseases 
including arthritis and cancer 
Sugars β-Glucuronidase Hydrolysis of carbohydrate 
moieties from proteins 
High concentrations in necrotic tissue 
and several cancer types 
Phosphorylation Kinases Activation of signal 
transducers and activators of 
transcription factors 
In the cell membrane; aberrantly 
activated in several cancer cells 
 
Redox potential 
The reductive environments found inside cells can be accounted to the high concentration of 
the tripeptide glutathione (GSH). Composed of L-glutamate, L-cysteine, and glycine, GSH 
presents a cellular reducing agent. Reduced GSH exists at millimolar (0.5–10 mM) 
concentrations in cellular fluids but is only found at micromolar (20–40 µM) levels in blood 
plasma.89 In addition, GSH levels, determined in vitro, were found to be 7–10 fold higher in 
tumor cells than in normal cells.90 The opposing redox environments of intra- and extracellular 
locations provide an opportunity for drug delivery. Disulfide bonds are formed through the 
oxidation of two thiols but can easily be cleaved by a reducing agent to two sulfhydryl 
moieties. These bonds play an important role in the structure and function of proteins, but 
exposed disulfide bonds are generally absent in intracellular proteins as a result of the redox 
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environment inside of cells.91 In accordance, disulfide-containing structures are introduced to 
nanocarriers for targeted drug release exploiting the elevated GSH concentration associated 
with intracellular space in tumor tissue as stimulus. The nanocarriers equipped with disulfide 
moiety are stable during the transport in blood plasma but sensitive to intracellular GSH levels. 
By attaching a drug molecule through a disulfide bond to the nanocarrier, a drug can be guided 
to a particular location and be predominantly released in the cytosol. Alternatively, a drug can 
be entrapped in a nanocarrier that is connected by disulfide bonds. Once the disulfide bonds 
are reduced, the carrier disintegrates and releases the drug. 
Taken together, nanocarriers with responsiveness to endogenous stimuli contain 
preprogrammed abilities to distinguish between diseased and healthy tissue and therefore 
proceed in an autonomous fashion to deliver the therapeutic cargo to the site of disease. 
Nowadays, multimodal system include materials or moieties that combine responsive to 
exogenous and endogenous stimuli into a single, elaborated system and will be discussed in 
the next chapter.92 
1.2.3 Multistimuli responsiveness  
As discussed in chapter 1.1.3, many obstacles; particularly, in the TME impair the successful 
delivery of the nanocarriers. To allow an adaption to diverse barriers, the response to one 
stimulus is often not enough to achieve effective delivery. For example, controlled release of 
the therapeutic payload by acidic pH or redox environment may not be effective to treat solid 
tumors with dense stroma due to poor penetration of nanoparticle when larger than 50 nm. 
Therefore, DDS are required that contain multi-responsive properties to tackle these obstacles 
(Figure 8).93-94 The triggered responses can happen either in a simultaneous way at the target 
site or in a consecutive manner. When the stimuli-induced actions take place in a step-wise 
process in which the nanoparticles facilitate the transport by adapting to each physiological 
barrier encountered, they are also termed multistage delivery systems.51 Here, specific stimuli 
in the TME such as pH or proteases are useful to achieve deeper tumor penetration, increased 
cellular uptake, and/or controlled drug release. 
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Figure 8. Schematic representation of the potential of multi-responsive DDS.95 Adapted with 
permission from reference 95. Copyright 2018 American Chemical Society. 
Nanocarriers have been reported that respond to the slightly acidic TME with size reduction 
by disintegration, sequential swelling/shrinking, or reorganization to facilitate the tumor 
penetration or cell internalization.93, 96-98 It can be noted that the slightly acidic pH exploited 
for these delivery systems may be also found in other sites such as inflamed tissue and that 
the pH difference may be not distinct enough to trigger a response since acidic pH is associated 
with non-vascularized regions of the tumor. Several examples of gelatin nanoparticles that 
encapsulate smaller entities like quantum dots or gold nanoparticle have been presented.99-
101 Here, the idea is that the gelatin shell can be degraded in the TME by extracellular MMPs 
and thereby, the smaller entities are released which can then more readily diffuse within the 
dense interstitial space. Besides size reduction, the change of surface properties or the 
emergence of targeting units can be employed to improve tumor penetration by enhanced 
cell interaction. For example, the dissociation of a neutral PEG shell triggered by stimuli in the 
TME can be applied to expose positive charges or cell penetrating peptides that enhance 
surface-cell interaction.102 Here, hypoxic., redox-, protease-, and acid-cleavable linker have 
been used to obtain PEG detachable nanocarriers. Figure 9 displays further strategies of 
nanocarriers that react to conditions in the TME to enhance the drug transport in tumor and 




Figure 9. Responsive modes of nanocarriers activated by TME.51 Adapted from reference 51 
with permission of Ivyspring under the terms of the Creative Commons Attribution (CC BY-NC) 
License. 
In addition, multi-responsive nanocarrier can also refer to a combination of different therapy 
approaches in one system with the goal to improve therapeutic outcome. For instance, when 
chemotherapy and hyperthermia are combined, the heating of the tumor leads to cell 
ablation, can facilitate the drug release, and at the same time widens the constricted blood 
vessels which allows a more effective distribution of the anticancer drug into deeper layers of 
the tumor.103-104  
1.2.4 Nanotheranostics 
The term theranostic was first mentioned by John Funkhouser 2002 describing his company’s 
business model in developing diagnostic tests directly linked to the application of specific 
therapies.105 Theranostics aim to combine therapeutic and diagnostic applications within a 
single formulation to individualize and improve treatments and has emerged as a highly 
interdisciplinary field since the early 2000s. The possibility of nanocarriers to incorporate 
multiple moieties with different functions in one device makes them an ideal tool for 
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theranostics. This coined the field of nanotheranostics for the application of nanoparticle for 
targeted therapy and diagnosis. 
Imaging modalities 
Different imaging modalities are available for non-invasive diagnostics including optical 
imaging, magnetic resonance imaging (MRI), ultrasound (US), and nuclear imaging (Positron 
emission tomography (PET)/ Single-photon emission computed tomography (SPECT)/ 
computed tomography (CT)).8 Depending on the information that is required an appropriate 
imaging modality can be chosen. Among the mentioned techniques, CT, MRI, and US can be 
used for high resolution anatomical and morphological imaging, whereas nuclear imaging such 
as PET, SPECT and optical imaging are applied to image and quantify functional or molecular 
processes with high sensitivity (Figure 10).  
In general, radiolabeling for PET and SPECT provides deep tissue penetration and high 
sensitivity due to distinctive detection of positron (PET) or gamma (SPECT) emission. These 
techniques are comparatively costly and special cautions must be applied in synthesis and 
handling due to ionizing radiation. MRI provides good soft tissue contrast and gives precise 
anatomical images with good spatial resolution (10-100 μm) and sensitivity. However, MRI, as 
well as CT and US, are semi-suitable for molecular imaging since these modalities require pre-
scans, to determine the background level of MRI, CT, and US signal prior to contrast agent 
administration. Optical imaging offers great sensitivity with the ability to detect molecules in 
picomolar concentrations. Here, fluorescence, Raman, and luminescence imaging are 
included, where fluorescence imaging is to date the most utilized technique to detect 
information on the molecular level (molecular imaging). Optical imaging is frequently used for 
in vivo imaging of small animals because of its safety and time- and cost-effectiveness. 
However, it is impractical to image deep tissues or large living objectives due to low tissue 
penetration.  
Multimodal imaging 
Due to the limitations and possibilities of the individual modalities, hybrid imaging techniques 
have been developed in which the anatomical information obtained by CT or MRI is used to 
assist in the assignment of functional and molecular information to the organ or tissue. As an 
example, PET and SPECT have relatively poor spatial resolution and lack of anatomical 
information. To allocate the obtained information, they are often combined with MRI and CT, 
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which enable sensitive high resolution soft and hard tissue visualization. Optical imaging used 
in preclinical situations, it is difficult to accurately assign the signal to animal organs and 
consequently, moderately informative feedback on the biodistribution. Therefore, optical 
imaging also profits from hybrid imaging techniques; e.g., in combination with CT. 
 
Figure 10. Non-invasive imaging modalities and overview of their applications, advantages, 
and limitation.8 Adapted with permission from reference 8. Copyright 2015 American 
Chemical Society. 
Theranostics in nanomedicine  
To apply the mentioned imaging modalities, contrast agents are required. Most contrast 
agents used for various imaging modalities are low in molecular weight and therefore suffer 
from similar limitations as small drugs which result in short imaging duration and low signal to 
noise ratio. Consequently, the integration of nanotechnology can improve these limitations. 
Diagnostic agents may benefit from increased stability and a higher accumulation at the target 
site. For example, sizes of iron oxide nanoparticles are tuned in the nanoscale to target 
different organs such as liver, spleen, or lymph nodes for contrast-enhanced MRI (Resovist).  
Besides the improvement of the specificity of contrast agents, the association of diagnostic 
probes with therapeutic nanocarriers can be applied to understand and optimize drug delivery 
to pathological sites and evaluate nanomedicine performance in terms of therapeutic efficacy. 
In this sense, theranostics can help to get a grip on the variability of passive targeting using 
non-invasive and quantitative assessment of tumor targeting efficiency. As an example, 
Mulder et al developed a nanoreporter technique that predicts the efficacy of cancer 
nanotherapy by combining a liposomal nanocarrier with a PET probe.106 Doxil (liposomal Dox 
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formulation) and a Doxil-mimic nanoreporter without Dox but with similar composition, size, 
and physicochemical properties were labeled with 89Zr. When the radiolabeled nanoreporter 
and Doxil were co-administered, they could find a correlation in tumor accumulation. 
Therefore, the nanoreporter can be used to estimate the accumulation of Doxil in tumor with 
a single non-invasive PET session. Apart from liposomes, they were able to predict the efficacy 
of nanotherapy for nanoemulsion and PLGA particles. In addition, a close correlation was 
found between the potency of the EPR effect and treatment efficacy. This approach can be 
used to pre-select suitable patients with acceptable/high tumor accumulation of 
nanomedicine for further treatment and it might thereby provide a rational framework for 
personalizing nanomedicine treatments (Figure 11a).107-108 Preselection of patients can be 
based on different functions of the nanodevice. Besides passive targeting, a selection of 
nanomedicine for a specific patient can be based on the expression receptors or enzyme 
activity which can be determined by non-invasive diagnosis.  
 
Figure 11. (a) Nanotheranostics can help evaluate nanomedicine performance in potential 
patients. Depending on the distribution optimized treatment is applied.109 Copyright 2012 
Elsevier. (b) Monitoring of therapeutic activity and response to therapy with the help of 
nanotheranostics.110 Copyright 2016 Elsevier. 
In addition, to decide whether to apply nanomedicine, it is also crucial to integrate imaging 
during the treatment by closely monitoring therapeutic responses. Here, clinical decisions can 
be facilitated whether a treatment should be continued or whether the drug doses should be 
adjusted. This image-guided therapy includes markers for malignant tissue in surgery and the 
monitoring of the nanomedicine in a non-invasive manner to precisely apply an external 
stimulus. In this regard, nanotheranostics has been discussed as a milestone towards precision 




Activatable theranostic prodrugs 
Within optical image technologies, the most sophisticated imaging methods are functional or 
activatable probes to gain information on biological processes (molecular imaging). The 
physical phenomenon called fluorescence resonance energy transfer (FRET) is in particular 
useful as it allows to monitor molecular distances within a range of 1–10 nm in real time.111 In 
general, FRET is a non-radiative process where an excited donor fluorophore transfers energy 
to a ground state acceptor through long-range dipole-dipole interactions. The energy transfer 
depends on many factors, such as the extent of spectral overlap, the relative orientation of 
the transition dipoles and, most importantly, the distance between the donor and acceptor 
dye.112 The distance dependence makes FRET a useful tool to observe conformational changes 
and protein-protein interactions.113 Furthermore, FRET is ideal to investigate bond cleavage 
or triggered release from a carrier in the context of a living system.114  
In fundamental studies, Mulder et al. used activatable FRET-probes to follow not only the fate 
of the nanoparticle after intravenous administration but also the release of a model drug in 
vivo. They connected the fluorescent dye Cy5 (donor dye) to PLGA-PEG polymers that self-
assemble to nanoparticles and used Cy7 (acceptor dye) with different hydrophobic tails as 
model drugs.115 By disruption of FRET, they could follow the release of the model drug in real 
time and the biodistribution of the nanocarrier in a tumor mouse model. They evaluated how 
the model drug–carrier compatibility affected the drug release and found that the 
hydrophobicity of the drug and its miscibility with the nanoparticles determine its 
accumulation in the tumor. These findings were applied to improve delivery of the 
chemotherapeutic drug Dox by increasing its compatibility with the nanocarrier. For this 
purpose, Dox was modified with hydrophobic tails linked through a hydrazone bond, thereby 
generating a prodrug approach. The modified drug achieved better antitumor efficacy due to 
higher compatibility with the hydrophobic nanocarrier. These result help to elucidate the fate 
of nanomedicine in vivo fate and provide guidelines for efficient drug delivery of self-
assembled nanocarriers. 
Besides clinical and preclinical studies, theranostic probes can be used as a research tool to 
further elucidate the mechanisms of action that are present during the delivery process and 
thereby increase the understanding of fundamental processes crucial for a successful 
delivery.116 For that purpose, activatable probes are designed that provide temporal and 
spatial information about the fate of the nanocarrier/drug and the occurrence of cleavage, 
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dissociation or conformational events during the delivery process on the cellular and even 
molecular level. Theranostic prodrugs have been shown to deliver and release the therapeutic 
drug Dox intracellularly mediated by biothiols in real time.117 Zhang et al. reported a dual FRET 
prodrug with the capability of real-time drug-release monitoring and in situ cell-apoptosis 
imaging (Figure 12).118 For this purpose, they connected the quencher dye 4‐
(dimethylaminoazo)benzene‐4‐carboxylic acid (Dabcyl) in proximity to DOX and 5(6)‐
carboxyfluorescein (FAM) which efficiently quenched the fluorescence of both. DOX was 
linked through a hydrazone bond that is cleaved under acidic conditions enabling the real-
time monitoring of DOX release whereas FAM was connected through a caspase3 enzyme-
responsive Asp-Glu-Val-Asp (DEVD) peptide sequence enabling caspase-3 imaging capabilities. 
This provides a cascaded imaging of real‐time drug release and subsequent cell apoptosis, 
which enables the direct, precise and quantitative in situ detection of the cell response and 
the therapeutic efficacy for the evaluation of the prodrug. 
 
Figure 12. Double FRET theranostic probe allows imaging of drug release and therapeutic 
effect within one probe. Reprinted with permission from reference 118. 118 Copyright 2015 
John Wiley and Sons. 
The theranostic prodrug approach was also extended to evaluate also non-fluorescent drugs 
by the incorporation of an activatable reporter unit between the cleavable trigger moiety and 
the therapeutic drug. The self-immolative nature of the prodrugs leads to cascade reaction 
that leads to the activation of the reporter and release of drug at the same time. For the optical 
probe, examples exist using a pair of identical dyes that exhibit homo-FRET due to self-
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quenching when in proximity and are activated by enzymatic activation,119 a latent 
fluorophore that is activated upon substrate cleavage and rearrangement,120 or recently a 
chemiluminescence diagnostic moiety that has superior signal‐to‐noise ratio during in vivo 
imaging.121 
As the prodrug concept, the theranostic prodrugs can be adapted for polymeric systems by 
smart synthetic design that includes a nanocarrier, a therapeutic cargo, a trigger moiety and 
a reporter entity in one nanotheranostics system. Zhao et al. reported a prodrug-based 
supramolecular amphiphile that was formed via host-guest interaction for the delivery of 
camptothecin.122 The prodrug host-guest complex self-assembled in aqueous solution to give 
nanosized vesicles that disassembled in the presence of glutathione. The assembled system 
was utilized as a drug/gene vector to achieve combinational gene therapy and chemotherapy 
with intracellular imaging of drug release in real time. For micellar architectures, the release 
of drug was followed by a light-induced change in polarity of the drug that can be followed by 
fluorescence due to the phototransformation to a fluorescent counterpart.123 
Theranostic polymer-drug conjugates were designed based on N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer for non-invasive intravital monitoring of drug release in 
real-time.124 The fluorescence-based monitoring of site-specific drug release was feasible by a 
self-quenched near-infrared fluorescence probe. Two HPMA copolymer-based systems were 
presented where the diagnostic system consists of self-quenched Cy5 dyes and the 
therapeutic system contains the anticancer agent paclitaxel were linked by an enzymatically 
cleavable linkage. Both HPMA copolymer released the drug/dye upon enzymatic cleavage 
which was accompanied by the activation of the fluorophore. Therefore, the probes could be 
applied to image breast cancer progression and drug release in vivo.  
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1.3 Classes of nanocarriers  
During the last decades, architectures for the delivery of pharmaceuticals with diverse forms, 
sizes, and surface properties have been designed that can be classified in polymer-, lipid-, and 
inorganic-based nanocarrier. 125 These include versatile architectures such as liposomes, 
polymer nanoparticles, micelles, dendrimers, as well as inorganic nanoparticles including 
quantum dots, iron oxide, gold, or metal oxide frameworks, among others (Figure 13). 
Eventually, also hybrid nanoparticles combining the materials and their characteristics of the 
mentioned ones evolved. 
 
Figure 13. Schematic illustration of classes of nanoarchitectures used in drug delivery. 
1.3.1 Polymeric nanostructures 
The application of polymers or macromolecules as building blocks for nanocarrier platforms is 
widespread due to the variability and versatility in structure and physicochemical 
properties.126-127 In the last decades, polymeric architectures evolved into more complex 
structures to encounter the requirements for effective drug delivery.128 Nano-sized 
macromolecular architecture ordered from smaller to bigger structures (with overlap) include 
dendrimers/dendritic polymers (1–15 nm), polymer-drug/protein conjugates (5–20 nm), 
polyplexes (40–60 nm), polymeric micelles (20–100 nm), polymersomes (40–800 nm), nano- 
and microgels (50 nm-1 µm) and polymeric nano- and microparticles (40 nm–>1 µm) 
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(Figure 14). One key feature of these nanostructures is the opportunity to design 
multifunctional DDS that combine the (i) polymeric nanocarrier, (ii) a targeting moiety, (iii) a 
therapeutic agent, (iv) controlled therapeutic activation, and/or (v) an imaging probe.  
 
Figure 14. The dimensions of macromolecular nanostructures for drug delivery. 
Polymer-drug conjugates 
The concept of applying polymeric structures for drug conjugation has been introduced by 
Helmut Ringsdorf with his universal model that consists of a synthetic hydrophilic polymeric 
backbone with one or several drug molecules preferentially attached through cleavable 
linkers. He further proposed that the conjugates can be optimized by the attachment of 
functional moieties to increase the solubility, include active targeting or imaging probes for 
diagnostic.129-130 
Together with other polymeric systems including polymeric drugs, protein–polymer 
conjugates, polymeric micelles covalently linked to drugs, multicomponent polyplexes and 
prodrug–protein complexes, polymer-drug conjugates are described with the term polymer 
therapeutic.131 These systems are designed to address several of the key issues faced during 
drug delivery, including prolonged blood circulation times, targeting, accumulation and 
retention.132  
Several polymeric materials from natural and synthetic origin have been explored for their 
potential as macromolecular nanocarriers. Natural polymers based on amino acids (peptides 
and proteins) or sugars (polysaccharides) have been evaluated as matrix material for 
nanocarriers for drug delivery owing to their intrinsic biocompatibility and biodegradability.133 
Polysaccharides include agarose, alginate, carrageenan, hyaluronic acid, dextran, and 
chitosan; whereas protein-based nanoparticles made of collagen, albumin, and gelatin are the 
most widely studied systems. Albumin was used in nanoparticulated systems as it offers 
specific binding sites for functionalization.134 The albumin-based conjugates of paclitaxel, 
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Abraxane, is an approved therapeutic to treat breast cancer, lung cancer and pancreatic 
cancer.135 
Synthetic polymers for biomedical application encompassed for a long time mainly linear, 
random-coil polymer. Among them are PEG; vinyl-based polymers such as poly(N-(2-
hydroxypropyl) methacrylamide) (PHPMA), poly(vinylpyrrolidone) (PVP), and poly(vinyl 
alcohol) (PVA); polyesters like poly(lactide-co-glycolide) (PLGA) or poly(caprolactone) (PCL); 
and poly(amino acids) such as poly(L-lysine), poly(glutamic acid) (PGA), poly(malic acid) and 
poly(aspartamides).136 The most widely applied macromolecule linked to the therapeutic to 
increase its solubility and circulation time is PEG. PEGylated nanoparticles have generally been 
considered to be benign and inert carriers. However, it has been found that PEG itself can 
evoke an immunogenic response and the search of alternatives is ongoing.137-138 Nowadays, a 
diversity of linear branched and hyperbranched architectures and their hybrids are accessible 
that allow tailored composition of the nanocarrier scaffold (Figure 15). To achieve this 
structural diversity a tremendous effort has been undertaken to develop new polymerization 
methodologies including living anionic polymerization, controlled free-radical polymerization 
(atom transfer radical polymerization (ATRP) and reversible addition-fragmentation chain 
transfer (RAFT)), ring-opening polymerization (ROP), and ring opening metathesis 
polymerization (ROMP).  
 
Figure 15. Examples of different polymer architectures for biomedical applications.131 
Adapted with permission from reference 131. Copyright 2003 Springer Nature. 
A key feature to achieve an effective polymer-drug conjugate includes cleavable polymer–
drug linkers that are stable during conjugate transport in blood and able to release drug at an 
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optimum rate upon arrival at the target site. Progress in this area will continue, especially, due 
to new linker methodologies. Synthetic effort has provided new cleavable linker that 
introduces controlled release properties to the conjugates. A promising strategy is the 
utilization of specific short peptide sequences that connect the drug molecules to the carrier. 
Peptide linkers for polymer–drug conjugation were popularized by the emergence of HPMA–
Gly-Phe-Leu-Gly-doxorubicin conjugate (PK1).139 This tetrapeptide linker is stable in the 
circulation but is cleaved by the lysosomal thiol-dependent protease cathepsin B following 
endocytic uptake. 140 pH-sensitive linkages have also been introduced as an alternative for 
drug conjugation. An HPMA copolymer conjugate containing doxorubicin bound via 
hydrazone linkages has shown significantly improved antitumor activity against lymphoma in 
vivo compared with the tetrapeptide conjugate.141  
Two HPMA copolymer–doxorubicin conjugates with peptide linkers and one containing 
galactosamine (PK2) to promote liver targeting have subsequently progressed into Phase I/II 
evaluation. Even though they did not make into clinics, polymer-drug conjugates proved to be 
successful drug delivery strategy which leads to the translation of other polymer therapeutics 
into clinics and several are currently under clinical evaluation in clinics or clinical trial.128 
Dendritic nanostructures 
Dendritic polymers have tree-like structures and encompass hyperbranched polymers, 
dendronized polymers, dendrons, and dendrimers. While dendrimers represent perfectly 
branched systems with a well-defined molecular mass that are prepared in a tedious step by 
step manner, hyperbranched polymers are conveniently prepared in one step but are non-
symmetrical and polydisperse. As nanocarrier, dendritic polymers offer defined and multiple 
functional groups to conjugate several drug molecules while adding targeting, imaging probes, 
and/or solubilizing modalities on the same construct in a controlled fashion.142 A beneficial 
feature of dendritic polymers is the multivalent presentation of surface groups, which 
considerably enhances the binding to cell receptors. Dendritic molecules such as 
polyamidoamine, poly(propylene imine), polyaryl ethers, polylysine, polyester, polyamide, 
polyglycerol, and triazine dendrimers, have been introduced as DDS.143  
Dendritic polyglycerol (dPG) presents a versatile platform for biomedical applications since it 
displays inertness in contact with biological systems.144-146 The synthesis allows for a structural 
range of dPG architectures from perfect dendrons to well-defined hyperbranched polymers, 
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amphiphilic structures, core-shell system, nano-, micro-, and hydrogels that can be optimized 
towards the specific application. The hyperbranched version can be synthesized in a one-step 
anionic, ring-opening multi-branching polymerization of glycidol on a large scale with a 
predetermined molecular weight and degree of branching.147 Materials based on dPG have 
been investigated several applications.148 Besides utilization, for instance, as support for 
organic synthesis and catalysis149 and for the preparation of surfaces with antifouling 
properties,150 dPG has been extensively exploited to design nanocarriers151-152 for drug-83, 153-
154 and gene-delivery,155-157 In addition, polyglycerol-based nano-, micro-, and hydrogel 
formulations158-161 were developed to investigate relevant architectures with various sizes for 
biological targets. 
Nanogels 
Among the macromolecular architectures, nanogels (NGs) are a promising platform for the 
creation of functional materials. Defined as nanometric aqueous dispersions of hydrogel 
particles that are formed by the physical or chemical crosslinking of polymer chains, NGs 
exhibit intrinsic features that are beneficial for the application in biomedicine. 62, 162 These 
polymeric nanoparticles usually possess a soft and hydrophilic nature, which helps to prevent 
unspecific interactions and prolongs circulation times compared to their hard counterparts.163 
The flexible and mechanical deformability enables the squeezing to otherwise inaccessible 
topologies.164 In addition, the size range of NGs between 50 nm and several hundred 
nanometers allows the modulation towards the requirements of the specific application and 
towards similar dimension as biologically relevant structures, such as viruses. 
Furthermore, NGs can incorporate stimuli-responsive polymers into their network to enable 
a triggered reaction ranging from morphological changes such as swelling or shrinkage to the 
disintegration of the polymer network.62 These responsive properties can be exploited for the 
triggered release of cargo, morphological changes or degradation of the gels (Figure 16).165 
Herein, thermoresponsive nanogels allow the controlled release of drug upon shrinking when 
a thermal trigger is applied.71 Apart from temperature-responsive NGs64, stimuli-sensitive 
polymers and bonds have been introduced into the backbone or crosslinking points of 
nanogels that react to endogenous stimuli, for instance, to changes in pH,166 redox 




Figure 16. Possible stimuli-sensitive properties of nanogels.  
For the fabrication of nanogels, multiple methodologies can be employed to obtain a 
crosslinked polymeric system. The most commonly employed methods are miniemulsion, 
precipitation and dispersion polymerization, inverse nanoprecipitation/solvent displacement, 
self-assembly, and template-assisted nanogel formation (lithographic methods, 
micromolding), as well as micelle crosslinking.62 The crosslinking reactions include radical 
polymerization with the vinyl-functionalized monomer, click chemistry (alkyne-azide 
cycloaddition, thiol-ene, Michael addition), Schiff-base reaction to form imine or hydrazone 
bonds, thiol-disulfide exchange reaction, photo-induced crosslinking, ester/amide-based 
crosslinking, and enzyme-catalyzed crosslinking.170 In addition, nanogels crosslinked by non-
covalent bonds can be prepared using ionic or hydrophobic interactions as well as hydrogen 
bonding.171 To form three-dimensional networks, at least one component, the so-called 
crosslinker, needs to present at least two or more reactive groups to form a network with the 
polymer chains. For radical polymerization, monomers can be polymerized in the presence of 
the crosslinker to build the network structure. Alternatively, preformed polymers with the 
corresponding functional groups are reacted in a template-assisted preparation method. 
Polymeric micelles  
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Polymeric micelles are among the most studied macromolecular structures. These structures 
are constructed by the self‐assembly of block copolymers to nano‐scaled drug carriers forming 
a core-shell structure.172 Kataoka et al. focused on the development of polymeric micelles, 
where the drug‐loaded core consists of poly(amino acids) and is surrounded by a 
biocompatible PEG shell, with a narrowly distributed size controllable in the range of 10–100 
nm.173 The desired chemotherapeutic drugs can be incorporated by non-covalent interaction 
within the core or by covalent conjugation to the core-forming polymer block through a 
cleavable linker. Engineering the micelle‐forming block copolymers endowed polymeric 
micelles with on‐demand and smart functionalities such as stimuli-responsive behavior and 
active targeting abilities. The group was able to transfer several systems to clinical trials and 
has currently five micellar formulations incorporating PTX (NK105), cisplatin (NC‐6004), SN‐38 
(NK102), DACH-platin (active complex of oxaliplatin) (NC‐4016), or epirubicin (NC‐6300/K‐912) 
under clinical evaluation.174 Polymeric micelles were found optimal to solubilize lipophilic 
drugs using amphiphilic block copolymers. However, important issues related to instability 
over long periods of time, the short duration of sustained release and poor bioavailability 
remain. Reversible crosslinking of the micelle core is one strategy to target these issues.175   
Polymeric nanoparticles 
Polymeric nanoparticles comprise of synthetic polymers forming a dense polymer matrix that 
is typically stabilized by hydrophobic interactions.176. Commonly used polymers for the 
formation of nanoparticles are polylactide and PLGA which degrade through hydrolysis of 
ester linkages.177 PLGA-based formulations for drug delivery were limited due to issues with 
reproducibility and scalability of polymer synthesis, toxicity due to the premature release of 
therapeutic cargo from nanoparticles, and polymer interactions with the encapsulated drug. 
New biodegradable polymers have been synthesized addressing these concerns;178 e.g., 
poly(caprolactone), poly(anhydrides),179 poly(phosphazenes),180 poly(phosphoesters);181 
poly(alkyl cyanoacrylates)182-183; and poly(orthoesters)184 of which some are at different stages 
of clinical development. For drug encapsulation, methods such as nanoprecipitation, 
electrospray, and emulsification are used. A key advantage of these systems is that they 
enable the controlled release of various cargo, ranging from hydrophobic small molecules to 
large proteins and the release of the cargo can be controlled by the degradation rate.185 As an 
example, solid poly(DL-lactide) (PLA) nanoparticles synthesized using an emulsion solvent 
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evaporation process were loaded with docetaxel and coated with both PEG and prostate-
specific membrane antigen-targeting ligand. The PLA particles are currently in clinical trials for 
the treatment of prostate and lung cancer.186 
1.3.2 Lipid-based nanocarriers 
Liposomes 
The most extensively studied among the classes of DDS are liposomes which are formed by 
self-assembly of amphiphilic phospholipids.187 The liposomal formulation of doxorubicin 
(Doxil) was the first nano-drug that received clinical approval for cancer treatment and marks 
a milestone in the history of nanomedicine. Despite success in the clinical translation of 
liposome-based nanotechnology, some challenges remain.188 The behavior of liposomes in a 
biological fluid is barely understood and their structural design is restricted. In addition, the 
loading capacities of liposomal formulations are comparably low. In combination with 
premature leakage, this results in insufficient drug amount reaching the target. 
Nanoemulsions 
Nanoemulsions (NEs) are biphasic dispersions of two immiscible liquids stabilized by an 
amphiphilic surfactant. The kinetically stable mixtures consist of either water in oil (W/O) or 
oil in water (O/W) nanodroplets with diameters of 20–500 nm.25 In contrast to microscale 
emulsions, NE exhibit optical transparency at high droplet volume fractions, strong elasticity 
at low droplet volume fractions, enhanced diffusive transport and shelf stability. Despite their 
metastability, NE can be stable for years without showing coalescence. NEs are applied in drug 
delivery since the dispersed phase represents a large volume with high drug loading capability 
and the mechanical properties protect them against disruption.189-190  
To form NE, usually, high shear stress using ultrasonication or homogenizer is applied to obtain 
small droplets of the dispersed phase. However, also low energy emulsification methods exist 
that utilize the energy stored in the system to produce ultra-fine droplets. Interactions of oil, 
surfactants, co-surfactants, drug, aqueous component, hydrophilic-lipophilic balance of 
utilized oil surfactant blend, and operative temperature must be optimized to enable low-
energy emulsification.191 Low-energy methods include spontaneous emulsification192, phase 
inversion,193 and the less utilized catastrophic phase inversion method.194 Utilization of such 
method enables the production of NE in large scale without the need for complex equipment 
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or processes. Furthermore, these methods are of interest as they prevent the potential 
degradation of fragile encapsulated cargo compared to the high energy procedure. Drug 
release from NE involves partitioning of the drug from oil into surfactant layer and then into 
the aqueous phase. It has been shown that the drug release can be triggered by application of 
ultrasound by the formation of microbubbles from the NE.72 When such external stimuli 
cannot be applied the drug retention within the formulation can be a concern. To facilitate 
this process, stimuli-sensitive prodrugs could be employed that change their partition 
coefficient after activation, and thereby allow the release of the cargo. Lipid or amphiphilic 
prodrugs can facilitate prodrug loading/insertion in lipid-based nanocarriers by membrane 
insertion. This strategy has been applied for liposomes, solid-lipid nanoparticles, and 
nanoemulsion and has appeared to be a valuable strategy to achieve improvements over 
conventional formulations.115, 195   
1.3.3 Clinical translation of nanomedicine 
Liposomes were the first class of therapeutic nanocarrier for cancer treatment to be 
successfully translated to clinics and Doxil received clinical approval in 1995. Along with other 
lipid-based DDS, liposomes still represent a large percentage of clinical-stage 
nanotherapeutics. Several other therapeutic nanocarrier platforms such as albumin 
nanoparticle, polymeric micelles, iron oxide nanoparticle, and polymeric nanoparticle have 
been approved for cancer treatment. Besides chemotherapy, new nanotechnology-based 
therapeutic modalities are under clinical investigation, including hyperthermia, radiation 
therapy, gene or RNA interference therapy, and immunotherapy (Table 2). 
Even though the number of nanocarrier-based therapeutics for cancer therapy entering 
clinical trials is increasing, many of them fail translation to the market due to disappointing 
efficacy and barely improved survival rates. Major issues are the specificity of drug release 
which leads to severe side effect, the prevention of metastasis which still is a determinant 
factor that impairs patient’s survival, and intratumoral barriers that impede homogenous drug 
transport in the malignant tissue. In this context, the EPR effect was shown to be highly 
variable depending on the tumor type and patient and is not sufficient for optimal targeted 
delivery.196-197 However, novel nanocarriers approaches with multistage or multi-responsive 
characteristics show that nanomedicines can still offer promising solutions in cancer therapy 
even when long-lasting principles such as the EPR effect are compromised. 
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Table 2. Examples of approved and clinical-stage nanomedicines for cancer therapy.15 















doxorubicin (Doxil)  
Pegylated 
liposome  
Doxorubicin HIV-related Kaposi sarcoma, 










SMANCS  Polymer 
conjugate  
Neocarzinostatin  Liver and renal cancer  Approved in 
Japan  
Genexol-PM  Polymeric 
micelle  
Paclitaxel  Breast cancer and non-small-
cell lung cancer 
Approved in 
Korea  
NK-105  Polymeric 
micelle  
Paclitaxel  Metastatic or recurrent breast 
cancer  
Phase III  
Nab-rapamycin 
(ABI-009)  
Albumin NP  Rapamycin  Advanced malignant 
perivascular epithelioid cell 
tumors  
Phase II  
Targeted delivery  MM-302  HER2-targeting 
liposome  
Doxorubicin  HER2-positive breast cancer  Phase II/III  
BIND-014  PSMA-
targeting 
polymeric NP  
Docetaxel  Non-small-cell lung cancer and 
metastatic castration-resistant 
prostate cancer 









ThermoDox  Liposome  Doxorubicin  Hepatocellular carcinoma  Phase III  
Combinatorial 
delivery  
CPX-351 or Vyxeos  Liposome  Cytarabine and 
daunorubicin 
(5:1)  
High-risk acute myeloid 
leukemia  
Phase III  
CPX-1  Liposome  Irinotecan and 
floxuridine (1:1)  
Advanced colorectal cancer  Phase II  
Hyperthermia  NanoTherm  Iron oxide NP  NA  Glioblastoma  Approved in 
Europe  
AuroLase  Silica core with 
a gold 
nanoshell  
NA  Head and neck cancer, and 
primary and metastatic lung 
tumors  
Pilot study  
Radiotherapy  NBTXR3  Hafnium oxide 
NP  
NA  Adult soft tissue sarcoma  Phase II/III  
Gene or RNAi 
therapy  
SGT53  TfR-targeting 
liposome  
Plasmid  Recurrent glioblastoma and 
metastatic pancreatic cancer  
Phase II  
CALAA-01  TfR-targeting 
polymeric NP  
siRNA  Solid tumors  Phase I  
Immunotherapy  Tecemotide  Liposome  MUC1 antigen  Non-small-cell lung cancer Phase III  
JVRS-100  Lipid NP  Plasmid DNA  Relapsed or refractory 
leukemia  
Phase I  




Advanced solid tumors  Phase I  
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2 MOTIVATION & OBJECTIVE 
Despite the high activity of conventional small molecular weight chemotherapeutic drugs, the 
lack of selective treatment results in severe side effects. The highly active anticancer drug 
doxorubicin (Dox) has been approved for several cancer types but shows major drawbacks as 
it is toxic to main organs, especially, the cardiotoxicity is life-threatening and therefore has 
dose-limiting effects. Using nanocarrier-based drug delivery platforms, side effects of 
therapeutic molecules and dose limits can be reduced by shielding the toxicity during 
transport and targeting the site of disease. Multiple barriers that are encountered during drug 
delivery, in particular in the tumor microenvironment (TME), impede nano-based drug 
delivery approaches indicating that conventional tumor targeting strategies alone are not 
sufficient to guide the therapy. However, the TME presents several features that can be 
utilized as endogenous triggers to activate nanotherapeutics. Hence, novel (multi)stimuli-
responsive nanoarchitectures can be designed that adapt to the barriers by taking advantage 
of the altered conditions in the TME and improve targeted delivery by on-demand activation 
of therapeutics. 
The main objective of this thesis is the incorporation of the prodrug concept into responsive 
nanocarrier designs to improve the pharmacological profile of chemotherapeutic drugs and 
tackle the issues of current nanomedicines. To approach this objective, nanocarrier 
architectures with different composition and sizes including polymer-drug conjugates, a 
nanoemulsion (NE), and nanogels (NGs) are combined with prodrugs of the chemotherapeutic 
drug Dox. The prodrugs contain cleavable motifs which provide the drug delivery system (DDS) 
with responsiveness for controlled drug release, change in hydrophilicity of the drug, or 
degradability of the carrier system, respectively (Figure 17).  
The choice of the cleavable motif is a crucial factor for the specificity of response at the site of 
action. This aspect will be addressed using Dox prodrugs with different cleavable linkages for 
a specific response to an endogenous trigger. The different linkages will be evaluated in terms 
of intracellular cargo release and therapeutic activity using activatable fluorescence probes 
for real-time feedback. The assessment of cleavable linker forms the basis for the rational 
design of two prodrug-based nanomedicines with adjusted cleavage properties for 
intracellular drug release or dual-responsive behavior, respectively. In a first facile approach, 
a pH-sensitive prodrug will be combined with a NE as carrier to ensure intracellular Dox 
release. The second more complex nanomedicine aims for the combination of stimuli-
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sensitive bonds with extracellular response to proteases and pH-mediated intracellular 
payload release.  
 
Figure 17. Main objectives of the thesis: incorporation of the prodrug concept into responsive 
nanocarrier designs to build smart nanomedicines for improved antitumor drug delivery. 
To introduce on-demand activation of the delivery system, dynamic covalent chemistry is 
employed using the reversible formation and cleavage of strong covalent bonds. These linkages 
can provide stability for the drug-carrier connection but allow drug release or disintegration 
under specific conditions. To gain information on the performance of the devised DDS, 
activatable fluorescence probes are employed that give real-time information about the 
action of the nanocarrier. In combination, biological methods shall be established including 
cell-based microplate assays and multicellular tumor spheroids for detailed in vitro evaluation. 
This should help to characterize the systems in detail and understand the underlying processes 
in terms of drug-carrier compatibility, drug release, the fate of the carrier, and degradability.  
Section 3 of this thesis comprises three chapters that describe the development and 
evaluation of responsive delivery approaches. Therefore, polymeric and lipid-based 
nanocarrier platforms are combined with prodrugs of the chemotherapeutic drug Dox. 
In section 3.1, the synthesis of theranostic polymer-drug conjugates (TPC) with Dox 
conjugated through different cleavable linkers shall be developed. Cleavage of the conjugate 
is mediated either by acidic environment or by protease activity. These model DDS are based 
on dendritic polyglycerol (dPG) and comprise an activatable fluorescence imaging probe that 
should allow real-time observation of drug release. The TPC are employed to assess the 
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implications of the cleavable linker design on the cell-mediated Dox release using a simple 
cell-based microplate assay. The release profiles should give insight into the fate of the TMP 
as well as temporal information about the drug release depending on the linker and the cell 
line. This theranostic platform could contribute to the characterization of the TPC regarding 
their performance as DDS which, eventually, can be extended to other carrier systems with 
different linkers, drugs, and dyes. Thereby, we try to confirm that the microplate assay can be 
employed to extend the current in vitro methods to evaluate the potential of macromolecular 
DDS. 
The assessed Dox prodrugs shall be employed in the design of novel nanocarrier systems with 
adjusted responsive behavior. In section 3.2, we aim for the development of a pH-sensitive 
Dox prodrug for the efficient entrapment of Dox into nanodroplets of an oil in water NE, as a 
new formulation approach. To achieve the entrapment, Dox shall be modified to provide it 
with an amphiphilic character for increased drug-carrier compatibility. In addition, the pH-
cleavable bond should allow the regeneration of the parent drug and subsequent transition 
from the oil droplets to the aqueous phase endowing the system with controlled release 
capability. The Dox-loaded nanoemulsion will be evaluated in vitro to determine the character 
of drug release and cytotoxicity. In vivo, the new formulation of Dox may reduce off-target 
effects which would allow the administration of higher dosage. Thereby, the treatment of 
tumors should be more effective compared to the free drug and may prevent the formation 
of metastasis. The low-cost and easily scalable nanoemulsion approach could be a promising 
candidate for clinical application in the near future. 
In section 3.3, dPG-based NGs are employed as alternative polymeric architecture to increase 
the size of the carrier endowing the system with improved pharmacokinetic and the possibility 
to incorporate multiple stimuli-responsive moieties. We aim for the combination of protease- 
and pH-sensitive moieties into one multistage delivery system that utilizes the proteolytic 
activity in TME and the intracellular drop in pH to enhance tumor penetration and drug 
distribution within diseased tissue. To implement the crucial design feature, matrix 
metalloproteinase (MMP)-sensitive NGs shall be developed that present suitable sizes to 
potentially accumulate in tumor tissue by the enhanced permeation and retention (EPR) 
effect. The incorporation of a fluorogenic peptide as crosslinker should integrate 
biodegradability into the nanocarrier and endow the nanocarrier with protease-mediated size 
reduction property in response to the TME. To complete the multistage design, a pH-
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responsive Dox prodrug shall be covalently attached to the NGs allowing a stable transport of 
the drug and controlled drug release in the second stage of the delivery. To evaluate the 
potential of the pNGs to promote the penetration of Dox into dense tumor tissue, multicellular 
tumor spheroid shall be established as a 3D model that resembles the tumor tissue physiology 
and TME.  
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3 PUBLICATIONS & MANUSCRIPTS 
In the following section, the published articles and submitted manuscripts are listed and the 
contributions of the author are specified. 
3.1 Modular approach for theranostic polymer conjugates with 
activatable fluorescence: impact of linker design on the stimuli-induced 
release of doxorubicin 
Gregor Nagel, Harald R. Tschiche, Stefanie Wedepohl, Marcelo Calderón, Journal of Controlled 
Release 285 (2018) 200–211. Journal of Controlled Release 2018, 285, 200–211. 
Reprinted with permission from reference 198.198 Copyright 2018 Elsevier. 
The article is electronically available: https://doi.org/10.1016/j.jconrel.2018.07.015. 
 
Figure 18. Schematic representation of modular theranostic polymer conjugates (TPC) for the 
evaluation of linker design. Reprinted with permission from reference 198. Copyright 2018 
Elsevier. 
Abstract: 
The introduction of cleavable motifs by dynamic covalent chemistry is widely applied in the 
design of drug delivery systems (DDS) to introduce controlled release properties. Since the 
cleavable moieties can be triggered by various exogenous or endogenous stimuli, the choice 
of the linker has substantial implications on the performance of the DDS. In this project, a pair 
of theranostic polymer conjugates (TPC) is presented to study the influence of the cleavable 
bond on the cell-mediated drug release by a facile in vitro fluorescence assay. The TPC 
represent model DDS that consist of dendritic polyglycerol as polymeric carrier labeled with 
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an indodicarbocyanine (IDCC) dye and the chemotherapeutic drug doxorubicin (Dox) 
conjugated through different cleavable linkers. Cleavage of the conjugate can be mediated by 
either acidic environment or protease activity. The spatial proximity of the IDCC dye and the 
fluorescent drug led to effective quenching of Dox fluorescence when bound to the carrier. 
The stimuli-induced linker cleavage was correlated with the recovery of fluorescence giving 
real-time information about the stimuli-dependent drug release. By tracking the fluorescence 
recovery in a cell-based high throughput microplate assay, we were able to obtain 
characteristic release profiles of Dox for different cell lines. Here, we found that the pH-
cleavable linker was more suitable for drug delivery applications since the enzyme-sensitive 
system suffered premature release due to the presence of extracellular proteases. This had a 
pronounced effect on the treatment of a multidrug-resistant cell line where an intracellular 
drug release is crucial to overcome the resistance mechanisms. We want to highlight that the 
modular synthetic approach combined with the cell-based assay has potential to extend the 
common in vitro methods to evaluate DDS performance and suitability as the design can be 
easily employed for diverse carrier/linker systems as well as various cell lines. 
Author’s contribution: 
In this publication, the author contributed to the conceptual development of the theranostic 
polymer conjugates (TPC) and the microplate assay. The synthesis and characterization of the 
TPC were conducted by the author including organic synthesis of the linker and prodrugs as 
well as the conjugation to the polymeric carrier. Analytical methods for physicochemical 
characterization of the linkers, prodrugs and the conjugates using NMR, ESI-MS, DLS, GPC, 
fluorescence and UV/Vis measurements were performed and analyzed by the author. In 
addition, the biological testing and data evaluation including the microplate assay, cytotoxicity 
test, and cellular uptake using confocal laser scanning microscopy or cytometry was 
performed by the author. The author developed the outline and wrote the manuscript with 
assistance from the co- and corresponding authors. 
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3.2 Acid-sensitive lipidated doxorubicin prodrug entrapped in 
nanoemulsion impairs lung tumor metastasis in a breast cancer model 
Ana Lygia dos Santos Câmara‡, Gregor Nagel‡, Harald R Tschiche, Camila Magalhães Cardador, 
Luis Alexandre Muehlmann, Daniela Mara de Oliveira, Paula Queiroz Alvim, Ricardo Bentes 
Azevedo, Marcelo Calderón & João Paulo Figueiró Longo, Nanomedicine (Lond.) (2017) 12(15), 
1751–1765. Nanomedicine 2017, 12, 1751–1765. 
‡ Authors contributed equally.  
Reprinted with permission from reference 199.199 Copyright 2017 Future Medicine Ltd. 
The article is electronically available: https://doi.org/10.2217/nnm-2017-0091. 
 
Figure 19. Schematic representation of the synthesis of acid-sensitive Dox prodrug C16-Dox, 
formulation into nanoemulsion (NE-C16-Dox), acid-mediated Dox release, and treatment of 
breast tumor model. Adapted with permission of reference 199. Copyright 2017 Future 
Medicine Ltd. 
Abstract: 
The highly active anticancer drug doxorubicin (Dox) has been approved for several cancer 
types but shows major drawbacks as it is toxic to main organs, especially, the cardiotoxicity is 
life-threatening and therefore has dose-limiting effects. To efficiently entrap Dox in the 
nanodroplets of an oil in water nanoemulsion (NE), we developed a novel Dox prodrug (C16-
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Dox) that provides the drug with an amphiphilic character for increased drug-carrier 
compatibility. pH-sensitive properties of the prodrug allowed a controlled release of the drug 
from the NE. The new formulation of Dox (NE-C16-Dox) was evaluated by in vitro experiments 
in terms of cell internalization and cytotoxicity. In addition, the novel prodrug formulated in 
NE was tested in an in vivo breast cancer model in mice regarding its biocompatibility, Dox 
delivery to tumor tissues and the prevention of metastasis. Improved delivery to tumor tissue 
and reduction of systemic toxicity allowed the administration of higher doses of Dox as 
compared to the free drug. The tumor treatment in a murine 4T1 breast cancer model with 
NE-C16-Dox in high dosage significantly inhibited the primary tumor growth and prevented 
the formation of distant lung metastasis. This is an important finding since the presence of 
metastasis is as a determinant factor for patient survival. The improved chemotherapeutic 
index compared to free Dox indicates that NE-C16-Dox is a promising formulation for breast 
cancer treatment; thus, creating possibilities to translate this nanotechnology concept into 
clinical applications. 
Author’s contribution: 
In this publication, the author contributed to the conceptual development of the Dox prodrug, 
the synthesis, and characterization of the same, and the preparation and characterization of 
the drug-loaded nanoemulsions such as drug release, stability, and data evaluation. Analytical 
data such as NMR and ESI-MS were evaluated by the author. In addition, the author 
contributed to the scientific discussion and experiment design of in vitro studies, the 
preparation of the manuscript, and assisted in writing the report in general. 
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3.3 Matrix metalloproteinase-sensitive multistage nanogels enhance 
drug transport in 3D tumor model 
Gregor Nagel, Ana Sousa-Herves, Stefanie Wedepohl, Marcelo Calderón, submitted 
manuscript. 
 
Figure 20. Schematic representation of the mechanism proposed for multistage drug delivery 
by peptide-crosslinked NG (pNG-Dox). 
Abstract: 
Physiological barriers inside of tumor tissue often result in poor interstitial penetration and 
heterogenous intratumoral distribution of nanoparticle-based drug delivery systems (DDS). 
Hence, novel matrix metalloproteinase (MMP)-sensitive peptide-crosslinked nanogels (pNGs) 
were developed as multistage DDS with a beneficial size reduction property to promote the 
process of deep tissue penetration. The pNG consists of dendritic polyglycerol (dPG) 
macrounits forming nanogel networks with an MMP-sensitive fluorogenic peptide crosslinker. 
The crosslinker integrates degradability to the nanocarrier comprised of otherwise non-
degradable polymers. Surfactant-free inverse nanoprecipitation was employed to prepare the 
nanogels using strain-promoted click chemistry. The size and crosslinking density of the pNGs 
were controlled by the functionalization degree of dPG with cyclooctyne groups and by the 
peptide crosslinker fraction. The intrinsic reporter moiety of the crosslinker allowed us to 
study the influence of different pNG compositions on the degradation profile in detail. One 
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pNG candidate was chosen to conjugate the therapeutic drug Dox through a pH-sensitive 
linkage to the dPG macrounits. The degradable multistage pNGs demonstrated deeper 
penetration into multicellular tumor spheroids (MCTS) as compared to their non-degradable 
counterparts. Hence, the triggered size reduction of the pNGs by enzymatic degradation can 
facilitate the infiltration of the nanocarrier into dense tissue and thereby promote the delivery 
of the therapeutic cargo. 
Author’s contribution: 
In this publication, the author contributed to the concept of dPG-based peptide-crosslinked 
nanogels (pNGs). The development of synthetic methodologies of the pNGs as well as their 
physicochemical characterization, dye labeling, drug release, and degradation studies were 
performed by the author. In addition, the author established a multicellular tumor spheroid 
model for the evaluation of drug and carrier penetration into dense tissue. The outline and 
manuscript were developed and written by the author with the assistance of the co- and 
corresponding authors.  
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ABSTRACT 
Physiological barriers inside of tumor tissue often result in poor interstitial penetration and 
heterogenous intratumoral distribution of nanoparticle-based drug delivery systems (DDS). 
We report novel matrix metalloproteinase (MMP)-sensitive peptide-crosslinked nanogels 
(pNGs) as multistage DDS with a beneficial size reduction property to promote the process of 
deep tissue penetration. The pNG consists of dendritic polyglycerol (dPG) forming nanogel 
networks crosslinked with a modified MMP-sensitive fluorogenic peptide. The crosslinker 
integrates degradability to the nanocarrier by endogenous stimulus present in the tumor 
microenvironment. Surfactant-free inverse nanoprecipitation was employed to prepare the 
nanogels using strain-promoted click chemistry. The size and crosslinking density of the pNGs 
were controlled by the functionalization degree of dPG with cyclooctyne groups and by the 
peptide crosslinker fraction. The intrinsic reporter moiety of the crosslinker allowed us to 
study the influence of different pNG compositions on the degradation profile in detail. One 
pNG candidate was chosen to conjugate the therapeutic drug Doxorubicin through a pH-
sensitive linkage to dPG. The degradable multistage pNGs demonstrated deeper penetration 
into multicellular tumor spheroids (MCTS) as compared to their non-degradable counterparts. 
Hence, the triggered size reduction of the pNGs by enzymatic degradation can facilitate the 
infiltration of the nanocarrier into dense tissue, and thereby promote the delivery of its 
therapeutic cargo. 
INTRODUCTION 
Despite all the advances that have been achieved in the field of nanocarrier-driven drug 
delivery, many challenges remain.1-4 One major obstacle is poor tumor penetration and 
heterogeneous distribution throughout the diseased tissue after extravasation of the 
nanoparticles from the vasculature.5-6 While the accumulation of nanocarrier-based drug 
delivery in tumor tissue mediated by the enhanced penetration and retention (EPR) effect has 
been well established for many setups in vivo, the corresponding improvement of the 
therapeutic efficiency has often been deficient.6-8 This can be accounted, for instance, to the 
hampered penetration and uneven distribution of the nanocarrier in deeper regions of the 
tumor which result from the heterogeneous vasculature, high interstitial fluid pressure, and 
dense interstitial matrix.6, 9-10 Nanocarriers aiming for EPR-based delivery are typically in the 
size of 100-300 nm.5 However, it was found that particles in this size range cannot easily 
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penetrate into the interstitial space,11 leading to a heterogeneous distribution of particles 
within the malignant tissue. This impairs the treatment, and additionally, the barely perfused 
center of the tumor harbors the most aggressive cells that have the potential to regenerate 
the tumor if not eliminated completely.12-14 Low exposure of drug in some regions of the 
tumor could even promote the development of drug resistance.15-16 Conventional small 
molecule therapeutic agents show fast diffusion in tumor stroma, they are however also 
rapidly cleared from body and tissues.  
One approach to improve intratumoral delivery is to carefully design multistage delivery 
systems that utilize specific stimuli in the tumor microenvironment such as pH or proteases to 
either achieve deeper tumor penetration, increased cellular uptake, and/or controlled drug 
release.17-18 The nanocarriers possess design features that allow the response to specific 
stimuli encountered in a consecutive manner.19 Examples have been reported that respond to 
the slightly acidic tumor microenvironment (pH 6–7) with a size reduction by disintegration, 
sequential swelling/shrinking, or reorganization to enhance the diffusive properties of the 
particles.17, 20-22 However, the acidic pH is typically located far from the blood vessels (pH 
gradient) which would hinder the response in the perivascular regions. As enzymatic reactions 
are highly specific and enzyme activity is strongly dependent on location, cell type, or the state 
of the targeted tissue, introduction of enzyme-responsive moieties into NGs can aid to adapt 
the responsiveness of a drug delivery system (DDS) to the abundant proteases in the tumor 
microenvironment.23-24 Therefore, nanoparticles based on the natural polymers gelatin have 
been presented that encapsulate smaller entities like quantum dots or gold nanoparticles.25-
27 The idea of these carriers is that the gelatin shell can be degraded by extracellular proteases 
and thereby release the smaller entities, which can then more readily diffuse within the dense 
interstitial space. Gelatin is a substrate for matrix metalloproteinases (MMPs), a family of 
extracellular endopeptidases with the ability to degrade components of the extracellular 
matrix (ECM). Upregulated MMP expression has been reported for several malignant 
conditions where they are involved in tumor proliferation and invasion as well as metastasis.28-
32 The enzymes are located in the extracellular space and can be used for early detection and 
as biomarkers of disease progression and metastasis.33-35. Alternative MMP-responsive 
moieties are peptides that can be applied as cleavable linkages to introduce site-specific 
biodegradation or drug release.36-39  
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Taking this into account, we designed multistage MMP-sensitive peptide-crosslinked nanogels 
(pNGs) that present suitable sizes to potentially accumulate in tumor tissue by the EPR effect 
and feature a protease-mediated size reduction property and acid-mediated drug release for 
enhanced tissue penetration. These degradable nanocarriers consist of a hydrophilic scaffold 
based on dendritic polyglycerol (dPG, Figure S1) that forms a three-dimensional network 
connected via MMP-specific peptide crosslinkers. The second building block was a rationally 
designed fluorogenic peptide crosslinker that comprises an MMP-specific amino acid 
sequence that is framed by a dye pair that exhibits fluorescence resonance energy transfer 
(FRET) and enables the monitoring of the peptide cleavage. The incorporation of the 
fluorogenic peptide as crosslinker integrates degradability to the nanocarrier comprised of 
otherwise non-degradable polymers, and additionally, the cleavage of the crosslinks can be 
conveniently monitored by the intrinsic fluorescence reporter. The design was inspired by 
hydrogels prepared by Janda and co-workers that include MMP-sensitive crosslinkers in 
acrylamide gels to introduce degradability into synthetic hydrogels.40 To transfer this concept 
to the nanoscale, we choose NGs as the nanometric equivalents of hydrogels that have 
emerged as a platform for the development of novel nanocarrier-based strategies.41 NGs are 
soft, hydrophilic hydrogel particles formed by physically or chemically crosslinked polymer 
chains that can incorporate stimuli-responsive moieties into their network to enable a 
triggered reaction ranging from morphological changes such as swelling or shrinkage to the 
disintegration of the polymer network.42  
Classically, NGs are prone to efficiently encapsulate their cargo by physical interactions in the 
network structure. However, encapsulation can cause premature release of the payload by 
diffusion mediated leakage before reaching the site of action. Additionally, the release of the 
drug should be prevented after MMP-mediated degradation as this could cause fast clearance 
of the small molecular weight drugs. As an alternative, covalently bound therapeutics can 
prevent leakage, mediate enhanced solubility, and, when attached by dynamic covalent 
chemistry, can be released in a controlled manner.43 To this end, we aimed to conjugate the 
chemotherapeutic drug doxorubicin (DOX) through a pH-sensitive linker to the dPG scaffold, 
thereby creating a multistage delivery system (pNG-DOX). In the first stage, pNGs can be 
degraded by MMPs which are present in the tumor microenvironment. After the resulting size 
reduction, the fragments constitute polymer-drug conjugates consisting of polyglycerol as 
polymeric carrier and DOX conjugated through an acid-cleavable linkage. These fragments 
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should facilitate the penetration into deeper areas of tumor tissue where the cargo could be 
released at acidic pH as present in intracellular compartments (pH 4-5) such as endosomes 
and lysosomes (Scheme 1).44 
Scheme 1. Schematic representation of the mechanism proposed for the multistage drug 
delivery by pNG-DOX.  
 
We expect that the synthetic approach based on multifunctional building blocks and directed 
incorporation of cleavable peptide allows precise control over the size and crosslinking density 
of the pNGs with varying the applied feed. Different crosslinking densities should result in 
different degradation profiles which can be tuned towards the specific application as 
multistage nanocarrier. In our system, the MMP-induced size reduction and degradation can 
be conveniently studied using the intrinsic fluorescence probe of the crosslinker. To prove the 
principle of the multistage drug delivery system, we investigate the diffusive transport of 
MMP-digested pNGs in a dense gel matrix mimicking the ECM. Furthermore, we want to 
confirm an enhanced penetration of the carrier fragments and the drug into multicellular 
tumor spheroids (MCTS) which should result in an improved therapeutic activity of the drug.  
So far, the majority of the peptide-crosslinked nanocarriers only described the degradation to 
small fragments to release encapsulated cargo. To the best of our knowledge, the controlled 
introduction of peptide-based crosslinkers into nanogels and the application as a multistage 
delivery system has not been reported before. 




All chemicals were purchased from Acros Organics, Alfa Aesar, Roth, Merck, Sigma-Aldrich (now 
Merck), Deutero GmbH, and used as received. The design of the peptide crosslinker was adapted 
and modified from the work of Janda et al.40 and the strategy of the crosslinker synthesis was 
developed in cooperation with Protein Research Inc. (UK). Structure and peptide sequence: 
Mca-Lys((OEG)8-N3)-Pro-Leu-Gly-Leu-Lys(Dnp)-Ala-Arg-Lys((OEG)8-N3)-NH2 (Mca: 7-
methoxycoumarinyl-4-acetic acid; Dnp: 2,4-dinitrophenyl; EG: ethylene glycol). Dendritic 
polyglycerol (dPG) was purchased from Nanopartica GmbH (Germany) with a weight average 
molecular weight (Mw) of 10 kDa (Dispersity Đ = 1.27). The cyclooctyne reagent (1R,8S,9s)-
Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate was purchased from Synaffix (AE 
Oss, Netherlands). Water used for the synthesis was obtained from a Millipore water 
purification system. The pH-sensitive (6-maleimidocaproyl) hydrazone derivative of DOX 
(aldoxorubicin), was synthesized starting from 6-aminocaproic acid following a procedure 
from literature.45 1H NMR and ESI-MS spectra are shown in the SI. 
HeLa cells (DSMZ-No. ACC-57, Leibnitz Institute DSMZ- German Collection of Microorganisms 
and Cell Cultures) were routinely maintained in RPMI 1640 medium (Lonza) containing 10% 
fetal bovine serum (FBS Superior, Merck), 1% Penicillin/Streptomycin (P/S, Thermo Fisher 
Scientific), and 1% MEM non-essential amino acids (Sigma-Aldrich) at 37 °C and 5% CO2. 
Human dermal fibroblasts from juvenile foreskin were isolated in accordance to local ethics 
and biosafety regulations (ethical approval EA1/345/14 by the Charité ethical committee) and 
were routinely cultured in Dulbecco's Modified Eagle Medium (DMEM) with 15% FBS and 1% 
P/S at 37 °C and 5% CO2. 
Synthetic procedure 
Functionalization of dPG 
The hydroxyl groups of dPG were modified in three steps to obtain amine functionalities 
following published procedure (Scheme S1).46 Briefly, dried dPG (250 mg dPG, 0.27 mmol OH’s 
for 8%, 1.0 equiv.) was dissolved in DMF (25 mL) with triethyl amine (113 µL, 0.81 mmol, 
3 equiv.) and cooled down to 0 °C. The hydroxy groups were activated by addition of 
methanesulfonyl chloride (23.0 µL, 0.30 mmol, 1.1 equiv.). The reaction was stirred overnight 
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(18 h) and allowed to reach rt. The reaction mixture was diluted with MeOH (4:1 v/v) and 
dialyzed against MeOH for 2 d (Molecular weight cut-off (MWCO) 1000 Da). The degree of 
functionalization was determined by 1H NMR. Degrees of functionalization for dPG-BCN are 
given as a percentage of the total dPG hydroxyl groups (~ 135 hydroxyl groups for 10 kDa dPG). 
For the next step, the polymer was dissolved in DMF and sodium azide (87.8 mg, 1.35 mmol, 
5 equiv.) was added to induce a nucleophilic substitution of the mesyl groups. The reaction 
mixture was heated to 60 °C and stirred for 3 d. After filtration, the filtrate was diluted with 
MeOH and dialyzed against MeOH for 2 d (1000 Da MWCO) to obtain dPG-azide. The 
appearance of a characteristic azide band was observed in the IR spectrum (2100 cm-1) and 
the disappearance of the NMR signal for mesyl groups was monitored. To obtain dPG with 
amine functionalization, the azide groups were reduced by Staudinger reaction. Therefore, 
dPG-azide was dissolved in water/THF (1:1 v/v) and triphenylphosphine (213 mg, 0.81 mmol, 
3 equiv.) was added before the solution was stirred for 3 d at 40 °C. Afterwards, TFA was 
evaporated and the remaining aqueous solution was filtered. The solution was dialyzed 
against MeOH for 3 d (MWCO 1000 Da). By this method, dPG-amine with 4% and 8% degrees 
of functionalization were obtained as determined by 1H NMR.  
Functionalization of dPG with bicyclononyne groups (BCN) 
For the functionalization with cyclooctyne groups, dPG-amine (250 mg, 0.27 mmol amine 
groups for 8%, 1.0 equiv.) was dissolved in DMF (20 mL) before triethylamine (112.3 µL, 
0.81 mmol, 3.0 equiv.) and (1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl 
carbonate (86.5 mg, 0.30 mmol, 1.1 equiv.) were added. The reaction was stirred for 3 h at rt. 
Then, the solution was diluted with MeOH (4:1 v/v) and dialyzed against MeOH for 3 d (MWCO 
1000 Da). The degree of functionalization was determined by 1H NMR yielding dPG-BCN with 
3.9% and 7.8% conversion (NMR in SI). 
Preparation of pNGs 
For the synthesis of the pNGs, nanoprecipitation was employed using different degrees of 
BCN-functionalization and different feed ratios (see Table 1). As an example, dPG-BCN (4% 
functionalization, 4.1 mg, 2.2∙10-3 mmol BCN groups) and peptide crosslinker (2.0 mg, 1.6∙10-
3 mmol azide groups, 70 mol%) were dissolved separately in water (1 mL) and cooled down in 
an ice bath. The cooled solutions were mixed and directly injected into NaCl-saturated acetone 
(20 mL) under vigorous stirring (900 rpm). After injection, the stirring was stopped, and the 
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nanoprecipitation was left for 2 d at rt before the excess of BCN groups was quenched with 
either azidopropanol (pNG-OH), indocarbocyanine azide (pNG-ICC) or 11-Azido-3,6,9-
trioxaundecan-1-amine (pNG-NH2). The dispersion was left for 1 d more before of water 
(1 mL) was added and acetone was evaporated. The aqueous dispersion was dialyzed against 
water for 3 d (MWCO 50 kDa). For the preparation of non-degradable controls, the same 
methodology was applied using the peptide crosslinker comprised of D-amino acids. 



















pNG 1 4 10 20 3.0 676 0.239 
pNG 2 4 20 25 3.0 414 0.345 
pNG 3 4 25 35 3.0 308 0.128 
pNG 4 4 40 50 3.0 270 0.205 
pNG 5 4 45 70 3.0 254 0.150 
pNG 6 4 50 80 3.0 193 0.276 
pNG 7 4 70 105 3.0 178 0.175 
pNG 8 8 25 17.5 3.0 635 0.077 
pNG 9 8 40 35 3.0 543 0.030 
pNG 10 8 45 40 3.0 502 0.108 
pNG 11 8 50 50 3.0 379 0.032 
pNG 12 8 70 60 3.0 367 0.314 
pNG 13 4 45 70 2.0 121 0.324 
pNG 14 4 45 70 4.0 270 0.023 
pNG 15 4 45 70 8.0 426 0.349 
a Mean hydrodynamic diameter obtained by dynamic light scattering (DLS) measurements in 
H2O at 25 °C. The intensity distribution is given. 
 
Synthesis of multistage pNGs (pNG-DOX) 
pNGs (5 mg) quenched with 11-Azido-3,6,9-trioxaundecan-1-amine were reacted with 
2-iminothiolane hydrochloride (1.1 mg, 8.1∙10-3 mmol, 3 equiv. of maximum amine groups) to 
convert the amine groups to thiols. After 20 min, the dispersion was filtered through a 
desalting column (PD10 column; GE Healthcare) to separate remaining 2-iminothiolane. The 
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pNGs dispersion was concentrated by centrifugal filter devices (Vivaspin ®, MWCO 100 kDa) 
before DOX-EMCH (2.1 mg, 2.7∙10-3 mmol, 1 equiv.), dissolved in DMF (0.1 mL), was added 
and left to stir for 4 h at rt. The pNGs were purified by size exclusion chromatography (SEC) 
using Sephadex G-25 fine matrix and subsequently dialyzed for 2 d in water (MWCO 50 kDa). 
The NGs were stored as highly concentrated dispersions (5 mg/mL) at 4 °C. The same 
methodology was applied for the preparation of non-degradable controls using the peptide 
crosslinker comprised of D-amino acids.  
Characterization of pNGs 
Dynamic light scattering (DLS) and zeta potential 
Size distribution and zeta potential of pNGs were measured at 25 °C by dynamic light 
scattering (DLS) using a Zetasizer Nano-ZS 90 (Malvern) equipped with a He-Ne laser (λ = 633 
nm) at a scattering angle of 173°. Samples with the concentration of 1 mg/mL in phosphate 
buffered saline (10 mM phosphate salts, 150 mM NaCl, PBS) were equilibrated for 5 min at 
the respective temperature prior to the measurement. Particle size distributions are given as 
the average of three measurements from intensity distribution curves. As DLS measurements 
of the NGs were monomodal in distribution, with autocorrelation functions showing a single 
exponential decay. The hydrodynamic diameters are reported from the intensity distribution 
curves. 
Transmission electron microscopy (TEM) 
Transmission electron microscopy samples were prepared by blotting samples (1 mg/mL) onto 
carbon-coated copper grids (400 meshes, Quantifoil Micro Tools GmbH). Then a droplet (5 μL) 
of 1% (w/v) uranyl acetate solution was applied and kept for 60 s before the excess of 
contrasting material was removed by means of filter paper and the sample could dry in air. 
Samples were visualized by using the TEM detector on a Hitachi scanning electron microscope 
(SU8030, Hitachi, Tokyo, Japan) at 20–30 kV and 10 µA at different magnifications.  
Degradation study of pNG 
By DLS 
To follow the degradation of the pNGs by DLS, recombinant human MMP-7 (R&D Systems) 
were activated at 100 µg/mL with 1 mM p-aminophenylmercuric acetate (APMA) in a solution 
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of 50 mM Tris base, 10 mM CaCl2, 150 mM NaCl, 0.05% (w/v) Brij-35, and pH 7.5 (TCNB) for 
1 h at 37 °C. The enzyme solution was diluted to 0.4 µg/mL. 50 µL of NGs solution at 1 mg/mL 
were filled into low volume cuvettes (Sarstedt) and placed in the Zetasizer Nano-ZS 90 
(Malvern). The reaction was initiated by addition of enzyme solution (50 µL at 0.4 µg/mL). The 
particle size distributions were measured every 30 min at 37 °C over 16 h. 
By fluorescence 
The degradation was monitored by fluorescence intensity measurements over time following 
the fluorescence of 7-methoxycoumarin. pNG solutions of 0.01–1.0 mg/mL were prepared in 
TCNB buffer and 50 µL were loaded into a 96-well microplate. The reaction was started by 
adding 50 µL of the activated MMP-7 solution (0.02 µg per well). Plates included a substrate 
and background controls containing pNGs with buffer and buffer only. As a positive control, a 
fluorogenic peptide (Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, Dpa: N-3-(2, 4-Dinitrophenyl)-L-
2,3-diamino propionyl, R&D systems) was included at a concentration of 10 µM to confirm 
enzyme activity. The microplate was sealed with optically clear adhesive seal sheets (Absolute 
qPCR Seal, Thermo Scientific) and placed into a microplate reader (Infinite M200 Pro, Tecan) 
heated to 37 °C. The excitation and emission wavelengths were set to 320 nm and 405 nm 
(top read), respectively, and fluorescence intensity was recorded every 5 min for 15 h. The 
background signal of pNGs in assay buffer was subtracted and the fluorescence intensities 
expressed as changes relative to the starting point, were plotted versus time.  
Release of DOX 
pNG-DOX dispersions in H2O were mixed with different buffers (1:1 v/v with acetate buffer 
(50 mM sodium acetate/acetic acid, 150 mM NaCl) at pH 5 or Tris buffer (50 mM Tris base, 
10 mM CaCl2, 150 mM NaCl, 0.05% w/v Brij-35, TCNB) at pH 7.5 with or without MMP-7) at 
5 mg/mL and incubated at 37 °C. At specific time points (t = 0 min, 1 h, 2.5 h, 5 h, 8 h, 24 h) an 
aliquot of the solution was transferred to a SEC column containing Sephadex G-25 fine matrix 
to separate the free DOX from the NGs. The collected NG fraction was analyzed for remaining 
DOX by UV/Vis spectroscopy (absorption at 490 nm). 
Diffusion in agarose gels 
Agarose gels were prepared by heating a suspension of agarose in PBS (0.5 w%) in a 
microwave oven at 500 W for 30 seconds. The clear agarose solution was filled into 
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rectangular capillaries of borosilicate glass (Hilgenberg, LxBxW: 80x4.2x1.25 mm, wall 
thickness 120 µm). After gel formation at rt, NGs labeled with ICC (pNG-ICC, 0.1 mg) were 
incubated with either MMP-7 (final concentration 0.02 µg/mL) in TCNB buffer or in buffer 
alone. After 16 h, EDTA was added to inactivate the enzyme and 20 µL of the solution was 
filled into the capillaries on top of the agarose gel. In addition, free ICC in the same 
concentration was added to a capillary and then, the capillaries were kept at 37 °C in a 
humidified chamber for another 16 h. The gels were imaged using a gel imaging system 
(GelDoc XRS+, Bio-Rad) with green epi-illumination (0.2 s exposure time) and 605/50 nm filter. 
The images were analyzed by ImageJ software.  
MCTS culture  
HeLa cells or HeLa/fibroblast cell mixtures were cultured in hanging drops using the 
GravityPLUSTM kit (InSphero AG). According to the manufacturer’s instructions, drops of 40 µL 
at various cell densities ranging from 500 to 10000 cells per drop were seeded to observe the 
formation of spheroids of at least 500 μm in diameter. After 3 d at 37 °C and 5% CO2, spheroids 
grew on the bottom of most of the drops. The spheroids were transferred to GravityTRAP™ 
plates, a non-adhesive coated 96-well microplate with conic wells for longtime cultivation, by 
adding 70 µL media to the drops and subsequent centrifugation of the plate at 300 rpm for 2 
min to force the spheroids into the wells. The spheroids were stored at 37 °C and 5% CO2. The 
medium was exchanged once per week. Between day 7 and 9 after seeding, spheroids reached 
a size of approximately 500–600 µm and showed dense circular structures and were ready to 
use for the penetration assay (Figure S2).  
MCTS penetration 
After 9 d in culture, spheroids were rinsed twice with PBS before fluorescently labeled pNGs-
ICC, degradable and non-degradable control, or free ICC in RPMI medium without FBS and 
phenol red were added to the spheroids. The pNGs were added to a final concentration of 
1.5 µM regarding the fluorescent dye. The spheroids were incubated for 2 or 16 h at 37 °C and 
5% CO2. Afterwards, the medium was discarded, spheroids were washed three times with PBS, 
and fixed for 40 min at rt in 10% neutral buffered formalin. Spheroids were washed again twice 
with PBS and cell nuclei were stained with DAPI solution (2.5 µg/mL in PBS, Sigma) for 1 h at 
rt. After washing with PBS, two complementary methods were applied to realize the 
visualization of the pNGs penetration into MCTS. For the first one, spheroids were transferred 
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using 1 mL pipetting tips onto microscope slides, squeezed under microscopy coverslips and 
mounted with ProTaqs MountFluor (Quartett GmbH) mounting medium. For the second 
method, the fixed spheroids were stained with methylene blue (0.1% in PBS) for 10 min at rt. 
After washing with PBS, spheroids were transferred to Peel-A-Way® S-22 embedding molds 
(Merck) embedding molds and embedded in Surgipath FSC 22 clear embedding compound 
(Leica) before the samples were frozen using liquid nitrogen. Then, the spheroids were cut 
into 16 µm-thick sections and mounted onto microscope slides. Images were acquired with a 
Leica SP8 CLSM using laser excitation at 488 nm (DOX) and 561 nm (ICC) with 20-fold and 64-
fold magnification. Image analysis was performed with LASX software and ImageJ. The 
circumference was determined in the brightfield images and then transferred to the intensity 
images. Subsequently, the measuring function was used to determine the mean fluorescence 
intensity in the area of the MCTS. The same procedure was followed for analyzing the 
penetration of multistage pNGs (degradable and non-degradable and free DOX) into 
spheroids. Here, a concentration of 5µM regarding DOX was applied for all samples. 
Cell viability assay  
To assess cell viability and proliferation inhibition, 10000 cells per well were seeded into 96-
well-plates (Sarstedt) with 100 µL of culture medium (RPMI for HeLa, DMEM for all other cell 
lines) with 10% FBS (FBS Superior, Merck), 1% Penicillin/Streptomycin (Thermo Fisher 
Scientific). The cells were incubated at 37 °C at 5% CO2 overnight. Then, the media was 
replaced with fresh media containing various dilutions of the corresponding NG or free drug 
in duplicates and cells were incubated for 48 h at 37 °C and 5% CO2. The cell culture 
supernatant was removed, and cells were washed twice with PBS (200 µL/well). Then, 
100 µL/well fresh full medium including 10 µL/well MTT (Sigma-Aldrich, 5 mg/mL in PBS) were 
added and incubated for another 4 h at 37 °C. After development of formazan crystals, the 
cell culture supernatant was removed, and crystals were dissolved by addition of 100 µL/well 
of isopropanol containing 0.04 M HCl. Absorbance was read at 590 nm in a Tecan Infinite 
M200 Pro microplate reader. In case of the 3D-model, spheroids were incubated with the 
corresponding pNGs or the free drug with DOX concentrations of 10 µM in triplicates for 48 h 
at 37 °C and 5% CO2. Afterwards, CellTiter-Glo® (Promega Corporation) viability assay solution 
was added and the contents were mixed for 5 min to induce lysis of the cells. The plate was 
incubated for 10 min at rt to stabilize the luminescence signal and luminescence was recorded 
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in the plate reader. Relative viabilities were calculated by dividing average absorbance or 
luminescence values of wells with treated cells by values of untreated cells (=100% viability). 
All tests were repeated 3 times independently and errors were expressed as standard error of 
the mean (SEM).  
RESULTS AND DISCUSSION 
We propose the use of peptide crosslinked nanogels (pNGs) as a multistage drug delivery 
systems (DDS) that feature MMP-mediated size reduction properties in response to the tumor 
microenvironment followed by controlled drug release at acidic pH conditions to aid 
enhancing tumor tissue penetration of attached DOX. To design a suitable pNG for this 
purpose, we needed to consider the initial size of the pNG that should potentially enable 
accumulation in tumor tissue by the EPR effect which requires rather large particle sizes (100–
300 m).8 In the tumor environment, extracellular MMPs would cleave the peptide linker and 
thereby cause a size reduction by degradation of the pNG that enables deeper tissue 
penetration of the fragments. The size of the degradation products must be carefully chosen 
as well, since particles smaller than 30 nm may be cleared from tumor tissue while larger 
particles are retained and continue to accumulate.47 It has been reported that micelles in size 
range of 50 nm are able to penetrate tumor tissues and at the same time are more likely to 
be retained in the tumor tissue while smaller micelles of 30 nm are susceptible to more rapid 
clearance.5, 7, 48 Therefore, we first systematically investigated the synthetic parameters and 
the influence of the different building blocks on the resulting properties of the pNGs with the 
goal to find a suitable candidate for proposed multistage DDS. 
Formation and characterization of pNGs 
In the first step, we developed the methodology for the preparation of the MMP-sensitive 
NGs. The pNGs consist of dendritic polyglycerol (dPG) crosslinked by a fluorogenic peptide 
that can be cleaved by MMPs, as well as a chemotherapeutic drug attached via an acid labile 
linker to the polymer. The hyperbranched polymer dPG was chosen to form the hydrophilic 
scaffold of the pNGs and to allow facile functionalization.49 Furthermore, dPG served as a 
polymeric carrier of DOX after fragmentation. The hydroxy groups of dPG were converted to 
amine groups in a three-step approach following a known procedure.46 Afterwards, the 
amines were reacted with (1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl 
carbonate to introduce cyclooctyne groups (dPG-BCN, Scheme S2). 
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To employ the fluorogenic peptide as crosslinker, it was modified with two terminal azide 
groups. These groups were attached through the γ-amino groups of lysine side chains 
including an 8-unit oligoethylene glycol (OEG)-chain as spacer leading to the final structure: 
Mca-Lys((OEG)8-N3)-Pro-Leu-Gly-Leu-Lys(Dnp)-Ala-Arg-Lys((OEG)8-N3)-NH2 (Scheme 2). The 
additional OEG chains were introduced to increase the water solubility and the accessibility 
for the proteases. The functional groups allow the strain-promoted alkyne-azide cycloaddition 
(SPAAC), a biorthogonal, metal-free click reaction that can be performed under mild 
conditions. Therefore, the reaction type allows the crosslinking of the building blocks without 
damaging the sensitive peptide and potentially could enable the encapsulation of sensitive 
cargos.50  
Scheme 2. Schematic representation of the building blocks, synthesis, and structure of 
multistage pNG-Dox. 
 
NGs are usually prepared by templating the polymer in confined spaces and subsequent 
crosslinking inside these templates.51 The most common methods are the mini- or 
microemlusion.52 However, the high shear stress impairs the encapsulation of sensitive cargos 
and the high amount of surfactants may alter surface properties when not carefully removed 
during purification. To bring the presented building blocks into nanosized assemblies, we 
employed the inverse nanoprecipitation technique.53-55 This mild method avoids extended 
stirring/sonification (shear stress) and is surfactant-free. For the inverse nanoprecipitation, 
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water was used as solvent and acetone was chosen as non-solvent. A constant polymer 
concentration of 3 mg/mL and a solvent/non-solvent ratio of 1:20 were selected as working 
parameters. These conditions were found to be optimal to obtain stable dispersions and were 
maintained for synthetic screening. The cyclooctyne functionalities were used in excess and 
were quenched with azidopropanol, or alternatively, with an azide-functionalized 
indocarbocyanine dye (ICC) as florescent label. The crosslinking reaction was monitored by FT-
IR spectroscopy which showed the disappearance of the azide signal at 2100 cm-1 indicating 
the formation of triazoles by SPAAC (Figure 1a). 
We hypothesized that by varying the fraction of the peptide crosslinker in the feed and the 
crosslinking points on the dPG surface, different sizes and network densities would be 
obtained. The size is crucial for the fate of the pNGs in a biological environment and the 
network has an influence on the degradation rate of the pNG which can be optimized for the 
size reduction or alternatively to tune the release of an encapsulated cargo. Therefore, a 
rational screening included the variation of dPG-BCN functionalization degree and the fraction 
of peptide crosslinker in the feed to study their effect on the composition of the polymeric 
particles. Two degrees of BCN functionalization with 4% and 8% of converted hydroxy groups 
(⁓ 5 and 10 groups per dPG) were tested and the peptide crosslinker feed was varied from 10 
to 70 w%. The hydrodynamic diameters and polydispersity indices (PDI) as determined by DLS 
showed narrow, monomodal distributions for the prepared pNGs (Table 1). To complement 
these results, we confirmed the formation of spherical particles by TEM measurements. The 
sizes determined by statistical analysis of the TEM images revealed smaller diameters 
compared to the DLS measurements, which is due to drying and associated deswelling of the 
particles. For example, particle sizes of ⁓270 nm were determined for pNG4 by DLS, while 
TEM images revealed sizes of ⁓180 nm. Interestingly, pNG7 with a higher peptide feed 
displayed a size of 180 nm measured by DLS and only slightly smaller sizes of 150 nm were 
determined by TEM indicating a denser network (Figure 1b).  
Overall, the screening of BCN functionalization and peptide feed confirmed that the sizes 
could be modulated in a broad range between 150 and 650 nm (Figure. 1c). As expected, the 
nanogel size depended on the weight fraction of the peptide crosslinker. Here, smaller particle 
sizes were obtained with increasing peptide feed. The higher amount of crosslinker allows a 
stronger interconnection and additionally may provide stabilization during the nucleation and 
aggregation process yielding smaller particles. For higher BCN functionalization, we expected 
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denser and smaller structures. Interestingly, an increase in sizes was observed when the 
number of BCN groups were doubled while maintaining the same peptide fraction. Besides 
the solvent/non-solvent and polymer concentration, eventually, the character of the polymer 
is responsible for the stabilization of the aggregates to prevent coalescence or Ostwald 
ripening in the nanoprecipitation process.56 Therefore, a higher functionalization of dPG 
seems to impair the potential of the polymer to stabilize smaller aggregates that has been 
observed for other dPG-based nanoparticles prepared by inverse nanoprecipitation.53, 55 Our 
screening revealed that the stabilization by dPG in inverse nanoprecipitation is reduced by 
functionalization with hydrophobic groups. Nevertheless, the tested feed composition allows 
an application-optimized size adaptation in a broad size range. 
 
Figure 1. Characterization of pNGs: (a) FT-IR spectra of dPG-BCN (red), peptide crosslinker 
(blue), and pNGs (green). (b) Representative TEM images of pNGs with 4% BCN 
functionalization and 40 w% (pNG4) and 70 w% (pNG7) peptide crosslinker and the 
corresponding statistical analysis of the particle size distribution. (c) Influence of the peptide 
crosslinker feed and dPG functionalization on pNGs size.  
Size reduction and degradation kinetics of pNGs 
For the MMP-specific peptide sequence it was reported before that MMP-7 was able to 
efficiently hydrolyze the crosslinker sequence which resulted in an increased fluorescence 
signal when incubated with the fluorogenic crosslinker (Figure S3).40, 57 To confirm the 
degradability of the prepared nanogels, pNG6 (BCN 4%, 50 w%) was incubated in the presence 
and absence of the protease MMP-7. Subsequently, particle sizes were monitored by DLS over 
time. In the first 4 hours, we observed a slight increase in size indicating a swelling of the 
particles, which we think is due to partial cleavage of crosslinking points and hence loosening 
of the network. After this time, apparent particle sizes were decreasing suggesting a 
disintegration of the pNG networks to smaller portions (Figure 2a). For pNG6, size reduction 
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of approximately 75% compared to the initial size was observed after 16 h (Figure 2b top). As 
controls for the specific degradation, pNGs were prepared by the same procedure but using a 
peptide crosslinker comprised of D-amino acids, which cannot be hydrolyzed by MMP-7 
(Figure S3). As seen in Figure 2b bottom, these non-cleavable pNGs were stable upon 
incubation with the protease. These results confirm the MMP-mediated degradability and 
consequently a size reduction of the pNGs. The degradation was also confirmed by GPC 
measurements. Here, longer retention times for pNGs were observed after incubated with 
MMP-7 (Figure S4).   
 
Figure 2. (a) Hydrodynamic diameters of degradable and non-degradable pNGs incubated 
with MMP-7 over time determined by DLS. (b) Normalized size distributions of degradable 
(top) and non-degradable (bottom) pNG before and after incubation with MMP-7 for 16 h.  
The fluorogenic peptide crosslinker was introduced to conveniently follow the degradation of 
pNGs by fluorescence measurement since upon cleavage of the peptide crosslinks, the 
fluorescence of the quenched 7-methoxycoumarin (Mca) dye is regained. A library consisting 
of four pNGs with 4% and 8% BCN functionalization as well as with low and high peptide 
crosslinker feed were incubated with MMP-7 and the fluorescence intensities were followed 
over time. The peptide feed and the BCN functionalization in the pNG formation should affect 
the interior composition. More BCN groups of the nanogels and higher peptide crosslinker 
feed should result in a denser network structure which eventually should be reflected in 
slower degradation rates. The plot of the fluorescence intensities versus time showed indeed 
that higher BCN functionalization and constant peptide fraction resulted in slower 
degradation indicating a denser network structure (Figure 3). Faster degradation was 
observed when the fraction of the peptide was reduced during the synthesis suggesting 
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network structures, which are easier accessible for the proteases. Since the number of 
crosslinking points on the dPG was kept constant, higher peptide fractions can form denser 
networks which eventually lead to smaller particles as observed in the synthetic screening. 
The effect of peptide fraction on the degradation rate was more pronounced for pNGs 
prepared with 4% BCN functionalization. Here, the time constant, which describes how rapidly 
the degradation process occurs, was nearly increased threefold when the peptide fraction was 
doubled (1.3 h to 3.7 h), whereas, for 8% functionalization, only a minor increase was 
observed (6.6 Table S1). It can be noted that the non-degradable pNGs did not show an 
increase of fluorescence signal when incubated with MMP-7 indicating that these NGs are 
stable at proteolytic conditions (Figure S5). 
Since the pNGs are used as DDS, we were interested to see if cells were able to induce the 
degradation. Therefore, pNGs were incubated with HeLa cells and the fluorescence intensities 
of Mca were measured over time. Even though with a slower rate, the fluorescence signal was 
increasing over time suggesting a digestion of the pNGs by cells is feasible (Figure S6).  
 
Figure 3. Degradation of pNGs with MMP-7 monitored by an increase of fluorescence signal 
at 405 nm with time constants of pNGs obtained by the exponential fit. Normalized 
fluorescence intensity  
The incorporation of the fluorogenic peptide crosslinker allowed us to study the impact of 
different feed ratios and the dPG functionalization degree on the degradation rates which 
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translates to different interior compositions of the pNGs. By varying the functionalization of 
dPG and the fraction of the peptide, the degradation rates showed time constants in the range 
of about 1 h to 6 h. Hence, we demonstrated that the formation of pNGs with an increased 
feed of peptide crosslinker generated higher crosslinking densities which correspond to the 
slower cleavage rate. This should allow the tuning of the release kinetics of encapsulated cargo 
from rather fast to sustained release depending on the desired application.   
Conjugation of Dox to obtain multistage pNGs 
Considering the previous data, we chose pNG6 as a suitable candidate because the nanogels 
presented sizes around 200 nm appropriate for the accumulation process by the EPR effect 
and constant degradation rates with the desired MMP-mediated size shrinkage to 40–50 nm 
fragments. To realize the conjugation of DOX through a pH-sensitive linkage, we chose a 
known prodrug of the anticancer drug, namely aldoxorubicin. This prodrug comprises a 
maleimide group readily reacting with free thiols. This thiol-binding DOX derivative was 
designed to hitchhike albumin as a carrier in the blood stream by probing a specific cysteine 
of the serum protein.58-60 After the crosslinking process, the pNGs were easily modified by 
quenching the excess of BCN groups with an azide-functionalized cyanine dye (ICC-azide) to 
label the pNGs or with 1-Azido-4,7,10-trioxa-13-tridecanamine (N3-TOTA) to introduce amine 
groups. The ICC label is used to follow the pNGs and the degradation fragments in the 
following diffusion and penetration experiments. After purification, the free amine groups 
were thiolated using 2-iminothiolane. The formed thiols readily reacted in a Michael addition 
reaction with the maleimide groups of aldoxorubicin yielding multistage pNGs (Scheme 2). The 
approach of in situ thiolation was chosen to avoid crosslinking of the reactive precursors. As 
before, non-degradable control pNGs were prepared using a peptide crosslinker synthesized 
with D-amino acids. The hydrodynamic diameters were barely affected by the modification of 
the pNGs, but the slightly positive surface charge was marginally increased by the attachment 
of aldoxorubicin HCl salt. The DOX content of the degradable and non-degradable pNGs was 
determined by UV/Vis spectroscopy with 1.8 w% and 2.0 w%, respectively (Figure S7). All 
synthesized pNGs had similar sizes and dye/drug loadings allowing to compare their potential 
to increase the penetration efficiency (Table 2). The acid-mediated release of DOX from the 
pNGs was confirmed by incubation of the multistage pNGs at pH 7.4 and pH 5 as well as in the 
presence of MMP-7. Here, we found that the release of DOX is accelerated in acidic pH and in 
the first 24 h ⁓50% of DOX was released. In earlier studies, we reported a release of 60% at 
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pH 5 for aldoxorubicin-derived polymer-drug conjugates,61 which is slightly higher than 
observed here, probably caused by interaction with the nanogel network. Therefore, an 
increase in the release is expected when the pNGs are first digested with MMP and 
subsequently, exposed to acidic pH values. Indeed, under these conditions, the release was 
increased to ⁓60% (Figure S8). At pH 7.4, a minor release of ⁓25% was observed indicating 
that DOX is partially encapsulated and can leak out of the nanogel network by diffusion. A 
small fraction of encapsulated DOX always remained in the network even after intensive 
purification by dialysis and SEC column. In the mentioned polymer-drug conjugates, release at 
pH 7.4 was marginal with less than 10% over several days. Therefore, we think that the peptide 
crosslinker may affect the hydrolysis of the hydrazone which leads to increased release at pH 
7.4. 
Table 2. Physicochemical characterization of multistage pNGs. 








pNG-NH2 cleavable 214 0.117 +4 - 
pNG-DOX cleavable 218 0.220 +9 1.8 
pNG-ICC cleavable 244 0.105 +2 0.8 
pNG- NH2 non-cleavable 193 0.043 +5 - 
pNG-DOX non-cleavable 220 0.100 +9 2.0 
pNG-ICC non-cleavable 212 0.026 +3 0.8 
a Mean hydrodynamic diameter obtained by DLS measurements in H2O at 25 °C. The intensity 
distribution is given; b For ζ-potential measurements, electrophoretic mobility of the NGs was 
analyzed following application of a 20 Vcm-1 electric field. c Determined by UV/Vis 
spectroscopy using the extinction coefficient of the ICC dye and DOX, respectively 
 
Diffusive transport in an agarose matrix 
The potential of pNGs fragmentation by MMPs to enhance diffusive transport was studied by 
the penetration of digested and undigested pNGs in dense agarose matrix mimicking the 
dense ECM in tissue. For this, we first brought solutions of ICC-labeled pNGs and the non-
degradable control pNGs before and after incubation with MMP-7 in contact with the agarose 
gel and incubated for 16 h at 37 °C. Before digestion, degradable and non-degradable pNGs 
PUBLICATIONS & MANUSCRIPTS 
96 
presented negligible penetration into the agarose gel. However, after incubation with MMP-
7, the smaller fragments were able to penetrate deep into the agarose matrix (Figure 4a). The 
intensity profiles of the fluorescence signal in the gel were plotted in Figure 4b. The signals for 
non-digested particles and for non-degradable control pNGs incubated with MMP-7 descends 
to 50% of the initial value after ⁓2.5 mm, whereas the intensity of digested pNGs was reduced 
to 50% of the initial value only after 8.9 mm indicating that the penetration is enhanced.  
Having confirmed an increased diffusion after pNG degradation using a dye-labeled model NG, 
we investigated the performance of the multistage DDS pNG-DOX in agarose gel diffusion. In 
this case, the intrinsic fluorescence of DOX allowed us to follow the infiltration. Before the 
incubation with MMP, only marginal penetration of DOX was observed (50% after 4.0 mm), 
whereas after incubation with MMP, the particles diffused into the gel matrix (50% after 
6.8 mm; Figure 4c+d).  
 
 
Figure 4. (a) Diffusion of free ICC and ICC-labeled pNGs in agarose gel before and after 
incubation with MMP-7. (b) Normalized intensity profiles of free ICC and ICC-labeled pNG in 
agarose gel. (c) Diffusion of free DOX and pNG-DOX in agarose gel before and after 
incubation with MMP-7 and at acidic pH. (d) Normalized intensity profiles of free DOX and 
pNG-DOX in agarose gel. 
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To emulate the second step in the multistage delivery—the pH-dependent release of DOX 
from dPG by cleavage of the linking hydrazone bond—we further incubated the digested pNGs 
at acidic pH. Penetration of DOX into the agarose matrix was notably increased to 50% after 
8.3 mm. This experiment confirmed an improved diffusion efficiency for degradable pNGs 
indicating that the fragmentation of the pNG could improve the penetration into the 
interstitial matrix of tumor tissue. 
Penetration into multicellular tumor spheroids 
To confirm that the MMP-induced size reduction of pNGs can enable penetration into tumor 
tissue, we employed multicellular tumor spheroids to test the hypothesis in a tumor-
resembling 3D model. MCTS capture complex 3D tissue physiology such as the presence of 
ECM as well as pH, oxygen, metabolic, and proliferative gradients and provides a useful 
technique to study anticancer strategies in vitro. 62-66 In particular; diffusion-based transport 
of nanoparticles in an environment that resembles the structural and microenvironmental 
conditions associated with solid tumors is of great interest.65, 67 For modeling the cellular 
diversity in tumor tissues, a variety of spheroid-based co-culture systems have been 
developed, e.g., with fibroblasts and endothelial cells.68 Among the major cell types that seem 
to be important for conditioning the microenvironment are fibroblasts.69 This cell type is 
known to be involved in tumor proliferation by promoting invasion to other tissue and by 
contributing to the formation of metastasis.70-71 In particular, fibroblasts contribute to tumor 
invasiveness by producing MMPs which regulate the remodeling of the surrounding ECM.70, 72 
Therefore, co-cultures of cancer cell lines and fibroblasts enable the formation of 3D spheroids 
models that resemble the tumor physiology and microenvironment and also provide the 
proteases necessary to degrade the pNGs. 
To grow MCTS, HeLa cells and primary fibroblasts at different ratios and cell numbers were 
screened to reproducibly obtain spheroids with sizes of ⁓500 µm. For a mixture of HeLa and 
fibroblasts in ratio 2:1, spheroids were obtained after 4 days and further grew to dense 
circular structures with sizes of approximately 500 µm after 7–9 days (Figure S2).  
To investigate the diffusion properties of the DDS in MCTS, we first used the dye-labeled 
model pNGs. MCTS with sizes of around 500 µm were treated with ICC-labeled degradable 
(pNG-ICC) and non-degradable pNGs (non-degradable pNG-ICC). In the first set of 
experiments, spheroids were washed after incubation with the compounds for 16 h, fixed, and 
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directly imaged using a CLSM. The z-stack function was used to optically section the spheroids 
in 20 µm steps. Here, we could indeed observe that the free dye and degradable pNGs 
penetrate deeper compared to the non-degradable control. However, when the images were 
compared with the brightfield image (Figure S9), it appeared that only the surface of the 
spheroids was imaged as the laser light is absorbed by the tumoroid tissue resulting in a 
limited penetration depth. To compensate for the absorption of the laser light in large objects, 
the spheroids were mounted between a microscope slide and cover glass and were thereby 
slightly squeezed (Figure 5b). With these MCTS, optical sectioning in the confocal microscope 
allowed to image the central region of the spheroids since the laser light does not need to 
penetrate into deeper layers. We found that the free dye used to label the pNGs had 
penetrated to the interior of the MCTS to a point where the signal abruptly decreased 
(Figure 5a) because the light absorption of the tissue is too large to obtain proper signals. 
Nevertheless, optical sections of spheroids treated with the degradable control displayed an 
efficient penetration into the spheroid. Compared to the free dye, the distribution of the 
fluorescence signal is not as homogeneous as for the degradable pNGs indicating that larger 
fragments may accumulate in more spacious regions of the spheroid. A distinct difference is 
apparent in comparison to the non-degradable control. Here, all sections displayed a low 
intensity and only a marginal signal was observed in deeper layers confirming that the non-
degradable pNGs are not able to diffuse into the MCTS.  
 
Figure 5. a) Penetration of free ICC, degradable, and non-degradable pNGs into MCTS in 
different layers. The black bars in the brightfield images represent 500 µm. (b) Schematic 
representation of the flattened spheroids and the optical sections. (c) Mean fluorescence 
intensities of ICC in the area of the MCTS for increasing depth. 
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The graph in Figure 5c shows the mean fluorescence intensity (MFI) over the area of the 
spheroid section illustrating that free dye and the degradable nanogel display similar intensity 
with a slow decrease for deeper sections. 
To confirm the results obtained from optical sections, cryosections of the spheroids incubated 
with labeled pNG-ICC for 2 h and 16 h were prepared. Representative cryosections from the 
mid-region of spheroids were imaged by fluorescence microscopy. Free ICC and DAPI were 
found to be homogeneously distributed throughout the sections at both time points indicating 
an unhindered diffusion of the free dye through the spheroid (Figure 6a). Only minor intensity 
was observed at the margins of the spheroids for the degradable pNGs and the non-
degradable control after 2 h. For longer incubation time, we found minimally increased 
fluorescence intensity when treated with the non-degradable pNGs. At the periphery, intense 
signals were observed, however, the intensity was rapidly declining over the first 20 to 30 µm 
towards the center of the section. When the degradable pNGs was incubated for 16 h with 
the MCTS, intense fluorescence was observed throughout the section area (Figure 6b). The 
sections showed a gradient with higher fluorescence intensity at the periphery that decreased 
towards the core which is apparent from the images with higher magnification (Figure 6c). It 
is notable that the core still possessed distinct fluorescence intensity suggesting that the 
degradation products penetrated to the core of the spheroids. These observations support 
the results of the optical sections and confirm that the degradable property of the pNGs 
enables an efficient penetration of the tumor-resembling 3D model. Since we have shown 
before that the fragmentation of the pNGs is caused by proteases (Figure 2), we can assume 
that fragmentation in the tumor model is also caused by expressed proteases. It has been 
reported that MMPs are indeed expressed by cancer cell lines and in particular in co-cultures 
using primary cells.73-74  
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Figure 6. (a) CLSM images of MCTS cryosections with 20-fold magnification. MCTS were 
incubated with free ICC, degradable, and non-degradable pNG-ICC for 2 h and 16 h, 
respectively. Images were obtained with flattened spheroids and optical sectioning. (b) Mean 
fluorescence intensity over the area of spheroid sections. (c) CLSM images of cryosections with 
64-fold magnification. 
To demonstrate that the results obtained from the dye-labeled pNG can be transferred to the 
performance of the multistage pNG-Dox, spheroids were incubated with the multistage pNGs, 
free DOX, and the non-degradable control. After incubation, we could see that the free drug 
was distributed homogeneously throughout the spheroids with slightly decreasing 
fluorescence intensity for deeper regions. In comparison, the penetration for the degradable 
pNG-DOX was considerably higher than for the non-degradable control especially for deep 
sections of the tumor spheroids (Figure 7a). This indicates that pNGs are degraded and that 
the small fragments possessed an advantage in penetrating into deep regions of the 3D tumor 
model. Comparing to the penetration study using dPG-ICC, it can be noted that the DOX 
penetration for the non-degradable system was higher than for the non-degradable dPG-ICC 
(Figure 7b). This can be explained by either premature DOX release or diffusion of small 
fractions of encapsulated DOX. The confocal images at higher magnification illustrate the 
enhanced penetration of DOX for the degradable pNGs (Figure 7c). 
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Figure 7. (a) Penetration of dPG-DOX into MCTS: Comparison of free DOX, degradable 
multistage pNGs, and the non-degradable control. The black bars in the brightfield images 
represent 500 µm. (b) Mean fluorescence intensity of DOX in the area of the MCTS for 
different penetration depth. (c) CLSM images of cryosections with 64-fold magnification.  
To complement this data, cryosections of MCTS incubated with pNG-DOX and controls were 
prepared for 2 h and 16 h (Figure S11). For the degradable dPG-Dox a time-dependent 
increase in penetration depth of DOX fluorescence was observed, whereas for the non-
degradable control no change was visible over time. These observations support the results 
of the optical sections and confirm that the size reduction property of the pNGs enhances the 
transport of the therapeutic agent into the tumor-resembling 3D model 
Therapeutic activity of multistage pNG 
To confirm that DOX is still therapeutically active after multistage degradation of the pNG and 
deep tissue penetration, we analyzed the activity of DOX on cell viability after the incubation 
with pNGs in monolayer culture as well as in MCTS. For the monolayered culture, the viability 
was determined by the ability of the cells to metabolize MTT. Since we obtained low signals 
with MTT for the evaluation of the spheroid model, we assessed the viability of cells in 
spheroids by measuring intracellular ATP content using the CellTiter-Glo® assay. The bare pNGs 
did not display any toxicity towards HeLa cells up to the highest concentration tested 
(0.25 mg/mL), whereas free DOX and the multistage pNG-DOX reduced the viability of HeLa 
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cells for higher DOX concentrations (Figure 8a). Interestingly, minor toxicity towards HeLa cells 
was also observed for the non-degradable control indicating that the degradability of the 
pNGs plays a crucial role in the therapeutic activity. Since the release of DOX for the pNGS was 
marginal at pH 7.4 but increased under acidic conditions as found in intracellular 
compartments this result suggest that the non-degradable pNG are internalized less by the 
cells and that the small fragments of the degradable pNGs can be taken up more easily. This 
observation is supported by the magnified images of the cryosections where we see the 
fluorescence associated with the digested pNGs and the drug is localized inside the cells 
(Figure 6c+7c).  
 
Figure 8. Therapeutic activity of DOX in the multistage DDS. Cell viability: (a) After treatment 
with different concentration of pNG-DOX and controls in monolayer culture of HeLa cells. (b) 
After treatment with pNG-DOX and controls at 10 µM DOX concentration in MCTS model after 
48 h of treatment, respectively. 
For the 3D model, the non-degradable control marginally inhibited the proliferation of the 
spheroids when treated with a DOX concentration of 10 µM. In contrast, when treated with 
the degradable pNG-DOX, ATP concentrations were reduced to 22% relative to the untreated 
control (Figure 8b). The difference emphasizes that degradation-induced penetration is crucial 
for the treatment of the tumor model to deliver the drug to the inner regions. Therefore, we 
suggest the two-stage strategy of the presented multistage pNGs as potential nanocarrier-
based DDS for systemically applied drug delivery. After extravasation to the tumor tissue, the 
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In summary, we prepared a novel MMP- and pH-sensitive multistage delivery system in the 
form of pNGs. The incorporation of a smart fluorogenic peptide crosslinkers into a hydrophilic, 
dPG-based scaffold provided degradability into synthetic NGs comprised of otherwise non-
degradable polymers. The size reduction of these particles can be triggered by an endogenous 
stimulus in the tumor microenvironment, and thereby promotes the penetration of polymer-
drug conjugates. The pNGs were prepared by surfactant-free inverse nanoprecipitation using 
strain-promoted click chemistry. The procedure yielded NGs with spherical morphology and 
good to excellent size distribution. The variation of BCN functionalization on dPG and the 
fraction of the peptide crosslinker allowed control over the size and the degree of crosslinking. 
The size reduction property of the pNGs in the presence of MMP was demonstrated by time-
dependent size measurements showing the desired reduction from several 100 nm to sub-
50 nm fragments. The MMP-mediated degradation was studied in detail by fluorescence 
measurements following fluorescence recovery of the intrinsic reporter moiety of the 
crosslinker. Here, we found that the degradation rate depends on the feed ratio and BCN 
functionalization with slower rates for higher crosslinker feed. This feature could be used to 
tune the release rate of an encapsulated cargo. The pNGs were post-synthetically modified to 
covalently attach the chemotherapeutic drug DOX through an acid-sensitive hydrazone 
linkage. The size and surface charge were barely affected by the modification, and the release 
of DOX from the pNGs was enhanced at acidic conditions. The digested multistage pNGs 
showed enhanced diffusive transport through a dense gel matrix and we could successfully 
demonstrate in tumor resembling MCTS models that the size-changing property of the pNGs 
can promote the infiltration of the functional chemotherapeutic drug into deeper tissue 
regions. Therefore, the multistage dPG constitutes a potential nanocarrier for systemic 
application to promote drug delivery in solid tumors. 
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4 CONCLUSION & OUTLOOK 
The development of nanocarriers was prompted by the goal to revolutionize drug delivery by 
improving pharmacokinetic profiles and the therapeutic index of conventional drugs by 
targeted delivery. Indeed, advances in the field lead to a multitude of delivery platforms that 
could improve common therapy strategies. However, the deficient clinical translation 
indicates that many challenges remain since the DDS often fail to overcome all the barriers 
that are encountered during the drug delivery process. The incorporation of stimuli-
responsive moieties into drug delivery system allows the adaptation to certain biological 
barriers and thereby help to optimize targeted delivery and controlled therapeutic activation.  
The present thesis consists of three main projects that deal with the incorporation of the 
prodrug concept to build stimuli-responsive nanocarriers for drug delivery. Prodrugs of the 
chemotherapeutic drug Dox were combined with nanoarchitectures to exploit the 
advantageous properties of nanocarriers and to introduce stimuli-responsiveness with the 
goal to improve the performance of the parent drug. The presented systems include 
theranostic polymer-drug conjugates (TPC) for the evaluation of in vitro drug release by 
activatable fluorescence probes. The results of this assessment were incorporated in the 
rational design of a NE approach for the treatment of a metastatic breast cancer in mice model 
and peptide-crosslinked NGs as a multistage delivery system. 
Stimuli-sensitive covalent chemistry is a versatile tool to introduce controlled cleavability into 
DDS that can enable controlled drug release, degradability, or other functional and 
morphological changes. Here, the choice of the cleavable moiety is crucial to fit the desired 
applications. In the first project, we aimed to assess the implication of the cleavable linkers in 
polymer-drug conjugates on the cell-mediated drug release, and subsequently, on the 
therapeutic efficacy of the DDS. A pair of TPC was synthesized that enabled the in situ 
monitoring of the cell-mediated drug release triggered by an acidic environment or enzymatic 
activity. The modular synthesis of the conjugates allowed the preparation of equal polymer-
drug conjugates comprised of high molecular weight dPG as a polymeric carrier with Dox as a 
therapeutic agent and reporter unit connected via different cleavable linkers to the polymer. 
Importantly, the fluorescence of Dox was efficiently quenched by the proximity of an 
indodicarbocyanine (IDCC) dye. The FRET between Dox and IDCC suppressed the fluorescence 
of the drug when bound to the carrier. Consequently, regeneration of Dox fluorescence could 
be correlated with the release of Dox-induced by endogenous stimuli. The theranostic 
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conjugates proved to be sensitive to their environment regarding the pH and protease 
concentration, respectively and enabled the monitoring of the drug release in real-time by 
measurement of fluorescence recovery.  
In a compatible microplate assay which allowed parallel screening of different cell lines and 
DDS, TPC were incubated with four cell lines (HeLa, A549, MDA-MB-231, KB-V1) to obtain 
characteristic release profiles for Dox by following the fluorescence signal. The correlation of 
the cell-mediated Dox release profiles with the cytotoxicity of the conjugates demonstrated 
the theranostic character of the conjugates and gave valuable information about the 
implication of the linker design on the drug release.  
For the linkers investigated, the pH-cleavable linker was found to be more suitable for the 
drug delivery approach, since premature, extracellular Dox release was observed for the 
protease-sensitive system. This was particularly important for the treatment of multidrug-
resistant KB-V1 cells where the intracellular drug release is crucial to circumvent the resistance 
mechanism. In contrast, the protease-sensitive conjugate proved to be more effective to 
inhibit the cell proliferation in MDA-MB-231 cells as the Dox release was hindered for the pH-
sensitive system for this cell line. These results suggest that the linker design must be carefully 
chosen according to the target characteristics. The approach for targeted drug delivery cannot 
be fulfilled by a “one fits all” solution but there is rather a need to design the DDS in 
compliance with the disease characteristics and patient-specific requirements. Here, the 
modular nanocarrier-based delivery system could be conceived that can be adjusted to the 
specific needs.  
It can be emphasized that the cell-based assay combined with activatable fluorescence 
probes, could be a valuable tool to expand the commonly used methods for the in vitro 
evaluation and screening of DDS in various cell lines. The modular approach for the synthetic 
methodology allows the systematic screening of different carrier architectures, a cleavable 
linker, and drug/dyes regarding their impact on the DDS performance. To improve the 
evaluated TPC towards an effective DDS, the application of more specific peptide sequences 
or disulfide units for the cleavable linker should ensure an intracellular drug release. The 
theranostic concept can be extended to non-fluorescent drugs when an additional fluorescent 
dye is introduced between the drug and the IDCC dye. The release of drug and dye could be 
realized by the application of self-immolative linkers. 119 By the application of NIR light 
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emitting dyes or chemiluminescence probes, the principle could be applied to track the 
release in an in vivo environment.  
Even though highly active, the chemotherapeutic drug Dox displays major drawbacks such as 
a short half-life which impairs delivery to the tumor tissue. At the same time, Dox is widely 
distributed into healthy tissue which results in severe side effects leading to dose limits. The 
results of the first project served as the basis for the simple but effective design of pH-sensitive 
prodrug-based nanomedicines to improve the pharmacologic profile of Dox. In the second 
project, Dox was modified to be efficiently entrapped in an oil/water NE consisting of castor 
oil, PEG-35-castor oil as a surfactant, and water. By attaching a C16-alkyl chain, the lipophilicity 
of Dox was increased giving an amphiphilic character that allowed to dissolve the prodrug in 
the nanodroplets of the NE which serve as a nanocarrier for the drug. The Dox-loaded NE (NE-
C16-Dox) showed droplet sizes of around 30 nm with an almost transparent appearance as 
well as high stability over long-time and in a large pH range. As responsive moiety, an acid-
sensitive hydrazone linkage was applied between the alkyl chain and the drug. In intracellular 
acidic conditions, the hydrazone bond is hydrolyzed inducing a change in hydrophobicity of 
Dox which facilitates the partitioning from the NE. Indeed, it was observed that Dox remains 
encapsulated at neutral pH and is only released in acidic conditions. The cell internalization of 
the Dox-loaded NE showed fast uptake even compared to the free drug. While the free drug 
accumulated directly in the nucleus, Dox from the NE was first localized in the cytoplasm and 
was then transferred to nucleus over time. Interestingly, none of the tested endocytic blocker 
and neither incubation at 4 °C could inhibit the uptake of NE-C16-Dox indicting an energy-
independent diffusion pathway. The internalization may occur by the fusion of nanodroplets 
with cell membranes as it has been observed before for surfactant-lipid droplets.200  
When evaluated in a murine breast cancer tumor model, Dox-loaded NE presented prolonged 
circulation leading to higher accumulation in the tumor as compared to free Dox. In addition, 
reduced systemic toxicity for NE-C16-Dox was indicated by an increase of body weight during 
treatment and reduction of cardiac toxicity. Even when the doubled concentration of the Dox 
dose limit was applied as NE formulation, it did not show any signals of toxic effects indicating 
an overall reduction of systemic toxicity. Due to the increased dose-limit, the NE formulation 
was eventually able to significantly inhibit the primary tumor growth, whereas treatment with 
free Dox and NE with the same Dox concertation did not show a significant reduction. 
Interestingly, the treatment with NE-C16-Dox impaired the formation of distant lung 
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metastasis compared to the treatment with the free drug. This is an important finding since 
the presence of metastasis is as a determinant factor for patient survival.201 
Related to this work, it has been shown by Mulder et al. that the miscibility and hydrophobicity 
of nanocarrier and drug is a major factor for the effectiveness of tumor delivery and 
subsequently the success of the treatment.106 In their study, the release of model dyes 
modified with a hydrophobic tail was monitored in vivo using FRET technology. They evaluated 
how the model drug–carrier compatibility affected the targeted delivery and drug release and 
found that the hydrophobicity of the drug and its miscibility with the nanoparticles determine 
its accumulation in the tumor. This supports the validity of our approach to modify the parent 
drug with a hydrophobic entity to improve the miscibility with the chosen lipid nanocarrier. In 
addition, the hydrolyzable moiety allows the regeneration of the native Dox which is crucial 
to ensure partitioning from the NE, delivery to the nucleus, and therapeutic activity. 
To gain a fundamental understanding of the processes that are involved in the cell 
internalization, investigation using fluorescence life time imaging microscopy are ongoing to 
elucidate the mechanism of action of the NE-C16-Dox-mediated intracellular delivery of Dox. 
We further hypothesize that the intracellular delivery can help to circumvent resistance 
mechanism in multi-drug resistant cell lines which should be studied in the future.   
The increase of size from the first polymer therapeutics around 10 nm to larger polymeric 
architecture of 100–200 nm proved to be beneficial for the loading capacity of anti-cancer 
drugs and has been shown to improve the biodistribution with regards to higher tumor 
accumulation in tumor tissue. However, intratumoral barriers impede the distribution of these 
bigger structures leading to limited penetration into avascular regions of the tumor. In the 
third project, enzyme- and pH-responsive features were combined to design a two-stage drug 
delivery system in the form of peptide-crosslinked nanogels (pNGs) that has size reduction 
properties mediated by MMP followed by controlled drug release at acidic pH conditions. The 
MMP-sensitive pNGs were prepared by incorporation of fluorogenic peptides as crosslinkers 
into a hydrophilic, polymeric scaffold. The peptides introduced degradability into synthetic 
NGs comprised of otherwise non-degradable dPG. Inverse nanoprecipitation in combination 
with strain-promoted click chemistry was utilized to prepare pNGs in a surfactant-free and 
mild manner. The synthetic methodology allowed control over the pNG size and degree of 
crosslinking to optimize for the desired application. In the presence of MMP, pNGs displayed 
fragmentation from several 100 nm to sub-50 nm particles. The rate of MMP-mediated 
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degradation was adjusted by the crosslinker feed and was characterized by fluorescence 
measurements enabled by the intrinsic fluorogenic reporter moiety of the crosslinker. 
For the multistage system, pNGs were post-synthetically modified by covalent attachment of 
the chemotherapeutic drug Dox through an acid-sensitive hydrazone thereby creating a 
multistage delivery system. In the first stage, pNGs can be degraded by MMPs which are 
present in the TME. After the resulting size reduction, the fragments constitute polymer-drug 
conjugates consisting of polyglycerol as polymeric carrier and Dox conjugated through an acid-
cleavable linkage (pNG-Dox). It was confirmed that the release of Dox was enhanced at acidic 
conditions indicating that the cargo could be released at acidic pH as present in intracellular 
compartments such as endosomes and lysosomes (pH 4-5). The digested multistage pNGs 
showed enhanced diffusive transport through a gel matrix mimicking the dense extracellular 
space. These fragments after digestion should facilitate the penetration into deeper areas of 
tumor tissue. As proof of concept, a multicellular tumor spheroid model (MCTS) was 
established resembling the TME. The size-reduction property to smaller entities was able to 
promote the infiltration of the nanocarrier and the functional chemotherapeutic drug into 
deeper regions of the MCTS. 
In the future, the control over the size and crosslinking density can be utilized to tune the 
encapsulation of therapeutic molecules with different molecular weight as well as the release 
rate of cargo. To confirm different densities in the pNG network, rigidity and flexibility could 
be determined by advanced atomic force microscopy (AFM) methods. 
The employed MCTS model cannot take dynamic processes into account that affect the 
transport of the nanocarrier and its cargo. To extend the validity of the spheroid model,  
microfluidic-based systems could be realized that simulate the blood flow and interstitial fluid 
pressure.202 Other studies related to the 3D model also enable to study tumor growth 
inhibition, drug sensitivity, targeting efficiency. 
Taken together, rational design was employed to integrate stimuli-responsive moieties in drug 
delivery systems combining prodrugs and nanocarriers to improve different aspects of 
antitumor therapy. Theranostic polymer conjugates allowed to evaluate the impact of the 
cleavable linker design on the cell-mediated drug release by integration of an activatable 
fluorescence probe. Based on this assessment, two nanocarrier systems of different 
compositions were developed that integrated the pH-sensitive linker design for intracellular 
release and protease-sensitivity for extracellular degradation. 
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The first system allowed the elegant entrapment of Dox in an oil in water NE by the 
development of an amphiphilic and pH-sensitive prodrug of the chemotherapeutic agent. The 
Dox-loaded formulation impeded tumor growth and prevented metastasis in a murine model, 
and therefore represents a simple, easily scalable, and economical DDS that could be 
translated into clinical application in the near future. 
In the second approach, NGs were designed that integrated dual-stimuli response to prepare 
a multistage DDS with the goal to overcome intratumoral barriers. Here, a protease-sensitive 
part was utilized to trigger the size reduction of the NGs by extracellular MMPs in the TME. 
Together with the pH-sensitive conjugation of Dox, which allowed acid-mediated intracellular 
drug release, the system successfully enhanced the drug transport in 3D tumor models. This 
NGs presents a rather complex approach that is designed for the complex nature of the tackled 
disease. At the moment, there are only a few examples of multistimuli-responsive DDS 
entering clinical trials but due to the complexity of tumor biology, it will be necessary to 
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III. Figures and Schemes 
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I. General information 
Plate reader 
After cells and samples were added, the microplates (Sarstedt or Brand) were covered with 
optically clear adhesive seal sheets (Absolute QPCR Seal, Thermo Scientific) and placed into 
a Tecan Infinite M200 Pro microplate reader heated to 37 °C. Fluorescence of Dox was 
monitored every 5 min over 16 h using an excitation wavelength of 490 nm (9 nm bandwidth) 
and an emission wavelength of 590 nm (20 nm bandwidth). 
GPC 
Gel permeation chromatography (GPC) analysis were performed on a Shimadzu Prominenze-i 
LC-2030 liquid chromatography system equipped with a Shimadzu RID-20A refractive index 
detector. The GPC column used was a Shodex OHpak SB-806M HQ with OHpak SB-G 6B as 
guard column. Solvents with HPLC grade by Fisher Chemical were employed. The oven 
temperature was set to 30 °C. The method included a flow 0.5 mL/min with an isocratic mobile 
phase (PBS 10 mM phosphate, 50 mM NaCl, pH 7.4). The injection volume was 50 μL and the 
UV-detectors were to 490 and 650 nm). GPC data was analyzed by Shimadzu LabSolution 
Version 5.85 software. 
Dynamic Light Scattering (DLS) Measurements 
DLS measurements were performed on a Malvern Zeta-sizer Nano-ZS ZEN 3600 instrument 
equipped with a He-Ne laser (532 nm) and a fixed detector oriented at 173°. Conjugate solutions 
(0.5 mL, 1 mg/mL) were analyzed in quartz fluorescence cuvettes with a round aperture. The 
autocorrelation functions of backscattered light were analyzed using the Zeta-sizer DTS 
software from Malvern to determine the size distribution by intensity and the polydispersity 
index. The measurements were performed at 25 °C in water, equilibrating the system at this 






Equation S1. Quenching efficiency 




QE=Quenching efficiency, FIto=fluorescence intensity at t=0, FImax=fluorescence intensity after 
cleavage 










III. Figures and Schemes 
 
 
Fig. S1. Structures of building blocks of theranostic polymer conjugates: (a) Doxorubicin (Dox) 
HCl salt, (b) symmetric indodicarbocyanine (IDCC) dye with carboxyl group, (c) representative 
structure of dendritic polyglycerol (dPG). 
 
Fig. S2: Spectral overlap of Dox emission spectrum and absorption spectrum of IDCC. 
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Scheme S1. Functionalization of dPG with azide groups in two steps. 
 
Scheme S2. Synthesis of Nα-IDCC-propargyl-L-lysine. 
 
Scheme. S3. (a) Cleavage mechanism for pH-sensitive aldoxorubicin; (b) cleavage mechanism 




Fig. S3. GPC chromatograms of (a) dPG-IDCC with detection at 490 nm and 650 nm and (b) the 
TPC and dPG-IDCC with absorbance at 490 nm (Dox absorption maximum). 
 
Fig. S4. Normalized (a) UV/Vis spectra and (b) fluorescence spectra of free Dox, dPG-IDCC 
(carrier) and the TPC (Excitation for Dox, protease- and pH-sensitive TPB: 490 nm; excitation 
for dPG-IDCC: 600 nm).  
 





Fig. S6. Fluorescence spectra of protease-sensitive conjugates incubated at pH 7.4 over a period 
of 24 h.  
 
Fig. S7. (a) Fluorescence signal (Ex.: 490 nm, Em.: 590 nm) of protease-sensitive TPC 
incubated at different pH over time and (b) ph-sensitive TPC at different cathepsin B 
concentrations.  
 
Fig. S8. pH-sensitive and protease-sensitive TPC incubated in cell-conditioned media 
incubated with (a) HeLa and (b) KB-V1. Error bars indicate SEM from two independent 
measurements. 
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Fig. S9. Dose-response relationship for (a) HeLa, (b) A549, (c) KB-V1 and (d) MDA-MB-231 




Fig. S10. Confocal laser scanning microscopy images of fixed, (a) untreated HeLa cells and 
HeLa cells incubated with (b) free Dox, (c) polymeric carrier dPG-IDCC, (d) pH-sensitive and 




Fig. S11. Confocal laser scanning microscopy images of fixed, (a) untreated A549 cells and 
A549 cells incubated with (b) free Dox, (c) polymeric carrier dPG-IDCC, (d) pH-sensitive and 




Fig. S12. Confocal laser scanning microscopy images of fixed, (a) untreated KB-V1 cells and 
KB-V1 cells incubated with (b) free Dox, (c) polymeric carrier dPG-IDCC, (d) pH-sensitive 




Fig. S13. Confocal laser scanning microscopy images of fixed, (a) untreated MDA-MB-231 
cells and MDA-MB-231 cells incubated with (b) free Dox, (c) polymeric carrier dPG-IDCC, 




Fig. S14. Flow cytometry a) comparison of internalization of dPG-IDCC and the TPC into 
HeLa, KB-V1, A549 and MDA-MB-231 (left to right) and b) comparison of internalization 
between the cell lines of medium, dPG-IDCC, pH-sensitive TPC and protease-sensitive TPC 





IV. Experimental Data  
Synthesis of Nα-Fmoc-Nε-Boc-propargyl-L-lysine 
 
Nα-Fmoc-Nε-Bocl-L-lysine (0.50 g, 1.07 mmol, 1.0 equiv.) was dissolved in 15 mL CH2Cl2 and 
(Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP, 0.568 g, 
1.28 mmol, 1.2 equiv.), DIPEA (1.12 mL, 6.6 mmol, 3.0 equiv.) and propargyl amine (64.8 mg, 
1.18 mmol, 1.1 equiv.) was added to the solution. After the reaction was stirred for 16 h at room 
temperature, solvent was evaporated and the residue was redissolved in 100 mL ethyl acetate. 
The organic layer was washed three times with 1 mol/L KHSO4 solution, once with H2O, three 
times with 5% NaHCO3 solution and three times with saturated NaCl solution. The organic 
layer was dried over NaSO4, filtered and concentrated in vacuum. Though the crude product 
Nα-Fmoc-Nε-Boc-propargyl-L-lysine contained propargyl amine it was used in the next step 
without further purification. Yield 85%. 
 
1H-NMR (400 MHz; MeOD-d4): δ (ppm) = 7.75 (d, 2H), 7.57 (d, 2H), 7.38 (t, 2H), 7.31 (t, 
2H), 6.78 (bs, 1H), 5.70-5.63 (m, 1H), 4.68 (bs, 1H), 4.38 (d, 2H), 4,16-4.22 (m, 2H), 4.03-3.97 
(m, 2H), 3.09 (s, 2H), 2.14 (t, 1H), 1.61-1.89 (m, 2H), 1.42 (s, 9H), 1.54-1.31 (m, 4H); HRMS 
(ESI-TOF): C29H35N3O5Na
+ [M+Na]+ calculated: 528.2474; found:528.2493. 
 
Synthesis of Nε-Boc-propargyl-L-lysine-NH2 
 
Nα-Fmoc-Nε-Boc-propargyl-L-lysine (0.40 g, 0.79 mmol, 1.0 equiv.) was dissolved in 20% 
piperidine in THF (10 mL). After the mixture was stirred for 1 h, solvent was removed under 
vacuum, and the residue was co-evaporated three times with toluene and three times with 
chloroform. The residue was purified by column chromatography with CH2Cl2/MeOH (9:1 v/v) 
as eluent. Nε-Boc-propargyl-L-lysine-NH2 was obtained as yellow oil. Yield 81%. 
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1H-NMR (400 MHz; MeOD-d4): δ (ppm) =3.96 ((t, J = 3.2 Hz,, 2H), 3.31 (t, J = 6.6 Hz, 1H), 3.01 (t, 
J = 6.9 Hz, 2H), 2.58 (t, J = 2.6 Hz, 1H), 1.41 (s, 9H), 1.71–1.26 (m, 6H); HRMS (ESI-ToF): m/z = 
C14H26N3O3+ [M+H]+ calculated: 284.1969; measured: 284.1985. 
 
Synthesis of Nα-IDCC-Nε-Boc-propargyl-L-lysine 
 
The reaction was performed under dry conditions. IDCC-COOH (0.230 g, 0.28 mmol, 1.0 
equiv.), (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU) (0.183 g, 0.48 mmol, 1.7 equiv.), N,N-diisopropylethylamine 
(DIPEA, 0.817 mL, 4.69 mmol, 5.5 equiv.) were dissolved in DMF (3 mL). The mixture was 
stirred for 30 min at room temperature, before Nε-Boc-propargyl-L-lysine-NH2 (0.122 g, 0.43 
mmol, 1.5 equiv.) was added and the solution mixture was stirred for 3 h .The reaction was 
quenched by precipitation in diethyl ether. The suspension was filtered through a G4 glass frit. 
The blue solid was purified by column chromatography (reversed phase C18 43g, 
water/methanol; linear gradient 0-100%). Yield 70%. 
1H-NMR (700 MHz MeOD-d4):δ=  8.33 (d, J = 14.0 Hz, 2H), 7.53 (d, J = 7.5 Hz, 2H), 7.49 
(d, J= 7.5 Hz, 2H), 7.43-7.18 (m, 8H), 5.82 (d, J = 14.0 Hz, 2H), 4.30 (dd, J = 9.1 Hz, 5.0 Hz, 
1H), 3.97 (ddd, J = 17.4 Hz, 2.5 Hz, 2H), 3.81 (m, 4H), 3.15- 2.97 (m, 4H), 2.83-2.68 (m, 6H), 
2.54 (t,  J = 2.5 Hz, 1H), 1.94-1.65 (m, 8H), 1.77 (s, 12H), 1.62-1.31 (m, 6H), 1.41 (s, 9H) ppm; 
HRMS (ESI-TOF): C56H72N5Na2O10S2
+ [M+Na]+ calculated: 1084.4511; found: 1084.4623. 




Nα-IDCC-Nε-Boc-propargyl-L-lysine (50 mg, 0.047 mmol, 1.0 equiv.) was dissolved in 0.5 mL 
CH2Cl2 and 0.5 mL trifluoroacetic acid (TFA) were added. After 1 h at room temperature, the 
solvent and TFA were removed under vacuum. The blue solid was purified by column 
chromatography (reversed phase C18 43g, water/methanol; linear gradient 0-100%). Yield: 
86%. 
1H-NMR (700 MHz, MeOD-d4): δ= 8.33 (d, J = 13.9 Hz, 2H), 7.54 (d, J = 7.5 Hz, 2H), 7.49 
(d, J = 7.4 Hz, 2H), 7.40-7.24 (m, 8H), 5.82 (d, J = 13.9 Hz, 2H), 4.33 (dd, J = 9.1 Hz, 5.0 Hz, 
1H), 3.97 (ddd, J = 25.5 Hz, 17.4 Hz, 2.5 Hz, 2H), 3.81 (m, 4H), 3.06 (tq, J = 19.1 Hz, 6.4 Hz, 
5.6 Hz, 2H), 2.99 (t, J = 7.2 Hz, 2H), 2.84-2.67 (m, 6H), 2.54 (t, J = 2.6 Hz, 1H), 1.93-1.49 (m, 
14H), 1.77 (s, 12H) ppm; HRMS (ESI-TOF): C51H65N5O8S2
+ [M+H]+ calculated: 940.4347; 
found: 940.4368; C51H65N5NaO8S2
+ [M+Na]+ calculated: 962.4167; found: 962.4197; 
C51H64N5Na2O8S2
+ [M+2Na]+ calculated: 984.3986; found: 984.4013. 
UV/Vis spectra of Nα-IDCC-propargyl-L-lysine in MeOH: 
 
Mass spectrum (ESI-TOF) of Nα-IDCC-propargyl-L-lysine 























Zoom of mass spectrum (ESI-TOF) of Nα-IDCC-propargyl-L-lysine 
 
 






208 kDa dPG (0.070 g, 0.00034 mmol, 1.0 equiv.) with 1% of azide functionalization was 
dissolved in a mixture of 2 mL H2O and 2 mL MeOH. To this solution Nα-IDCC-propargyl-L-
lysine (0.49 mg, 0.00050 mmol, 1.5 equiv.), sodium ascorbate (0.020 mg, 0.00010 mmol, 0.3 
equiv.) and copper sulphate pentahydrate (0.038 mg, 0.00015 mmol, 0.45 equiv.) were added. 
The pH of the solution was adjusted to pH 8 - 9 by DIPEA, purged with N2 and then stirred for 
one overnight. The crude mixture was purified by ultrafiltration (MWCO 5000 g/mol) using 
H2O/MeOH (1:1 v/v) as solvent with one running-circle EDTA solution to remove all copper 
content. The product was obtained as a blue honey-like solid. The product was characterized 
by UV-Vis spectroscopy, fluorescence spectroscopy, and GPC. The conjugate has a loading of 
3.2 µg IDCC (4.0 ∙ 10-3 µmol) per mg conjugate determined by UV/Vis spectroscopy, using the 
molar extinction coefficient ε650=106000 M-1 cm-1of IDCC. Conjugate formation was proven 
by faster polymer band on SEC compared to the free dye and by GPC. Yield 73%. 
 
UV/Vis spectra of dPG- Nα-IDCC-propargyl-L-lysine in H2O: 
 
Synthesis of (6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin) 
 
The pH-sensitive (6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin), 
was synthesized starting from 6-aminocaproic acid following a procedure from literature.[1] 
1H-NMR (500 MHz, MeOD-d4): δ = 7.91 (s, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.65 (dd, J = 5.7, 
4.1 Hz, 1H), 6.98 (s, 2H), 5.77 (t, J = 4.8 Hz, 1H), 5.51 (s, 1H), 5.46 (d, J = 6.2 Hz, 1H), 5.30 


















(d, J = 2.9 Hz, 1H), 4.95 (t, J = 6.7 Hz, 1H), 4.40 (dd, J = 7.6, 4.8 Hz, 2H), 4.03 (q, J = 6.5, 6.1 
Hz, 1H), 3.98 (s, 3H), 3.57 (d, J = 4.3 Hz, 1H), 3.25 – 3.20 (m, 2H), 2.75 (d, J = 17.3 Hz, 1H), 
2.21 (dd, J = 15.4, 7.7 Hz, 1H), 2.14 (dd, J = 13.4, 6.8 Hz, 1H), 2.07 (s, 2H), 1.89 (td, J = 12.6, 
3.5 Hz, 1H), 1.73 (dd, J = 12.0, 4.1 Hz, 1H), 1.55 – 1.42 (m, 1H), 1.30 (q, J = 7.7 Hz, 3H), 1.16 
(d, J = 6.5 Hz, 3H), 1.02 (p, J = 7.9 Hz, 2H) ppm; HRMS (ESI-TOF): C37H43N4O13+ [M+H]+ 
calculated: 751.2821; found: 751.2861; C37H42N4NaO13+ [M+Na]+ calculated: 773.2641; 
found: 773.2664. 
 
1H-NMR of (6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin)  
 








Synthesis of mal-Phe-Lys-PABC-Dox 
 
Mal-Phe-Lys-PABC-Dox was synthesized following slightly modified literature procedure.[2-3]  
 
1H NMR (700 MHz MeOD-d4): δ= 7.81 (s, 1H), 7.75 (s, 1H), 7.46 (dd, J = 8.3, 4.0 Hz, 2H), 
7.28 (d, J = 8.3 Hz, 2H), 7.23 - 7.12 (m, 5H), 7.07 (s, 1H), 6.80 (s, 2H), 5.40 (d, J = 3.7 Hz, 
1H), 5.11 – 5.00 (m, 2H), 4.76 (d, J = 4.5 Hz, 2H), 4.42 (dd, J = 9.1, 5.1 Hz, 1H), 4.27 (d, J = 
6.7 Hz, 1H), 3.97 (s, 3H), 3.92 (d, J = 11.5 Hz, 1H), 3.65 (s, 1H), 3.42 (t, J = 7.2 Hz, 2H), 3.06 
(d, J = 17.7 Hz, 1H), 2.97 – 2.85 (m, 4H), 2.37 (d, J = 14.3 Hz, 1H), 2.22 – 2.11 (m, 2H), 1.96 
(td, J = 13.1, 4.0 Hz, 1H), 1.86 (dq, J = 13.6, 6.2 Hz, 1H), 1.80 (dd, J = 13.1, 4.6 Hz, 1H), 1.76 
– 1.61 (m, 3H), 1.56 – 1.39 (m, 6H), 1.29 (d, J = 6.4 Hz, 3H), 1.18 (dt, J = 16.2, 7.6 Hz, 2H) 
ppm; HRMS (ESI-TOF): C60H69N6O18+ [M+H]+ calculated: 1161.4663; found: 1161.4675. 
 













To a solution of dPG-Nα-IDCC-propargyl-L-lysine (20 mg, 0.0001 mmol, 1.0 equiv.) in 2 mL 
phosphate buffer (PB, 50 mM, pH 7.4), 2-iminothiolane (0.04 mg, 0.00029 mmol, 3.0 equiv.) 
was added and the reaction mixture was stirred for 20 min. The following reaction was 
performed in situ. 





After thiolation with 2-iminothiolane, 1 mL of a PB (50 mM, pH 7.4) solution containing 
(6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin, 0.36 mg, 0.0005 
mmol, 5.0 equiv.) was added dropwise. The reaction mixture was stirred for 3 h. Afterwards 
the solution was purified by SEC using a Sephadex LH20 superfine gel followed by a Sephacryl 
G25 superfine HR column eluted with PB (50mM, pH 7.4). The conjugate loading was 
determined by UV/Vis spectroscop with 3.4 ∙ 10-3 µmol Dox (2.0 µg) and 4.0 ∙ 10-3 µmol IDCC 
(3.2 µg) per mg polymer, using the molar extinction coefficients ε495=10590 M-1 cm-1for Dox 
and ε650=106000 M-1 cm-1 for IDCC. Conjugate formation was proven by faster polymer band 
on SEC compared to the free dye and by the detection of UV-absorption at 490 nm at the 
retention time of the polymer by GPC (Fig. S3). Yield 71% 
UV/Vis spectra of pH-sensitive TPC: 
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After thiolation with 2-iminothiolane, 1 mL of a PB (50 mM, pH 7.4) solution containing mal-
Phe-Lys-PABC-Dox (protease-sensitive prodrug, 0.56 mg, 0.0005 mmol, 5.0 equiv.) was added 
dropwise. The reaction mixture was stirred for 3 h. Afterwards the solution was purified by 
SEC using a Sephadex LH20 superfine gel followed by a Sephacryl G25 superfine HR column 
eluted with PB (50mM, pH 7.4). The conjugate had a loading of 3.20 ∙ 10-3 µmol Dox (1.9 µg) 
and 4.0 ∙ 10-4 µmol IDCC (3.2 µg) per mg polymer determined by UV/Vis spectroscopy, using 
the molar extinction coefficients ε495=10590 M-1 cm-1for Dox[4] and ε650=106000 M-1 cm-1 for 
IDCC. Conjugate formation was proven by faster polymer band on SEC compared to the free 
dye and by the detection of UV-absorption at 490 nm at the retention time of the polymer by 
GPC (Fig. S3). Yield 74%. 
UV/Vis spectra of protease-sensitive TPC: 
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6.1.2 Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs 
lung tumor metastasis in a breast cancer model 
Methods  
C16-Dox pH-sensitive properties analysis 
Water-insoluble C16-DOX was dispersed in phosphate buffer saline (PBS, Termo Fisher), pH 
7.2, at 25 °C and, after 1 minute, the pH was adjusted with an excess of PBS (pH 3) to pH 3. 
During this process, the fluorescence (Excitation: 488 nm/Emission: 588 nm) of the system 
was recorded using Lumina Fluorescent and Luminescent chamber (IVIS Spectrum, Caliper, 
USA). Data was represented as the relative fluorescent unit (RFU).  
Quantification of doxorubicin in NE-C16-DOX 
Dox was spectrometrically quantified by its absorption at 580 nm (Spectra Max). The standard 
curve was prepared with solutions of free Dox in ultrapure water at concentrations ranging 
from 0.0125 to 1.0 mg mL-1.The data was collected in triplicate, and a linear regression was 
performed to determine the amount of Dox in the formulations. The theoretical amount of 
Dox in NE-C16-Dox was experimentally confirmed by UV/Vis measurements and a 
spectrophotometric correlation between C16-Dox (mg mL-1 in NE dispersion) and free Dox (mg 
mL-1 in PBS) (Figure S3A). 
NE-C16-Dox pH-mediated Dox Release 
Doxorubicin release from nanoemulsions was conducted by cellulose dialysis tubing using 
dialysis bag-diffusion (Spectrum Lab.com) method with a molecular cut-off of 10,000 Da. 
Dialysis tubes (AMICON, Milipore), containing 1 mL of NE C16-DOX solution, were placed in an 
in vitro release medium containing 7 mL 0.1 M potassium phosphate buffer pH 7.4 or 1 M 
acetate buffer pH 4. Both assemblies were kept at room temperature and mixed on a stir plate. 
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At different point times, 1 mL samples were withdrawn from the outer compartment and 
replaced with fresh release medium to maintain the same conditions. DOX concentrations in 
the samples were determined by spectrophotometry measurements at (580 nm). The drug 
concentration was calculated from the measured absorbance using a calibration curve. 
In addition to the dialysis bag experiment, we evaluated Dox release by centrifugation (14,000 
rpm; 20 minutes) of the NE-C16-Dox in Amicon tubes. As these tubes have filtering 
membranes with 10,000 Da pores, it is possible to separate the released free Dox. For that, 
the NE were kept under different pH conditions (7.2 and 2) for 6 hours. After centrifugation, 
the released Dox fluorescence (Excitation: 488 nm/Emission: 588 nm) was observed at the 
bottom of the tube using Lumina Fluorescent and Luminescent chamber (IVIS Spectrum, 
Caliper, USA).   
Dox Internalization  
Dox internalization was assessed in 4T1 cells incubated with NE-C16-DOX (equivalent to 100 
µg Dox mL-1) and free DOX (100 µg mL-1) at 37 °C and 5% CO2. After different time points (15, 
30, 60 and 120 min) the supernatant was removed, cells trypsinized, inactivated, centrifuged, 
suspended in PBS and read by flow cytometry. Untreated cells were used as negative control. 
Dox fluorescence data were collected on a FACS (BD Biosciences) and all data analyzed using 
FlowJo Software (Tree Star Inc).  
Hemolytic Analysis 
The hemolytic capacity of NE C16-DOX was analyzed in vitro by a hemolytic activity assay using 
BALB/c mouse erythrocytes. The whole blood was centrifuged at 3000 RPM for 5 minutes at 
10 °C and then suspended in 10 mL of saline (NaCl 150 mM). This procedure was repeated 
twice to remove all the plasma components. The samples were incubated for 120 minutes 
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with different concentrations of NE-C16-Dox and blank nanoemulsion at room temperature 
and then centrifuged again at 402.48 g for 5 minutes at 10 °C. The positive control was 
produced by suspending the red blood cells in distilled water, and the negative control in 150 
mM NaCl. The supernatant was transferred to a 96-well plate, and the supernatants were 
measured using a spectrophotometer with a microplate reader at a wavelength of 540 nm 
(Bio-Rad, Hercules, CA). The data represent a triplicate analysis.  
Maximum Tolerated Dose  
Twenty-four healthy female BALB/c mice (8 weeks of age) were randomly distributed among 
the following 6 experimental groups (n=4 per group): NE-C16-DOX (40 mg kg-1); NE-C16-DOX 
(20 mg kg-1); free DOX (20 mg kg-1); free DOX (10 mg kg-1); free DOX (5 mg kg-1) and NE-Blank. 
For all treatments the doses of DOX were equivalent. Four animals without treatment were 
used as a control. The experimental groups were treated intraperitoneally (each injection 
represents 20% of total dose) once a day for 5 consecutive days. Body weight and clinical 
observations were monitored after infection. On day 14, all 28 animals were euthanized; 
hearts were weighed, fixed overnight with 4% paraformaldehyde and proceeded to 
histological analyses according to Bicalho et all. (2013) 1.  
Hemogram and Histology  
For blood collection, mice were anesthetized with ketamine (100 mg kg-1) and xylazine (20 mg 
kg-1). Blood samples (1 mL) were collected by cardiac puncture using syringe containing EDTA 
(Ethylenediamine tetraacetic acid). Hematological analyses were conducted in an automated 
hematology system (Sysmex pocH-100iV Diff), which was calibrated for mice blood. After 
blood collection, mice were euthanized with an excess of anesthetic (xylazine and ketamine), 
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organs were dissected, weighed, and processed for histological analysis as described by Longo 
et al. 2016 2. 
Immunofluorescence and Immunohistochemical  
The immunofluorescence and immunohistochemical analyses were conducted as described 
by Longo et al. 2016 2. For the immunofluorescence, the GR1 and CD11b markers (Termo 
Fisher) were detected in liver tissue sections. The antibodies against these two markers were 
coupled with red and green fluorochromes, respectively. The combination of these two 
markers identify the myeloid derived suppressor cells (MDSC) in liver tissue.  For 
immunohistochemical analysis, CD34 was used to identify hematopoietic stem cell to confirm 
the extramedullary hematopoiesis. Figures S12 A and B represent the CD11b (green) and GR1 
(red) expression in liver tissue. Figure S9C represent liver tissue stained with DAPI for nucleus 
identification and Figure S9D shows the area where both markers were identify together. The 
MDSC, doubled marked with CD11b and GR1, are highlighted with a circle.  
Results  
MRN and Mass Spectroscopy  
1H-NMR (400 MHz, DMSO): δ = 7.92 – 7.83 (m, 2H), 7.62 (dd, J = 6.3, 3.1 Hz, 1H), 5.82 (t, J = 
4.8 Hz, 1H), 5.48 (s, 1H), 5.30 (s, 1H), 4.94 (q, J = 7.2, 6.6 Hz, 1H), 4.41 (t, J = 4.4 Hz, 2H), 4.05 
(t, J = 6.7 Hz, 1H), 3.96 (s, 3H), 3.90 (ddd, J = 8.9, 3.8, 2.2 Hz, 1H), 3.28 – 3.19 (m, 3H), 3.22 – 
3.10 (m, 1H), 2.79 (d, J = 17.1 Hz, 1H), 2.73 – 2.57 (m, 2H), 2.45 (t, J = 3.0 Hz, 1H), 2.33 – 2.21 
(m, 1H), 2.21 – 2.06 (m, 2H), 1.89 (dd, J = 13.9, 10.1 Hz, 1H), 1.73 (d, J = 12.4 Hz, 1H), 1.55 – 
1.41 (m, 3H), 1.39 – 1.26 (m, 4H), 1.23 – 1.12 (m, 27H), 1.08 (t, J = 7.0 Hz, 2H), 0.83 (t, J = 6.7 
Hz, 3H).  
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HRMS (High resolution mass spectrometry) (ESI-TOF) (ESI-Time-of-Flight LC/MS mass 
spectrometer 6210 from Agilent Technologies): m/z calculated for ([M+H+]):1009.5279; found: 
1009.5220 (Figure S1A). The compound was further confirmed by ESI-TOF mass spectrometry 
where the found mass is in good accordance to the calculated mass (Figure S1B).  
 
Figure S1. a) C16-Dox weight and structure analyzed by magnetic nuclear resonance 
spectroscopy (MNR). b) C16-Dox mass spectroscopy.  
C16-Dox pH-sensitive properties analysis 
The responsiveness of C16-Dox towards acidic pH-values was confirmed in an experimental 
set-up, following the solubilization of the prodrug at acidic pH. For that, C16-Dox was 
dispersed in PBS (pH 7.2), and the Dox fluorescence (Ex.: 488 nm/Em.: 590 nm) was recorded 
in a fluorescence chamber. After reducing the pH to 3, a significant increase in fluorescence 
intensity was observed over time, indicating that the displacement of the Dox molecule from 
the C16-Dox aggregates in acidic conditions due to a cleavage of the hydrazone bonds (Figure 
S2). In section S2A, the increase in fluorescence is seen to depend on pH and time. In section 





Figure S2. pH-responsiveness of C-16. Images shows Dox displacement from C16 after 
reducing pH: a) Qualitative representation of fluorescence intensity over time in pH 7.2 and 3; 
b) Quantitative image analysis in Absolute Fluorescence Intesity (RFU) over time.  
NE-C16-Dox Characterization 
In order to measure the amount of Dox concentration in the NE, a spectrophotometric 
correlation between C16-Dox (mg mL-1 in NE dispersion) and free Dox (mg mL-1 in PBS) was 
traced (Figure S3A). Both solutions presented a positive linear correlation, and the correlation 
tests confirmed (~55% w/w) the theoretical content of Dox in C16-Dox (54% w/w) 
experimentally. The tested NE-C16-Dox had the following final Dox concentrations: 0.22, 0.44, 
and 0.66 mg Dox mL-1 respectively.  
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Figure S3. NE C16-DOX characterization: a) Theoretical DOX amount confirmation and 
calculation in NE C16-DOX by UV/Vis; b) NE C16-DOX Hydrodynamic Diameter stability in 
different environment over time. c) Qualitative evaluation of Dox release by fluorescence in 
amicon tubes; d) Quantitative evaluation of Dox release profile by dialysis experiments. Dox 
was quantified by spectrophotometry measurement at 580 nm. 
The release of free Dox from the NE-C16-Dox nanocarrier, a key feature of this system, was 
evaluated qualitatively by centrifugation experiments and quantitatively by dialysis 
experiments. In both, a porous membrane allowed the permeation of free Dox, but not of NE-
C16-Dox, from the NE dispersion to a collector compartment. Figure S3C shows Amicon tubes 
with Dox under different conditions. Free Dox solution can pass the membrane, and the 
molecule is detected at the bottom of the tube after centrifugation. In NE-C16-Dox, a pH-
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dependent release is qualitatively observed (Figure S3C), where under acidic conditions (pH 
2) the Dox molecule is released from the NE, while at physiological pH (7.2) Dox fluorescence 
is observed only in the upper part of the tube. 
Long-term stability of NE-C16-Dox  
The long-term NE-C16-Dox stability was evaluated measuring the hydrodynamic diameter, as 
well as the polidispersity index. As presented in Figure S3B, it is possible to note that the NE 
was stable in 4 0C and room temperature. At 37 0C, the formulation was stable for two weeks.  
Dox Internalization  
The absolute fluorescence intensity analysis, obtained in the cytometry experiments, shows 
that cells treated with NE-C16-Dox presented a more intense signal compared to the cells 
treated with free Dox. Furthermore, Dox fluorescence was detected in almost all cells (98%) 
in the first 15 minutes of exposure (Figure S4A) when associated to the NE, while for the free 
Dox treatment its fluorescence was detected in 65% of the cells in the same period, achieving 





Figure S4. Dox internalization in 4T1 cells quantified by Flow Cytometry after Free Dox and NE 
C16-DOX exposure over time.   
Maximum Tolerated Dose  
 
Figure S5: Maximum tolerated dose experiments in mice: A) Hemolytic activity assay analysis 
after treatment with NE Blank (blue) and NE-C16-Dox (red); B) Changes in mice body weight  
over 15 days after different treatments; C) Mice survival percentage over 15 days after 
different treatments; D) Changes in mice heart weight/mice body weight ratio over 15 days 
after different treatments. Error bars indicate the standard error of the mean (SEM) in 5 
independent animal measurements. 
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Maximum Tolerated Dose  
After in vitro evaluations, the potential in vivo effects of the NE-C16-Dox were evaluated in 
murine models. The first step was to establish the maximum tolerated dose (MTD) of the 
formulation in healthy mice. It is well known that the adverse effects of Dox, particularly its 
potentially severe cardiotoxicity, are dose-limiting, intensely lowering its therapeutic index. 
For the MTD study, healthy mice were evaluated for 15 days after different treatments. In a 
previous hemolytic assay, it was observed that neither blank NE and NE-C16-Dox induced 
significant hemolysis (Figure S5A), indicating that these formulations are safe for systemic 
parenteral administrations. These data are highlighted here due to some literature reports 
that link the toxicity of nanoemulsions to the surfactant used for oil droplet stabilization 3, an 
event that was not noticed with the experimental protocols used in this study.  
In our MDT experiments, we neither observed weight loss (Figure S5B), mouse death (Figure 
S5C), nor a difference in heart weight (Figure 6D) in all the experimental treatments. In this 
experimental design, we compared the NE-C16-Dox MTD (20 and 40 mg Dox kg-1) with the 
free Dox MTD (5, 10, and 20 mg kg-1). It is important to highlight that free Dox at the higher 
concentration (40 mg kg-1) was not used because previous experiments (unpublished data) 
showed that this dose is too toxic and causes mouse mortality at 10 days after drug 
administration.  
The data show that NE-C16-Dox is more tolerated by healthy mice at concentrations of at least 
twice those of the free drug, probably due to its lower systemic toxicity in comparison to free 
Dox. Prevention of drug toxicity is one of the goals of drug delivery systems 4, 5 and has been 
the aim of various studies. The increased tolerability of Dox associated with NE-C16-Dox may 
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be due to the change in its pharmacokinetics, which is discussed below, or even to altered 
intracellular dynamics, as discussed before.  
It is worth noting that the histopathological analysis of the heart in the MDT study (Figure S6) 
showed that the intensity of cardiac injury induced by NE-C16-Dox, even in the higher 
concentration treatments (NE-C16-Dox 40 mg Dox kg-1), was less intense in comparison to that 
induced by free Dox.  
 





Figure S7: Qualitative Dox biodistribution in tumor-bearing mice 4 and 12 hours after 
treatment with NE C16-Dox (4 mg kg-1) and Free Dox  (4 mg kg-1). A scale bar of emission 
quantification is placed in the right part of the figure. Yellow emission indicates higher Dox 
quantification, while red emission denotes lower quantification.  
Lung Microtomography 
Figure S8A and B represents the morphological aspects of bidimensional and tree dimensional 
lungs micro-CT images. Following the color scale, it is possible to note the significant density 
differences in the bidimensional images among the experimental groups. Noteworthy, the X-
ray densities from lungs of animals treated with NE-C16-Dox are similar to those of the naïve 




Figure S8. Mouse lung densities by X-ray in a micro computed tomography (micro-CT): a) 
Bidimensional cross section from mice lungs after treatments; b) a 3 dimensional aspect of 
mice lungs after different treatments are represented.  
Lung Histopathology  
Figure S9A represents the normal histological aspect of naïve control mice lungs, without 
metastatic proliferating cells. In Figure S9D, it is possible to note the presence of a dense tissue 
with metastatic tumor cells. In a higher magnification view (Figure S9F-arrow), it is possible to 
confirm the typical morphology of colonies of 4T1 cells in the lung tissue. Noteworthy, the 
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lungs from mice treated with NE-C16-Dox (40 mg kg-1) presented a histological pattern similar 
(Figure S9B) to that of untreated control mice. 
 
Figure S9. Lung histopatological photomicrographs. Photomicrographs represent normal 
naïve mice lungs histology (a); NE-C16-Dox (40 mg kg-1) (b); NE-C16-Dox (20 mg kg-1) (c); Free 
Dox (20 mg kg-1) (d); and PBS treated (e) mice respectively. In section (f) a higher magnification 





Figure S10 shows the blood cell counting for the different experimental groups. The absolute 
red blood cells (RBC) counting was statistically equal for the treated groups. On the other 
hand, the total white blood cell (WBC) counting presented significant increases in all 
experimental groups compared to the naive group (Figure S10A). The differential WBC 
counting showed an inversion of blood cell populations in all tumor-bearing mice, compared 
to naive mice (Figure S10B). The most frequently WBC in naive mice were the lymphocytes 
(SCC, >75%), which presented reduced percentages in all others experimental groups. The 
decrease in lymphocyte cell percentages is followed by a significant increase in monocyte 
(MCC) proportion. The percentage of neutrophils (LCC) did not vary among experimental 
groups. 
 
Figure S10. Hematological analysis: a) Counting of Red and White blood cells in different 
experimental groups; b) Counting of white blood cells types after different treatments. Error 
bars indicate the standard error of the mean (SEM) in 5 independent animal measurements. 
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Immunofluorescence and immunohistochemical analyses 
Figure S11 shows the CD34 expression in liver histological sections. This procedure was used 
to confirm the presence of extramedullary hematopoiesis in the liver. The brown spots 
represent the immunohistochemical stain. CD34 is also expressed in endothelial cells that 
were used as internal control of the reaction (Figure S11A). In Figure S11B, the positive CD34 
cells are clearly identified among the negative CD34 hepatocytes. These cells are atypical in 
adult mice, and confirm the presence of hematopoietic cells proliferating among normal liver 
tissue. Figure 12 represent the immunofluorescent confirmation of MDSC in liver tissue. Thus, 
specific myeloid cell line is characterized by the double expression of GR1 and CD11b.  
 
Figure S11. Liver immunohistochemical images staining in brown the CD34 expression. In 
section (a) the normal liver histology showing the normal CD34 expression in endothelial cells. 




Figure S12. Represents immunofluorescent of MDSC (myeloid derived suppressor cells) in liver 
tissue. This specific myeloid cell line is characterized by the double expression of GR1 (red) in 
section (b) and CD11b (green) in section (a). Section (c) represents nuclei staining (DAPI) and 
section (d) represents the images superposition, confirming the double expression of MDSC.  
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I. General information 
Plate reader 
After samples and protease were added, the microplates (Sarstedt or Brand) were covered with 
optically clear adhesive seal sheets (Absolute QPCR Seal, Thermo Scientific) and placed into 
a Tecan Infinite M200 Pro microplate reader heated to 37 °C. Fluorescence of methoxy 
coumarine  was monitored every 5 min over 16 h using an excitation wavelength of 320 nm 
(9 nm bandwidth) and an emission wavelength of 405 nm (20 nm bandwidth). 
GPC 
Gel permeation chromatography (GPC) analysis were performed on a Shimadzu Prominenze-i 
LC-2030 liquid chromatography system equipped with a Shimadzu RID-20A refractive index 
detector. The GPC column used was a Shodex OHpak SB-806M HQ with OHpak SB-G 6B as 
guard column. Solvents with HPLC grade by Fisher Chemical were employed. The oven 
temperature was set to 30 °C. The method included a flow 0.5 mL/min with an isocratic mobile 
phase (PBS 10 mM phosphate, 50 mM NaCl, pH 7.4). The injection volume was 50 μL and the 
UV-detectors were set to 490 and 650 nm. GPC data was analyzed by Shimadzu LabSolution 
Version 5.85 software. 
Dynamic Light Scattering (DLS) Measurements 
DLS measurements were performed on a Malvern Zeta-sizer Nano-ZS ZEN 3600 instrument 
equipped with a He-Ne laser (532 nm) and a fixed detector oriented at 173°. Conjugate solutions 
(0.5 mL, 1 mg/mL) were analyzed in quartz fluorescence cuvettes with a round aperture. The 
autocorrelation functions of backscattered light were analyzed using the Zeta-sizer DTS 
software from Malvern to determine the size distribution by intensity and the polydispersity 
index. The measurements were performed at 25 °C in water, equilibrating the system at this 




II. Figures and Schemes 
 
Figure S1. Representative structure of dendritic polyglycerol (dPG). 
 
Scheme S1. Functionalization of dPG with amine groups in three steps. 
 
Scheme S2. Functionalization of dPG with bicyclo[6.1.0]non-4-yn (dPG-BCN). 
 
Figure S2. Morphology of multicellular tumor spheroids (MCTS) over time. After 7 days 




Figure S3. (a) Change of fluorescence intensity (Ex: 320 nm; Em: 405 nm) over time for a 
commercial substrate and cleavable fluorogenic peptide crosslinker incubated with matrix 
metalloprotease 7 (MMP-7) at 37 °C. Time constants: Substrate 0.26 h; crosslinker: 0.58 h with 
same concentration. (b) Change of Fluorescence intensity (Ex: 320 nm; Em: 405 nm) over time 
for cleavable and non-cleavable fluorogenic peptide crosslinker incubated in buffer or in the 
presence of MMP-7 at 37 °C. 
 
Figure S4. Normalized gel permeation chromatography traces of multistage pNG-Dox before 
and after incubation with MMP-7 for 16 h.  
 
Table S1: Time constants of degradation rate determined from the exponential fit of the 
fluorescence intensities over time. 
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Figure S5. Change of fluorescence intensity (Ex: 320 nm; Em: 405 nm) over time for pNG 
incubated in buffer or in the presence of MMP-7 at 37 °C. 
 
 
Figure S6. Change of fluorescence intensity (Excitation (Ex): 320 nm; Emission (Em): 405 nm) over 
time for peptide-crosslinked nanogel (pNG) incubated with Hela cells (10E5 cells/mL) at 37 °C.  
 
 
Figure S7. UV/Vis-spectra of (a) degradable and (b) non-degradable pNGs including 




Figure S8. Release of DOX from multistage pNGs under different conditions. The red squares 
describe the release at pH 5 after the pNG-Dox was digested with MMP-7 over night.  
 
 
Figure S9. Two examples of Z-stack optical sections using CLSM of live spheroids incubated 
for 16 h with free ICC, degradable, or non-degradable pNG-ICC. The white dotted line displays 
the outside margin of the spheroids in the brightfield image. The black bars in the brightfield 




Figure S10. Mean fluorescence intensity over the area of spheroid sections after 2 h and 16 h 
incubation. 
 
Figure S11. CLSM images of MCTS cryosections with 20-fold magnification. MCTS were 
incubated degradable and non-degradable pNG-DOX for (a) 2 h and (b)16 h, respectively. 




III. Experimental Data 
 
Synthesis of (6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin) 
 
The pH-sensitive (6-maleimidocaproyl) hydrazone derivative of doxorubicin (aldoxorubicin), 
was synthesized starting from 6-aminocaproic acid following a procedure from literature.1  
1H-NMR (500 MHz, MeOD-d4): δ = 7.91 (s, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.65 (dd, J = 5.7, 
4.1 Hz, 1H), 6.98 (s, 2H), 5.77 (t, J = 4.8 Hz, 1H), 5.51 (s, 1H), 5.46 (d, J = 6.2 Hz, 1H), 5.30 
(d, J = 2.9 Hz, 1H), 4.95 (t, J = 6.7 Hz, 1H), 4.40 (dd, J = 7.6, 4.8 Hz, 2H), 4.03 (q, J = 6.5, 6.1 
Hz, 1H), 3.98 (s, 3H), 3.57 (d, J = 4.3 Hz, 1H), 3.25 – 3.20 (m, 2H), 2.75 (d, J = 17.3 Hz, 1H), 
2.21 (dd, J = 15.4, 7.7 Hz, 1H), 2.14 (dd, J = 13.4, 6.8 Hz, 1H), 2.07 (s, 2H), 1.89 (td, J = 12.6, 
3.5 Hz, 1H), 1.73 (dd, J = 12.0, 4.1 Hz, 1H), 1.55 – 1.42 (m, 1H), 1.30 (q, J = 7.7 Hz, 3H), 1.16 
(d, J = 6.5 Hz, 3H), 1.02 (p, J = 7.9 Hz, 2H) ppm; HRMS (ESI-TOF): C37H43N4O13+ [M+H]+ 
calculated: 751.2821; found: 751.2861; C37H42N4NaO13+ [M+Na]+ calculated: 773.2641; 
found: 773.2664. 





Mass spectrum (ESI-TOF) of (6-maleimidocaproyl) hydrazone derivative of doxorubicin 
(aldoxorubicin)  
 
Snthesis of dPG-(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl (dPG-BCN) 
1H-NMR (500 MHz, D2O): δ (ppm) = 4.24-3.42 (m, 5H, dPG backbone), 2.31-2.14 (m, 6H, 





8. % functionalization 
1H-NMR (500 MHz, MeOD-d4): δ (ppm) = 4.24-3.42 (m, 5H, dPG backbone), 2.42-2.50 (m, 
6H, 
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